BackgroundFile: background.txt 
Geneset: data/c2.all.v6.1.symbols.gmt SaveFile: BRNPUT.PARP4.top50genes.c2.txt
TestFile: BRNPUT.PARP4.top50genes.txt 
CHANG_CORE_SERUM_RESPONSE_UP 	4	46	192	16796	7.606884057971015	0.002587400883686901	1	HSPB11,ZWILCH,PPIH,LSM3
ASTON_MAJOR_DEPRESSIVE_DISORDER_UP 	2	48	41	16947	17.222560975609756	0.007058192480135516	1	CCKBR,PENK
DANG_MYC_TARGETS_UP 	3	47	133	16855	8.089105743081108	0.0074158451598320034	1	CCKBR,MSH2,FASN
SONG_TARGETS_OF_IE86_CMV_PROTEIN 	2	48	55	16933	12.828030303030303	0.012153819668750426	1	MSH2,PPIH
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13 	3	47	161	16827	6.671203911721951	0.012328297851023793	1	PSMG4,LSM3,PPIH
KOKKINAKIS_METHIONINE_DEPRIVATION_48HR_DN 	2	48	60	16928	11.755555555555556	0.014267049674155288	1	NOXA1,RAD54B
KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_DN 	2	48	71	16917	9.92781690140845	0.01942676018169411	1	NOXA1,RAD54B
BILANGES_SERUM_SENSITIVE_GENES 	2	48	77	16911	9.150974025974026	0.022523619353255725	1	HSPB11,PENK
KAUFFMANN_DNA_REPAIR_GENES 	3	47	210	16778	5.099696048632219	0.02455217411078286	1	MSH2,CETN2,RAD54B
KOBAYASHI_EGFR_SIGNALING_24HR_DN 	3	47	210	16778	5.099696048632219	0.02455217411078286	1	ZWILCH,MSH2,RAD54B
GAVIN_FOXP3_TARGETS_CLUSTER_T4 	2	48	81	16907	8.697016460905349	0.02469407112651367	1	PENK,FAM26F
FIGUEROA_AML_METHYLATION_CLUSTER_4_UP 	2	48	90	16898	7.823148148148148	0.029874746361759016	1	SCG5,BHLHB9
FIGUEROA_AML_METHYLATION_CLUSTER_7_UP 	2	48	92	16896	7.6521739130434785	0.031080064485374894	1	SCG5,BHLHB9
PUJANA_BREAST_CANCER_LIT_INT_NETWORK 	2	48	93	16895	7.569444444444445	0.03168989995246735	1	MSH2,BAP1
REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS 	2	48	95	16893	7.40921052631579	0.0329237636736978	1	CCKBR,PENK
FIGUEROA_AML_METHYLATION_CLUSTER_1_UP 	2	48	98	16890	7.1811224489795915	0.034809565349056014	1	SCG5,BHLHB9
ODONNELL_TFRC_TARGETS_DN 	2	48	100	16888	7.036666666666667	0.03608973697284687	1	FAM26F,RAD54B
LAIHO_COLORECTAL_CANCER_SERRATED_UP 	2	48	103	16885	6.830501618122978	0.03804382809816002	1	COMMD3,LSM3
BROWN_MYELOID_CELL_DEVELOPMENT_DN 	2	48	109	16879	6.452217125382263	0.04207077947404512	1	RCOR2,MSH2
FIGUEROA_AML_METHYLATION_CLUSTER_6_UP 	2	48	115	16873	6.113405797101449	0.046250679145163766	1	SCG5,BHLHB9
YAUCH_HEDGEHOG_SIGNALING_PARACRINE_UP 	2	48	116	16872	6.060344827586207	0.04696175119275965	1	SCG5,PENK
RUIZ_TNC_TARGETS_DN 	2	48	120	16868	5.856944444444444	0.049846182914100375	1	ZWILCH,RAD54B
KEGG_SPLICEOSOME 	2	48	121	16867	5.808195592286501	0.050577183771976446	1	PPIH,LSM3
JIANG_VHL_TARGETS 	2	48	127	16861	5.531824146981627	0.05504411722712939	1	HSPB11,LSM3
WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_36HR 	2	48	130	16858	5.403205128205128	0.0573283595382447	1	ORC5,FAM26F
KAUFFMANN_DNA_REPLICATION_GENES 	2	48	131	16857	5.361641221374046	0.05809711307175154	1	MSH2,ORC5
BASSO_B_LYMPHOCYTE_NETWORK 	2	48	133	16855	5.280388471177945	0.05964546690234308	1	ORC5,LSM3
FIGUEROA_AML_METHYLATION_CLUSTER_3_UP 	2	48	137	16851	5.125	0.06278481230671885	1	SCG5,BHLHB9
REACTOME_MITOTIC_M_M_G1_PHASES 	2	48	144	16844	4.873842592592593	0.06841106818926448	1	ZWILCH,ORC5
LU_AGING_BRAIN_DN 	2	48	147	16841	4.773526077097506	0.07087209483792842	1	CCKBR,PENK
MUELLER_COMMON_TARGETS_OF_AML_FUSIONS_DN 	1	49	25	16963	13.84734693877551	0.0736178209858481	1	CACNB1
REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX 	1	49	25	16963	13.84734693877551	0.0736178209858481	1	ORC5
FARMER_BREAST_CANCER_CLUSTER_2 	1	49	25	16963	13.84734693877551	0.0736178209858481	1	RAD54B
KANG_GLIS3_TARGETS 	1	49	25	16963	13.84734693877551	0.0736178209858481	1	SCG5
LIANG_SILENCED_BY_METHYLATION_UP 	1	49	25	16963	13.84734693877551	0.0736178209858481	1	SCG5
AMIT_SERUM_RESPONSE_480_MCF10A 	1	49	26	16962	13.31397174254317	0.07634055253044753	1	HSPBP1
BAKKER_FOXO3_TARGETS_DN 	2	48	155	16833	4.525	0.07757417569723118	1	BTBD9,CETN2
VANTVEER_BREAST_CANCER_ESR1_UP 	2	48	155	16833	4.525	0.07757417569723118	1	SPEF1,BTBD9
KEGG_CALCIUM_SIGNALING_PATHWAY 	2	48	159	16829	4.410115303983228	0.08099826885907203	1	CCKBR,PLCD3
JOSEPH_RESPONSE_TO_SODIUM_BUTYRATE_UP 	1	49	28	16960	12.361516034985423	0.08176250934438711	1	CETN2
NEMETH_INFLAMMATORY_RESPONSE_LPS_DN 	1	49	28	16960	12.361516034985423	0.08176250934438711	1	ORC5
REACTOME_NEUROTRANSMITTER_RELEASE_CYCLE 	1	49	28	16960	12.361516034985423	0.08176250934438711	1	RIMS1
GRADE_COLON_VS_RECTAL_CANCER_UP 	1	49	28	16960	12.361516034985423	0.08176250934438711	1	ZWILCH
BENPORATH_NOS_TARGETS 	2	48	161	16827	4.354813664596273	0.08272790296459942	1	COMMD3,RAD54B
VANASSE_BCL2_TARGETS_UP 	1	49	29	16959	11.934553131597466	0.08446177881994678	1	KIAA0753
REACTOME_E2F_MEDIATED_REGULATION_OF_DNA_REPLICATION 	1	49	29	16959	11.934553131597466	0.08446177881994678	1	ORC5
CHESLER_BRAIN_HIGHEST_GENETIC_VARIANCE 	1	49	29	16959	11.934553131597466	0.08446177881994678	1	SCG5
ZHAN_MULTIPLE_MYELOMA_PR_UP 	1	49	29	16959	11.934553131597466	0.08446177881994678	1	ZWILCH
REACTOME_DNA_REPLICATION 	2	48	164	16824	4.274390243902439	0.08534380613093767	1	ZWILCH,ORC5
REACTOME_TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES 	2	48	165	16823	4.248232323232323	0.08622140082333311	1	CACNB1,RIMS1
LEE_LIVER_CANCER 	1	49	30	16958	11.536054421768707	0.08715327170929521	1	CETN2
WONG_IFNA2_RESISTANCE_DN 	1	49	30	16958	11.536054421768707	0.08715327170929521	1	MSH2
REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS 	1	49	30	16958	11.536054421768707	0.08715327170929521	1	ORC5
YOKOE_CANCER_TESTIS_ANTIGENS 	1	49	30	16958	11.536054421768707	0.08715327170929521	1	TDRD9
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_DN 	1	49	31	16957	11.16326530612245	0.08983700995784269	1	CASP7
HAHTOLA_MYCOSIS_FUNGOIDES_SKIN_UP 	2	48	170	16818	4.122058823529412	0.09065053720287031	1	ORC5,PPIH
BIOCARTA_DEATH_PATHWAY 	1	49	32	16956	10.813775510204081	0.09251301545740775	1	CASP7
PID_HIV_NEF_PATHWAY 	1	49	32	16956	10.813775510204081	0.09251301545740775	1	CASP7
JIANG_HYPOXIA_VIA_VHL 	1	49	32	16956	10.813775510204081	0.09251301545740775	1	LSM3
HU_GENOTOXIC_DAMAGE_4HR 	1	49	32	16956	10.813775510204081	0.09251301545740775	1	ORC5
SANSOM_APC_TARGETS 	2	48	173	16815	4.04985549132948	0.0933401293735091	1	ORC5,PLCD3
SHEPARD_CRUSH_AND_BURN_MUTANT_UP 	2	48	175	16813	4.003095238095238	0.09514619531578249	1	PTGES2,FTSJ1
REACTOME_APOPTOTIC_CLEAVAGE_OF_CELLULAR_PROTEINS 	1	49	33	16955	10.485466914038343	0.0951813100320272	1	CASP7
MODY_HIPPOCAMPUS_NEONATAL 	1	49	33	16955	10.485466914038343	0.0951813100320272	1	FASN
LANDIS_ERBB2_BREAST_TUMORS_65_DN 	1	49	33	16955	10.485466914038343	0.0951813100320272	1	PENK
GAUSSMANN_MLL_AF4_FUSION_TARGETS_D_UP 	1	49	33	16955	10.485466914038343	0.0951813100320272	1	RIMS4
REACTOME_SIGNAL_TRANSDUCTION_BY_L1 	1	49	33	16955	10.485466914038343	0.0951813100320272	1	RPS6KA4
KASLER_HDAC7_TARGETS_1_UP 	2	48	176	16812	3.9801136363636362	0.09605306302657989	1	FASN,HSPBP1
LEE_CALORIE_RESTRICTION_MUSCLE_UP 	1	49	34	16954	10.176470588235293	0.09784191544769712	1	FASN
CUI_TCF21_TARGETS_UP 	1	49	34	16954	10.176470588235293	0.09784191544769712	1	PENK
BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_UP 	2	48	178	16810	3.934925093632959	0.097874357936078	1	PSMG4,FAM26F
ZUCCHI_METASTASIS_DN 	1	49	35	16953	9.885131195335276	0.10049485340994842	1	BAP1
REACTOME_TRIGLYCERIDE_BIOSYNTHESIS 	1	49	35	16953	9.885131195335276	0.10049485340994842	1	FASN
RUAN_RESPONSE_TO_TNF_TROGLITAZONE_DN 	1	49	35	16953	9.885131195335276	0.10049485340994842	1	FASN
REACTOME_G2_M_CHECKPOINTS 	1	49	35	16953	9.885131195335276	0.10049485340994842	1	ORC5
BERNARD_PPAPDC1B_TARGETS_UP 	1	49	35	16953	9.885131195335276	0.10049485340994842	1	PENK
TRAYNOR_RETT_SYNDROM_UP 	1	49	35	16953	9.885131195335276	0.10049485340994842	1	PENK
AMIT_EGF_RESPONSE_120_MCF10A 	1	49	35	16953	9.885131195335276	0.10049485340994842	1	RPS6KA4
HARRIS_BRAIN_CANCER_PROGENITORS 	1	49	35	16953	9.885131195335276	0.10049485340994842	1	SCG5
MEISSNER_NPC_HCP_WITH_H3K27ME3 	1	49	36	16952	9.609977324263038	0.10314014557352519	1	CCKBR
WHITFIELD_CELL_CYCLE_LITERATURE 	1	49	36	16952	9.609977324263038	0.10314014557352519	1	MSH2
ZHAN_EARLY_DIFFERENTIATION_GENES_DN 	1	49	36	16952	9.609977324263038	0.10314014557352519	1	MSH2
STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_DN 	1	49	36	16952	9.609977324263038	0.10314014557352519	1	ZWILCH
REACTOME_NCAM1_INTERACTIONS 	1	49	37	16951	9.349696635410922	0.1057778135124553	1	CACNB1
CHOI_ATL_STAGE_PREDICTOR 	1	49	37	16951	9.349696635410922	0.1057778135124553	1	COMMD3
PID_P38_ALPHA_BETA_DOWNSTREAM_PATHWAY 	1	49	37	16951	9.349696635410922	0.1057778135124553	1	RPS6KA4
AMIT_EGF_RESPONSE_480_MCF10A 	1	49	37	16951	9.349696635410922	0.1057778135124553	1	SCG5
PAL_PRMT5_TARGETS_UP 	2	48	188	16800	3.723404255319149	0.10712640238624238	1	CETN2,LSM3
BOYLAN_MULTIPLE_MYELOMA_D_CLUSTER_DN 	1	49	38	16950	9.103114930182599	0.10840787877100065	1	CASP7
BIOCARTA_CHREBP2_PATHWAY 	1	49	38	16950	9.103114930182599	0.10840787877100065	1	FASN
GROSS_HYPOXIA_VIA_ELK3_ONLY_DN 	1	49	38	16950	9.103114930182599	0.10840787877100065	1	FASN
KEGG_ARACHIDONIC_ACID_METABOLISM 	1	49	38	16950	9.103114930182599	0.10840787877100065	1	PTGES2
PID_IFNG_PATHWAY 	1	49	38	16950	9.103114930182599	0.10840787877100065	1	PTGES2
AFFAR_YY1_TARGETS_DN 	2	48	192	16796	3.6449652777777777	0.11089198842141897	1	MSH2,RPS6KA4
AUNG_GASTRIC_CANCER 	1	49	39	16949	8.869178440607012	0.11103036280069895	1	ZWILCH
PID_DELTA_NP63_PATHWAY 	1	49	40	16948	8.646938775510204	0.11364528702161998	1	FASN
ABRAMSON_INTERACT_WITH_AIRE 	1	49	40	16948	8.646938775510204	0.11364528702161998	1	MSH2
CAIRO_HEPATOBLASTOMA_UP 	2	48	197	16791	3.5513959390862944	0.11564807101310542	1	FASN,CETN2
HEIDENBLAD_AMPLICON_8Q24_DN 	1	49	41	16947	8.435540069686411	0.11625267277542085	1	BTBD9
BURTON_ADIPOGENESIS_4 	1	49	41	16947	8.435540069686411	0.11625267277542085	1	LSM3
REACTOME_DEADENYLATION_DEPENDENT_MRNA_DECAY 	1	49	41	16947	8.435540069686411	0.11625267277542085	1	LSM3
KEGG_NUCLEOTIDE_EXCISION_REPAIR 	1	49	42	16946	8.234207968901847	0.11885254135421902	1	CETN2
MCDOWELL_ACUTE_LUNG_INJURY_DN 	1	49	42	16946	8.234207968901847	0.11885254135421902	1	FASN
ZHAN_MULTIPLE_MYELOMA_CD1_UP 	1	49	42	16946	8.234207968901847	0.11885254135421902	1	RGAG4
ROESSLER_LIVER_CANCER_METASTASIS_DN 	1	49	42	16946	8.234207968901847	0.11885254135421902	1	RPS6KA4
MARTORIATI_MDM4_TARGETS_FETAL_LIVER_UP 	2	48	201	16787	3.4798922056384742	0.11949064798507672	1	COMMD3,HSPBP1
XU_GH1_AUTOCRINE_TARGETS_UP 	2	48	202	16786	3.4624587458745872	0.12045636497346653	1	FAM26F,RIMS1
REACTOME_APOPTOTIC_EXECUTION_PHASE 	1	49	43	16945	8.042240151874703	0.12144491398851037	1	CASP7
GUILLAUMOND_KLF10_TARGETS_UP 	1	49	43	16945	8.042240151874703	0.12144491398851037	1	CCKBR
BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_DN 	1	49	43	16945	8.042240151874703	0.12144491398851037	1	FASN
ZHAN_MULTIPLE_MYELOMA_CD2_DN 	1	49	43	16945	8.042240151874703	0.12144491398851037	1	FASN
YAUCH_HEDGEHOG_SIGNALING_PARACRINE_DN 	2	48	204	16784	3.4281045751633985	0.12239374971181882	1	MRAP2,RAD54B
KLEIN_PRIMARY_EFFUSION_LYMPHOMA_UP 	1	49	44	16944	7.85899814471243	0.1240298118523325	1	CASP7
SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN 	1	49	44	16944	7.85899814471243	0.1240298118523325	1	FTSJ1
PID_A6B1_A6B4_INTEGRIN_PATHWAY 	1	49	45	16943	7.68390022675737	0.126607256055931	1	CASP7
GERHOLD_ADIPOGENESIS_UP 	1	49	45	16943	7.68390022675737	0.126607256055931	1	FASN
RICKMAN_HEAD_AND_NECK_CANCER_E 	1	49	45	16943	7.68390022675737	0.126607256055931	1	MRAP2
FIGUEROA_AML_METHYLATION_CLUSTER_2_UP 	1	49	45	16943	7.68390022675737	0.126607256055931	1	SCG5
BENPORATH_MYC_TARGETS_WITH_EBOX 	2	48	209	16779	3.3450956937799043	0.1272710271037507	1	CCKBR,FASN
MARKEY_RB1_ACUTE_LOF_UP 	2	48	209	16779	3.3450956937799043	0.1272710271037507	1	PENK,LSM3
MIDORIKAWA_AMPLIFIED_IN_LIVER_CANCER 	1	49	46	16942	7.516415261756877	0.1291772676603266	1	CACNB1
WUNDER_INFLAMMATORY_RESPONSE_AND_CHOLESTEROL_UP 	1	49	46	16942	7.516415261756877	0.1291772676603266	1	CASP7
YANG_BREAST_CANCER_ESR1_LASER_DN 	1	49	47	16941	7.356057316543639	0.13173986766173706	1	ACOT9
LINDSTEDT_DENDRITIC_CELL_MATURATION_B 	1	49	47	16941	7.356057316543639	0.13173986766173706	1	CASP7
APPIERTO_RESPONSE_TO_FENRETINIDE_DN 	1	49	47	16941	7.356057316543639	0.13173986766173706	1	PPIH
SMIRNOV_RESPONSE_TO_IR_2HR_DN 	1	49	47	16941	7.356057316543639	0.13173986766173706	1	RAD54B
KORKOLA_YOLK_SAC_TUMOR 	1	49	48	16940	7.2023809523809526	0.13429507699846435	1	CCKBR
REACTOME_METABOLISM_OF_VITAMINS_AND_COFACTORS 	1	49	48	16940	7.2023809523809526	0.13429507699846435	1	FASN
HU_GENOTOXIN_ACTION_DIRECT_VS_INDIRECT_24HR 	1	49	48	16940	7.2023809523809526	0.13429507699846435	1	HSPB11
FRASOR_TAMOXIFEN_RESPONSE_UP 	1	49	48	16940	7.2023809523809526	0.13429507699846435	1	MSH2
DOANE_RESPONSE_TO_ANDROGEN_DN 	2	48	217	16771	3.2202380952380953	0.13517024701786534	1	CASP7,RAD54B
PID_CASPASE_PATHWAY 	1	49	49	16939	7.054977092877968	0.1368429165468648	1	CASP7
RADAEVA_RESPONSE_TO_IFNA1_UP 	1	49	49	16939	7.054977092877968	0.1368429165468648	1	CASP7
PUJANA_BREAST_CANCER_WITH_BRCA1_MUTATED_UP 	1	49	49	16939	7.054977092877968	0.1368429165468648	1	MSH2
MAYBURD_RESPONSE_TO_L663536_DN 	1	49	50	16938	6.913469387755102	0.13938340714434264	1	MSH2
MENSSEN_MYC_TARGETS 	1	49	50	16938	6.913469387755102	0.13938340714434264	1	MSH2
LANDIS_ERBB2_BREAST_PRENEOPLASTIC_DN 	1	49	50	16938	6.913469387755102	0.13938340714434264	1	PENK
KEGG_INOSITOL_PHOSPHATE_METABOLISM 	1	49	50	16938	6.913469387755102	0.13938340714434264	1	PLCD3
BROWNE_HCMV_INFECTION_20HR_UP 	2	48	223	16765	3.132473841554559	0.14116696546402102	1	CASP7,BAP1
ASTIER_INTEGRIN_SIGNALING 	1	49	51	16937	6.77751100440176	0.14191656953618076	1	CASP7
HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_UP 	1	49	51	16937	6.77751100440176	0.14191656953618076	1	MSH2
REACTOME_CDT1_ASSOCIATION_WITH_THE_CDC6_ORC_ORIGIN_COMPLEX 	1	49	51	16937	6.77751100440176	0.14191656953618076	1	ORC5
CAFFAREL_RESPONSE_TO_THC_24HR_5_DN 	1	49	51	16937	6.77751100440176	0.14191656953618076	1	PPIH
VANTVEER_BREAST_CANCER_METASTASIS_UP 	1	49	51	16937	6.77751100440176	0.14191656953618076	1	SPEF1
DIRMEIER_LMP1_RESPONSE_LATE_UP 	1	49	52	16936	6.646781789638933	0.1444424244493417	1	FASN
KAUFFMANN_MELANOMA_RELAPSE_UP 	1	49	52	16936	6.646781789638933	0.1444424244493417	1	MSH2
REN_BOUND_BY_E2F 	1	49	52	16936	6.646781789638933	0.1444424244493417	1	MSH2
PID_RAC1_PATHWAY 	1	49	52	16936	6.646781789638933	0.1444424244493417	1	NOXA1
WAKASUGI_HAVE_ZNF143_BINDING_SITES 	1	49	53	16935	6.520985752791683	0.1469609925257543	1	MSH2
HOWLIN_PUBERTAL_MAMMARY_GLAND 	1	49	53	16935	6.520985752791683	0.1469609925257543	1	PENK
MCCLUNG_CREB1_TARGETS_DN 	1	49	53	16935	6.520985752791683	0.1469609925257543	1	PENK
HOLLMANN_APOPTOSIS_VIA_CD40_DN 	2	48	230	16758	3.0358695652173915	0.14823578886688774	1	CASP7,ACOT9
REACTOME_AXON_GUIDANCE 	2	48	231	16757	3.0225468975468974	0.14925168385099352	1	CACNB1,RPS6KA4
REACTOME_LOSS_OF_NLP_FROM_MITOTIC_CENTROSOMES 	1	49	54	16934	6.399848828420257	0.14947229436632328	1	CETN2
DASU_IL6_SIGNALING_UP 	1	49	54	16934	6.399848828420257	0.14947229436632328	1	FASN
KEGG_RNA_DEGRADATION 	1	49	54	16934	6.399848828420257	0.14947229436632328	1	LSM3
BIOCARTA_HIVNEF_PATHWAY 	1	49	55	16933	6.283116883116883	0.15197635049463654	1	CASP7
PEART_HDAC_PROLIFERATION_CLUSTER_UP 	1	49	55	16933	6.283116883116883	0.15197635049463654	1	CETN2
HESS_TARGETS_OF_HOXA9_AND_MEIS1_UP 	1	49	55	16933	6.283116883116883	0.15197635049463654	1	MSH2
RICKMAN_METASTASIS_DN 	2	48	236	16752	2.957627118644068	0.1543527932761414	1	BAP1,RPS6KA4
RIGGINS_TAMOXIFEN_RESISTANCE_UP 	1	49	56	16932	6.170553935860059	0.15447318140117866	1	FASN
CORRE_MULTIPLE_MYELOMA_DN 	1	49	56	16932	6.170553935860059	0.15447318140117866	1	PENK
KEGG_MAPK_SIGNALING_PATHWAY 	2	48	237	16751	2.944971870604782	0.1553772254074131	1	CACNB1,RPS6KA4
DOANE_BREAST_CANCER_CLASSES_UP 	1	49	57	16931	6.061940565699964	0.15696280751748948	1	FASN
POMEROY_MEDULLOBLASTOMA_DESMOPLASIC_VS_CLASSIC_DN 	1	49	57	16931	6.061940565699964	0.15696280751748948	1	SCG5
ONDER_CDH1_TARGETS_2_UP 	2	48	240	16748	2.907638888888889	0.15845864602777357	1	SCG5,RIMS1
FONTAINE_PAPILLARY_THYROID_CARCINOMA_DN 	1	49	58	16930	5.95707248416608	0.15944524918321695	1	BAP1
HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_DN 	1	49	58	16930	5.95707248416608	0.15944524918321695	1	HSPBP1
CASTELLANO_NRAS_TARGETS_UP 	1	49	58	16930	5.95707248416608	0.15944524918321695	1	PENK
FORTSCHEGGER_PHF8_TARGETS_UP 	2	48	243	16745	2.871227709190672	0.1615519123821142	1	RIMS4,PTGES2
KYNG_DNA_DAMAGE_BY_4NQO_OR_UV 	1	49	59	16929	5.855759252853684	0.16192052673269625	1	BAP1
BOYLAN_MULTIPLE_MYELOMA_PCA3_DN 	1	49	59	16929	5.855759252853684	0.16192052673269625	1	CASP7
REACTOME_ASSEMBLY_OF_THE_PRE_REPLICATIVE_COMPLEX 	1	49	59	16929	5.855759252853684	0.16192052673269625	1	ORC5
RAMASWAMY_METASTASIS_UP 	1	49	60	16928	5.757823129251701	0.16438866042011696	1	FASN
PID_AP1_PATHWAY 	1	49	60	16928	5.757823129251701	0.16438866042011696	1	PENK
REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH 	1	49	61	16927	5.6630980260956845	0.16684967042925747	1	CACNB1
REACTOME_RECRUITMENT_OF_MITOTIC_CENTROSOME_PROTEINS_AND_COMPLEXES 	1	49	61	16927	5.6630980260956845	0.16684967042925747	1	CETN2
KEGG_COLORECTAL_CANCER 	1	49	61	16927	5.6630980260956845	0.16684967042925747	1	MSH2
ZHAN_MULTIPLE_MYELOMA_CD1_VS_CD2_UP 	1	49	61	16927	5.6630980260956845	0.16684967042925747	1	RGAG4
REACTOME_NEURONAL_SYSTEM 	2	48	249	16739	2.801037483266399	0.16777225863196973	1	CACNB1,RIMS1
FONTAINE_FOLLICULAR_THYROID_ADENOMA_DN 	1	49	62	16926	5.571428571428571	0.1693035769124649	1	BAP1
BYSTROEM_CORRELATED_WITH_IL5_DN 	1	49	62	16926	5.571428571428571	0.1693035769124649	1	CASP7
ZHONG_RESPONSE_TO_AZACITIDINE_AND_TSA_DN 	1	49	62	16926	5.571428571428571	0.1693035769124649	1	HSPBP1
REACTOME_ORC1_REMOVAL_FROM_CHROMATIN 	1	49	62	16926	5.571428571428571	0.1693035769124649	1	ORC5
MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_UP 	1	49	62	16926	5.571428571428571	0.1693035769124649	1	SCG5
NATSUME_RESPONSE_TO_INTERFERON_BETA_UP 	1	49	63	16925	5.482669258179462	0.17175039995726432	1	CASP7
MORI_PRE_BI_LYMPHOCYTE_UP 	1	49	64	16924	5.396683673469388	0.1741901595919495	1	HSPBP1
DELPUECH_FOXO3_TARGETS_UP 	1	49	65	16923	5.313343799058085	0.17662287579642377	1	HSPB11
HOFFMANN_PRE_BI_TO_LARGE_PRE_BII_LYMPHOCYTE_DN 	1	49	65	16923	5.313343799058085	0.17662287579642377	1	HSPBP1
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP 	1	49	65	16923	5.313343799058085	0.17662287579642377	1	SCG5
MANALO_HYPOXIA_DN 	2	48	259	16729	2.6912805662805663	0.17823182214415006	1	ZWILCH,FASN
PID_E2F_PATHWAY 	1	49	66	16922	5.232529375386518	0.17904856847337683	1	CASP7
LANDIS_BREAST_CANCER_PROGRESSION_DN 	1	49	66	16922	5.232529375386518	0.17904856847337683	1	PENK
MARTINEZ_RESPONSE_TO_TRABECTEDIN_UP 	1	49	66	16922	5.232529375386518	0.17904856847337683	1	SCG5
BOYLAN_MULTIPLE_MYELOMA_D_DN 	1	49	67	16921	5.15412732257082	0.18146725750573472	1	CASP7
CHESLER_BRAIN_QTL_CIS 	1	49	67	16921	5.15412732257082	0.18146725750573472	1	SCG5
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5 	1	49	68	16920	5.078031212484994	0.1838789627039638	1	CCKBR
JI_RESPONSE_TO_FSH_UP 	1	49	68	16920	5.078031212484994	0.1838789627039638	1	FASN
TAYLOR_METHYLATED_IN_ACUTE_LYMPHOBLASTIC_LEUKEMIA 	1	49	68	16920	5.078031212484994	0.1838789627039638	1	MRAP2
BENPORATH_OCT4_TARGETS 	2	48	266	16722	2.619360902255639	0.18561532167090355	1	COMMD3,RAD54B
BOYLAN_MULTIPLE_MYELOMA_PCA3_UP 	1	49	69	16919	5.004140786749482	0.18628370380509798	1	BHLHB9
KEGG_CARDIAC_MUSCLE_CONTRACTION 	1	49	69	16919	5.004140786749482	0.18628370380509798	1	CACNB1
MILI_PSEUDOPODIA_CHEMOTAXIS_UP 	1	49	69	16919	5.004140786749482	0.18628370380509798	1	HSPB11
GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN 	1	49	69	16919	5.004140786749482	0.18628370380509798	1	MSH2
LEE_CALORIE_RESTRICTION_NEOCORTEX_UP 	1	49	69	16919	5.004140786749482	0.18628370380509798	1	MSH2
WEST_ADRENOCORTICAL_TUMOR_UP 	2	48	268	16720	2.599502487562189	0.18773341135678767	1	ZWILCH,RNF34
SESTO_RESPONSE_TO_UV_C8 	1	49	70	16918	4.932361516034986	0.18868150053209573	1	FASN
BILANGES_RAPAMYCIN_SENSITIVE_VIA_TSC1_AND_TSC2 	1	49	70	16918	4.932361516034986	0.18868150053209573	1	HSPB11
JAIN_NFKB_SIGNALING 	1	49	70	16918	4.932361516034986	0.18868150053209573	1	ORC5
REACTOME_MITOTIC_PROMETAPHASE 	1	49	70	16918	4.932361516034986	0.18868150053209573	1	ZWILCH
KEGG_ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDIOMYOPATHY_ARVC 	1	49	71	16917	4.8626041966082205	0.1910723725169193	1	CACNB1
REACTOME_M_G1_TRANSITION 	1	49	71	16917	4.8626041966082205	0.1910723725169193	1	ORC5
QUINTENS_EMBRYONIC_BRAIN_RESPONSE_TO_IR 	1	49	72	16916	4.794784580498866	0.1934563393573078	1	C2orf80
HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_2NM_UP 	1	49	72	16916	4.794784580498866	0.1934563393573078	1	CASP7
PID_P73PATHWAY 	1	49	72	16916	4.794784580498866	0.1934563393573078	1	FASN
HADDAD_T_LYMPHOCYTE_AND_NK_PROGENITOR_UP 	1	49	72	16916	4.794784580498866	0.1934563393573078	1	MSH2
KEGG_PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM 	1	49	72	16916	4.794784580498866	0.1934563393573078	1	PLCD3
DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_DN 	2	48	275	16713	2.5322727272727272	0.19517417193855496	1	IFT27,FTSJ1
REACTOME_MITOTIC_G2_G2_M_PHASES 	1	49	74	16914	4.6646442360728075	0.19820363568426058	1	CETN2
MCCLUNG_COCAINE_REWARD_5D 	1	49	74	16914	4.6646442360728075	0.19820363568426058	1	PENK
CROMER_METASTASIS_UP 	1	49	74	16914	4.6646442360728075	0.19820363568426058	1	PPIH
VANLOO_SP3_TARGETS_DN 	1	49	74	16914	4.6646442360728075	0.19820363568426058	1	RPS6KA4
MUELLER_PLURINET 	2	48	279	16709	2.4953703703703702	0.19944389462751022	1	MSH2,LSM3
MOREAUX_B_LYMPHOCYTE_MATURATION_BY_TACI_UP 	1	49	75	16913	4.602176870748299	0.20056700407846437	1	NOXA1
ONDER_CDH1_SIGNALING_VIA_CTNNB1 	1	49	75	16913	4.602176870748299	0.20056700407846437	1	SCG5
RUAN_RESPONSE_TO_TNF_DN 	1	49	76	16912	4.541353383458647	0.20292354516510736	1	FASN
SCHUHMACHER_MYC_TARGETS_UP 	1	49	76	16912	4.541353383458647	0.20292354516510736	1	FASN
ACEVEDO_LIVER_CANCER_WITH_H3K9ME3_DN 	1	49	76	16912	4.541353383458647	0.20292354516510736	1	SCG5
STEIN_ESR1_TARGETS 	1	49	77	16911	4.482109727007686	0.2052732782386582	1	ZWILCH
ZHANG_TLX_TARGETS_DN 	1	49	77	16911	4.482109727007686	0.2052732782386582	1	ZWILCH
KEGG_HYPERTROPHIC_CARDIOMYOPATHY_HCM 	1	49	79	16909	4.368121932317231	0.20995239740613317	1	CACNB1
BOSCO_TH1_CYTOTOXIC_MODULE 	1	49	79	16909	4.368121932317231	0.20995239740613317	1	FAM26F
KEGG_APOPTOSIS 	1	49	80	16908	4.313265306122449	0.2122818218783979	1	CASP7
LABBE_WNT3A_TARGETS_DN 	1	49	80	16908	4.313265306122449	0.2122818218783979	1	CASP7
IGARASHI_ATF4_TARGETS_DN 	1	49	80	16908	4.313265306122449	0.2122818218783979	1	HSPB11
REACTOME_L1CAM_INTERACTIONS 	1	49	80	16908	4.313265306122449	0.2122818218783979	1	RPS6KA4
LEE_TARGETS_OF_PTCH1_AND_SUFU_DN 	1	49	81	16907	4.2597631645250695	0.21460451509492315	1	PENK
BURTON_ADIPOGENESIS_8 	1	49	81	16907	4.2597631645250695	0.21460451509492315	1	RPS6KA4
KYNG_WERNER_SYNDROM_AND_NORMAL_AGING_UP 	1	49	82	16906	4.207565953210553	0.21692049612000333	1	RPS6KA4
SEIDEN_ONCOGENESIS_BY_MET 	1	49	83	16905	4.156626506024097	0.21922978394984888	1	COMMD3
RICKMAN_HEAD_AND_NECK_CANCER_A 	1	49	83	16905	4.156626506024097	0.21922978394984888	1	PENK
LI_DCP2_BOUND_MRNA 	1	49	84	16904	4.10689990281827	0.22153239753647663	1	LSM3
ALCALA_APOPTOSIS 	1	49	84	16904	4.10689990281827	0.22153239753647663	1	MSH2
ROVERSI_GLIOMA_COPY_NUMBER_UP 	1	49	84	16904	4.10689990281827	0.22153239753647663	1	ORC5
GAVIN_FOXP3_TARGETS_CLUSTER_P4 	1	49	84	16904	4.10689990281827	0.22153239753647663	1	PENK
BIOCARTA_MAPK_PATHWAY 	1	49	85	16903	4.058343337334934	0.22382835578210097	1	RPS6KA4
KEGG_DILATED_CARDIOMYOPATHY 	1	49	86	16902	4.010915994304699	0.22611767753041837	1	CACNB1
REACTOME_SYNTHESIS_OF_DNA 	1	49	86	16902	4.010915994304699	0.22611767753041837	1	ORC5
LABBE_TGFB1_TARGETS_UP 	1	49	87	16901	3.964578935022285	0.22840038157048648	1	ACOT9
WINZEN_DEGRADED_VIA_KHSRP 	1	49	87	16901	3.964578935022285	0.22840038157048648	1	SCG5
NIELSEN_GIST 	1	49	91	16897	3.7894146669656874	0.23746539466235841	1	CETN2
KIM_MYCN_AMPLIFICATION_TARGETS_DN 	1	49	91	16897	3.7894146669656874	0.23746539466235841	1	KIAA0753
ZHU_CMV_24_HR_UP 	1	49	92	16896	3.748003549245785	0.23971529023193455	1	PENK
NIKOLSKY_BREAST_CANCER_17Q11_Q21_AMPLICON 	1	49	93	16895	3.707482993197279	0.24195867975297222	1	CACNB1
HUMMERICH_SKIN_CANCER_PROGRESSION_DN 	1	49	94	16894	3.667824576639166	0.2441955816697064	1	FASN
NAKAMURA_ADIPOGENESIS_LATE_UP 	1	49	95	16893	3.629001074113856	0.24642601435271275	1	FASN
HOSHIDA_LIVER_CANCER_SURVIVAL_DN 	1	49	96	16892	3.5909863945578233	0.2486499961273706	1	SCG5
BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_UP 	1	49	98	16890	3.517284464806331	0.25307868003979617	1	FAM26F
LABBE_TARGETS_OF_TGFB1_AND_WNT3A_UP 	1	49	99	16889	3.48155019583591	0.25528341856311826	1	ACOT9
CERVERA_SDHB_TARGETS_2 	1	49	99	16889	3.48155019583591	0.25528341856311826	1	SCG5
REACTOME_G1_S_TRANSITION 	1	49	100	16888	3.446530612244898	0.257481779003665	1	ORC5
TSENG_IRS1_TARGETS_UP 	1	49	100	16888	3.446530612244898	0.257481779003665	1	PPIH
REACTOME_INTEGRATION_OF_ENERGY_METABOLISM 	1	49	101	16887	3.412204485754698	0.25967377942396164	1	FASN
SENESE_HDAC2_TARGETS_UP 	1	49	101	16887	3.412204485754698	0.25967377942396164	1	SCG5
REACTOME_S_PHASE 	1	49	102	16886	3.378551420568227	0.2618594378400362	1	ORC5
WOOD_EBV_EBNA1_TARGETS_UP 	1	49	103	16885	3.345551812958193	0.264038772242544	1	FASN
REACTOME_CELL_CYCLE_CHECKPOINTS 	1	49	103	16885	3.345551812958193	0.264038772242544	1	ORC5
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_CIS 	1	49	103	16885	3.345551812958193	0.264038772242544	1	PSMG4
HOOI_ST7_TARGETS_DN 	1	49	103	16885	3.345551812958193	0.264038772242544	1	PSMG4
PID_ERBB1_DOWNSTREAM_PATHWAY 	1	49	103	16885	3.345551812958193	0.264038772242544	1	RPS6KA4
SMID_BREAST_CANCER_ERBB2_UP 	1	49	105	16883	3.281438289601555	0.26837854065065236	1	FASN
MARKEY_RB1_CHRONIC_LOF_UP 	1	49	105	16883	3.281438289601555	0.26837854065065236	1	MSH2
ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER 	1	49	106	16882	3.2502887947631884	0.270539010343743	1	HSPB11
MCBRYAN_PUBERTAL_BREAST_5_6WK_UP 	1	49	106	16882	3.2502887947631884	0.270539010343743	1	PENK
MISSIAGLIA_REGULATED_BY_METHYLATION_DN 	1	49	107	16881	3.2197215334732023	0.27269322743748037	1	FASN
PUJANA_BRCA_CENTERED_NETWORK 	1	49	108	16880	3.1897203325774752	0.27484120962739084	1	MSH2
NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON 	1	49	108	16880	3.1897203325774752	0.27484120962739084	1	RAD54B
KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_UP 	1	49	110	16878	3.1313543599257887	0.27911854002106506	1	CASP7
INGRAM_SHH_TARGETS_UP 	1	49	111	16877	3.102960102960103	0.2812479234293733	1	PENK
SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP 	1	49	111	16877	3.102960102960103	0.2812479234293733	1	PENK
AZARE_NEOPLASTIC_TRANSFORMATION_BY_STAT3_UP 	1	49	111	16877	3.102960102960103	0.2812479234293733	1	SCG5
KEGG_CELL_CYCLE 	1	49	114	16874	3.020766201217329	0.287599156730137	1	ORC5
YAGI_AML_SURVIVAL 	1	49	114	16874	3.020766201217329	0.287599156730137	1	ORC5
YAGI_AML_WITH_T_9_11_TRANSLOCATION 	1	49	115	16873	2.994321206743567	0.28970398698430117	1	PENK
BURTON_ADIPOGENESIS_5 	1	49	115	16873	2.994321206743567	0.28970398698430117	1	PTGES2
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP 	1	49	115	16873	2.994321206743567	0.28970398698430117	1	RAD54B
ZHU_CMV_ALL_UP 	1	49	117	16871	2.9427873713587998	0.2938953802584371	1	PENK
DARWICHE_SKIN_TUMOR_PROMOTER_UP 	1	49	117	16871	2.9427873713587998	0.2938953802584371	1	RPS6KA4
KEGG_NEUROTROPHIN_SIGNALING_PATHWAY 	1	49	120	16868	2.868707482993197	0.3001370608278435	1	RPS6KA4
KOKKINAKIS_METHIONINE_DEPRIVATION_48HR_UP 	1	49	121	16867	2.8448304941811435	0.3022055804864593	1	CASP7
WHITFIELD_CELL_CYCLE_G1_S 	1	49	121	16867	2.8448304941811435	0.3022055804864593	1	MSH2
DARWICHE_PAPILLOMA_RISK_HIGH_UP 	1	49	121	16867	2.8448304941811435	0.3022055804864593	1	RPS6KA4
DARWICHE_SQUAMOUS_CELL_CARCINOMA_UP 	1	49	121	16867	2.8448304941811435	0.3022055804864593	1	RPS6KA4
REACTOME_MITOTIC_G1_G1_S_PHASES 	1	49	122	16866	2.821344931415189	0.3042681083255468	1	ORC5
CHUNG_BLISTER_CYTOTOXICITY_UP 	1	49	122	16866	2.821344931415189	0.3042681083255468	1	ZWILCH
BENPORATH_PROLIFERATION 	1	49	124	16864	2.7755102040816326	0.30837525654038767	1	MSH2
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_UP 	1	49	124	16864	2.7755102040816326	0.30837525654038767	1	TDRD9
PID_P53_DOWNSTREAM_PATHWAY 	1	49	125	16863	2.753142857142857	0.31041991078100134	1	MSH2
REACTOME_G_ALPHA_I_SIGNALLING_EVENTS 	1	49	125	16863	2.753142857142857	0.31041991078100134	1	PENK
JOHNSTONE_PARVB_TARGETS_2_UP 	1	49	126	16862	2.731130547457078	0.3124586409491597	1	FASN
KEGG_INSULIN_SIGNALING_PATHWAY 	1	49	126	16862	2.731130547457078	0.3124586409491597	1	FASN
REACTOME_G_ALPHA_Q_SIGNALLING_EVENTS 	1	49	130	16858	2.646467817896389	0.3205546563730923	1	CCKBR
DARWICHE_PAPILLOMA_RISK_LOW_UP 	1	49	130	16858	2.646467817896389	0.3205546563730923	1	RPS6KA4
REACTOME_APOPTOSIS 	1	49	131	16857	2.6261099859791246	0.32256401740895885	1	CASP7
RAO_BOUND_BY_SALL4_ISOFORM_A 	1	49	132	16856	2.606060606060606	0.3245675545728784	1	COMMD3
IVANOVA_HEMATOPOIESIS_INTERMEDIATE_PROGENITOR 	1	49	135	16853	2.547694633408919	0.33054338783074727	1	CASP7
PUIFFE_INVASION_INHIBITED_BY_ASCITES_DN 	1	49	136	16852	2.528811524609844	0.3325237943270149	1	CETN2
WELCSH_BRCA1_TARGETS_DN 	1	49	136	16852	2.528811524609844	0.3325237943270149	1	FASN
ELVIDGE_HYPOXIA_DN 	1	49	136	16852	2.528811524609844	0.3325237943270149	1	ZWILCH
TSAI_RESPONSE_TO_IONIZING_RADIATION 	1	49	137	16851	2.510204081632653	0.33449845913979837	1	MSH2
LANDIS_ERBB2_BREAST_TUMORS_324_DN 	1	49	137	16851	2.510204081632653	0.33449845913979837	1	PENK
MIKKELSEN_MEF_ICP_WITH_H3K27ME3 	1	49	138	16850	2.491866311742088	0.336467398621679	1	NOXA1
NING_CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE_UP 	1	49	140	16848	2.45597667638484	0.34038816648674974	1	FASN
IWANAGA_CARCINOGENESIS_BY_KRAS_UP 	1	49	143	16845	2.40402454688169	0.3462267831707394	1	COMMD3
GROSS_HYPOXIA_VIA_ELK3_DN 	1	49	143	16845	2.40402454688169	0.3462267831707394	1	RAD54B
MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_DN 	1	49	143	16845	2.40402454688169	0.3462267831707394	1	SCG5
MOHANKUMAR_TLX1_TARGETS_DN 	1	49	144	16844	2.38718820861678	0.34816171042217037	1	FAM26F
LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_DN 	1	49	144	16844	2.38718820861678	0.34816171042217037	1	MSH2
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP 	1	49	144	16844	2.38718820861678	0.34816171042217037	1	SCG5
DURAND_STROMA_NS_UP 	1	49	146	16842	2.3542074363992174	0.35201474343731487	1	RCOR2
GARCIA_TARGETS_OF_FLI1_AND_DAX1_DN 	1	49	149	16839	2.3063963840569786	0.35775247791512044	1	ZWILCH
KEGG_ALZHEIMERS_DISEASE 	1	49	150	16838	2.2908843537414967	0.3596539686745738	1	CASP7
REACTOME_GASTRIN_CREB_SIGNALLING_PATHWAY_VIA_PKC_AND_MAPK 	1	49	150	16838	2.2908843537414967	0.3596539686745738	1	CCKBR
PUJANA_XPRSS_INT_NETWORK 	1	49	150	16838	2.2908843537414967	0.3596539686745738	1	MSH2
DOANE_RESPONSE_TO_ANDROGEN_UP 	1	49	151	16837	2.2755777807811866	0.36154994199948187	1	FASN
UEDA_PERIFERAL_CLOCK 	1	49	152	16836	2.26047261009667	0.3634404135554891	1	FASN
HEDENFALK_BREAST_CANCER_BRCA1_VS_BRCA2 	1	49	152	16836	2.26047261009667	0.3634404135554891	1	MSH2
SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_UP 	1	49	152	16836	2.26047261009667	0.3634404135554891	1	MSH2
MOREAUX_MULTIPLE_MYELOMA_BY_TACI_DN 	1	49	153	16835	2.245564892623716	0.36532539900867467	1	ORC5
TIEN_INTESTINE_PROBIOTICS_6HR_DN 	1	49	153	16835	2.245564892623716	0.36532539900867467	1	RNF34
VERHAAK_GLIOBLASTOMA_CLASSICAL 	1	49	154	16834	2.2308507818711902	0.36720491393659566	1	HSPBP1
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP 	1	49	154	16834	2.2308507818711902	0.36720491393659566	1	TDRD9
HAMAI_APOPTOSIS_VIA_TRAIL_DN 	1	49	155	16833	2.216326530612245	0.3690789738950583	1	CCKBR
PENG_GLUCOSE_DEPRIVATION_DN 	1	49	155	16833	2.216326530612245	0.3690789738950583	1	MSH2
FIRESTEIN_PROLIFERATION 	1	49	155	16833	2.216326530612245	0.3690789738950583	1	RPS6KA4
MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_UP 	1	49	156	16832	2.2019884877027733	0.3709475943956296	1	COMMD3
PEDRIOLI_MIR31_TARGETS_UP 	1	49	156	16832	2.2019884877027733	0.3709475943956296	1	FASN
REACTOME_FATTY_ACID_TRIACYLGLYCEROL_AND_KETONE_BODY_METABOLISM 	1	49	156	16832	2.2019884877027733	0.3709475943956296	1	FASN
PURBEY_TARGETS_OF_CTBP1_AND_SATB1_DN 	1	49	158	16830	2.1738568845259625	0.37466857885422467	1	LSM3
BLALOCK_ALZHEIMERS_DISEASE_INCIPIENT_DN 	1	49	159	16829	2.160056475420357	0.3765209736277151	1	ORC5
LEE_LIVER_CANCER_SURVIVAL_DN 	1	49	160	16828	2.1464285714285714	0.3783679905256621	1	ZWILCH
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_TRANS 	1	49	162	16826	2.1196775006298814	0.38204595191485446	1	CETN2
MIKKELSEN_MEF_HCP_WITH_H3_UNMETHYLATED 	1	49	162	16826	2.1196775006298814	0.38204595191485446	1	SCG5
FERNANDEZ_BOUND_BY_MYC 	1	49	164	16824	2.093578894972623	0.3857025849043719	1	CCKBR
BROWNE_HCMV_INFECTION_48HR_UP 	1	49	165	16823	2.0807668521954237	0.3875229411415271	1	MSH2
JISON_SICKLE_CELL_DISEASE_DN 	1	49	165	16823	2.0807668521954237	0.3875229411415271	1	MSH2
BURTON_ADIPOGENESIS_6 	1	49	168	16820	2.043245869776482	0.39295234967983983	1	FASN
SHEPARD_BMYB_MORPHOLINO_DN 	1	49	168	16820	2.043245869776482	0.39295234967983983	1	MSH2
FOSTER_KDM1A_TARGETS_UP 	1	49	169	16819	2.0310348991667673	0.3947516491303459	1	RIMS1
JISON_SICKLE_CELL_DISEASE_UP 	1	49	170	16818	2.018967587034814	0.3965457217772128	1	CASP7
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_17 	1	49	170	16818	2.018967587034814	0.3965457217772128	1	RPS6KA4
ZHANG_TLX_TARGETS_36HR_DN 	1	49	170	16818	2.018967587034814	0.3965457217772128	1	ZWILCH
SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A4 	1	49	174	16814	1.9720853858784892	0.4036700412671805	1	CACNB1
FISCHER_G1_S_CELL_CYCLE 	1	49	174	16814	1.9720853858784892	0.4036700412671805	1	MSH2
BOYAULT_LIVER_CANCER_SUBCLASS_G3_UP 	1	49	175	16813	1.9606997084548106	0.4054382022029765	1	ZWILCH
MCBRYAN_PUBERTAL_BREAST_4_5WK_DN 	1	49	177	16811	1.9383143087743573	0.40895912420738023	1	PTGES2
EBAUER_TARGETS_OF_PAX3_FOXO1_FUSION_UP 	1	49	178	16810	1.9273102499426737	0.4107119144568258	1	CACNB1
PENG_LEUCINE_DEPRIVATION_DN 	1	49	179	16809	1.9164291414889978	0.4124596102936619	1	FASN
CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN 	1	49	179	16809	1.9164291414889978	0.4124596102936619	1	MSH2
RIZKI_TUMOR_INVASIVENESS_3D_UP 	1	49	180	16808	1.9056689342403628	0.4142022262485156	1	FTSJ1
FUJII_YBX1_TARGETS_DN 	1	49	180	16808	1.9056689342403628	0.4142022262485156	1	RAD54B
GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP 	1	49	182	16806	1.8845032518501905	0.4176722762039906	1	CASP7
HOLLMANN_APOPTOSIS_VIA_CD40_UP 	1	49	182	16806	1.8845032518501905	0.4176722762039906	1	HSPBP1
GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN 	1	49	183	16805	1.874093899855024	0.4193997390504787	1	PENK
LINSLEY_MIR16_TARGETS 	1	49	185	16803	1.8536127964699394	0.42283961215631083	1	CASP7
REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION 	1	49	185	16803	1.8536127964699394	0.42283961215631083	1	RNF34
ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP 	1	49	186	16802	1.8435374149659864	0.424552051009489	1	RGAG4
GROSS_HYPOXIA_VIA_ELK3_UP 	1	49	187	16801	1.833569791552985	0.4262595103571807	1	FASN
AFFAR_YY1_TARGETS_UP 	1	49	188	16800	1.8237082066869301	0.42796200438957094	1	CASP7
SHEPARD_BMYB_MORPHOLINO_UP 	1	49	188	16800	1.8237082066869301	0.42796200438957094	1	PTGES2
FOSTER_KDM1A_TARGETS_DN 	1	49	188	16800	1.8237082066869301	0.42796200438957094	1	RPS6KA4
BHAT_ESR1_TARGETS_NOT_VIA_AKT1_UP 	1	49	191	16797	1.7947430281012928	0.4330398358703027	1	RIMS4
BROWNE_HCMV_INFECTION_1HR_DN 	1	49	192	16796	1.7852891156462585	0.4347226097301547	1	PPIH
MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN 	1	49	193	16795	1.7759331711959394	0.43640048857921593	1	SCG5
LEE_RECENT_THYMIC_EMIGRANT 	1	49	194	16794	1.7666736797811908	0.43807348642775173	1	FAM26F
KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION 	1	49	195	16793	1.7575091575091575	0.4397416171466941	1	CCKBR
KIM_WT1_TARGETS_12HR_DN 	1	49	195	16793	1.7575091575091575	0.4397416171466941	1	SCG5
RAMALHO_STEMNESS_UP 	1	49	196	16792	1.7484381507705122	0.4414048946090426	1	MSH2
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1 	1	49	197	16791	1.739459235470838	0.4430633326585206	1	ACOT9
SENESE_HDAC1_AND_HDAC2_TARGETS_DN 	1	49	201	16787	1.7044369986800691	0.4496489660339582	1	PRRT3
OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_UP 	1	49	201	16787	1.7044369986800691	0.4496489660339582	1	ZWILCH
KAYO_AGING_MUSCLE_UP 	1	49	202	16786	1.695898161244696	0.4512834131646759	1	PENK
SENESE_HDAC1_AND_HDAC2_TARGETS_UP 	1	49	202	16786	1.695898161244696	0.4512834131646759	1	SCG5
CHEN_HOXA5_TARGETS_9HR_UP 	1	49	203	16785	1.6874434502865185	0.45291310304466587	1	SCG5
VANOEVELEN_MYOGENESIS_SIN3A_TARGETS 	1	49	203	16785	1.6874434502865185	0.45291310304466587	1	ZWILCH
MARKEY_RB1_ACUTE_LOF_DN 	1	49	204	16784	1.6790716286514606	0.4545380492728666	1	RNF34
KYNG_WERNER_SYNDROM_AND_NORMAL_AGING_DN 	1	49	205	16783	1.6707814833250374	0.4561582653630819	1	BAP1
REACTOME_METABOLISM_OF_MRNA 	1	49	205	16783	1.6707814833250374	0.4561582653630819	1	LSM3
KYNG_DNA_DAMAGE_UP 	1	49	206	16782	1.6625718248464434	0.4577737648147352	1	BAP1
DAZARD_RESPONSE_TO_UV_NHEK_UP 	1	49	206	16782	1.6625718248464434	0.4577737648147352	1	SCG5
BROWNE_HCMV_INFECTION_16HR_UP 	1	49	213	16775	1.607262623359203	0.46895132005819484	1	BAP1
ZHANG_TLX_TARGETS_36HR_UP 	1	49	213	16775	1.607262623359203	0.46895132005819484	1	SPEF1
DELYS_THYROID_CANCER_DN 	1	49	214	16774	1.5996566851039482	0.47052956744621754	1	HSPB11
AGUIRRE_PANCREATIC_CANCER_COPY_NUMBER_DN 	1	49	214	16774	1.5996566851039482	0.47052956744621754	1	LSM3
CHICAS_RB1_TARGETS_GROWING 	1	49	214	16774	1.5996566851039482	0.47052956744621754	1	MSH2
KUMAR_PATHOGEN_LOAD_BY_MACROPHAGES 	1	49	219	16769	1.5626689031777095	0.4783521122400122	1	IFT27
REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION 	1	49	220	16768	1.5554730983302412	0.4799029740731513	1	RNF34
IVANOVA_HEMATOPOIESIS_STEM_CELL 	1	49	222	16766	1.5412759698473983	0.4829911543201791	1	RPS6KA4
PLASARI_TGFB1_TARGETS_10HR_DN 	1	49	226	16762	1.5136355427126602	0.4891137010322832	1	ZWILCH
SENESE_HDAC1_TARGETS_DN 	1	49	228	16760	1.5001790189760114	0.49214827184173743	1	MDP1
CONCANNON_APOPTOSIS_BY_EPOXOMICIN_UP 	1	49	229	16759	1.4935389002762678	0.4936589260294738	1	CASP7
QI_PLASMACYTOMA_UP 	1	49	229	16759	1.4935389002762678	0.4936589260294738	1	CASP7
PENG_RAPAMYCIN_RESPONSE_DN 	1	49	229	16759	1.4935389002762678	0.4936589260294738	1	FASN
MITSIADES_RESPONSE_TO_APLIDIN_DN 	1	49	229	16759	1.4935389002762678	0.4936589260294738	1	MSH2
BROWNE_HCMV_INFECTION_4HR_DN 	1	49	233	16755	1.467548392747657	0.49965762865350394	1	PPIH
RIZKI_TUMOR_INVASIVENESS_3D_DN 	1	49	234	16754	1.461189604046747	0.5011463883795122	1	FASN
MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_UP 	1	49	235	16753	1.4548849326964828	0.5026308066944083	1	PLCD3
ZHOU_INFLAMMATORY_RESPONSE_FIMA_DN 	1	49	237	16751	1.4424352019288729	0.5055866685137272	1	ORC5
WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP 	1	49	241	16747	1.4181556440003387	0.5114468383010872	1	MRAP2
KOYAMA_SEMA3B_TARGETS_UP 	1	49	241	16747	1.4181556440003387	0.5114468383010872	1	RGAG4
ZHANG_TLX_TARGETS_60HR_DN 	1	49	241	16747	1.4181556440003387	0.5114468383010872	1	ZWILCH
BASAKI_YBX1_TARGETS_UP 	1	49	245	16743	1.3946688879633486	0.5172389218531557	1	ZWILCH
LU_EZH2_TARGETS_UP 	1	49	247	16741	1.3832107741882178	0.5201096738529969	1	CASP7
NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_UP 	1	49	249	16739	1.371936726497828	0.5229636942563369	1	ACOT9
FOURNIER_ACINAR_DEVELOPMENT_LATE_2 	1	49	253	16735	1.349923368556909	0.528621921984328	1	ACOT9
BHAT_ESR1_TARGETS_VIA_AKT1_UP 	1	49	255	16733	1.3391756702681072	0.5314263187673464	1	RIMS4
MARTINEZ_RESPONSE_TO_TRABECTEDIN_DN 	1	49	258	16730	1.3233665559246954	0.5356022819712178	1	RAD54B
ENK_UV_RESPONSE_EPIDERMIS_UP 	1	49	261	16727	1.3079208694972242	0.5397417665120807	1	PPIH
GABRIELY_MIR21_TARGETS 	1	49	273	16715	1.2495327801450251	0.5559411230919954	1	MSH2
ZHANG_TLX_TARGETS_60HR_UP 	1	49	280	16708	1.2177842565597667	0.5651313021327603	1	ACOT9
ABBUD_LIF_SIGNALING_1_UP 	0	50	37	16951	0.0	1.0	1	
ABE_INNER_EAR 	0	50	43	16945	0.0	1.0	1	
ABE_VEGFA_TARGETS_2HR 	0	50	28	16960	0.0	1.0	1	
ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_UP 	0	50	234	16754	0.0	1.0	1	
ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN 	0	50	144	16844	0.0	1.0	1	
ACEVEDO_LIVER_CANCER_WITH_H3K9ME3_UP 	0	50	80	16908	0.0	1.0	1	
ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN 	0	50	229	16759	0.0	1.0	1	
ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_UP 	0	50	145	16843	0.0	1.0	1	
ACOSTA_PROLIFERATION_INDEPENDENT_MYC_TARGETS_DN 	0	50	104	16884	0.0	1.0	1	
ACOSTA_PROLIFERATION_INDEPENDENT_MYC_TARGETS_UP 	0	50	75	16913	0.0	1.0	1	
ADDYA_ERYTHROID_DIFFERENTIATION_BY_HEMIN 	0	50	67	16921	0.0	1.0	1	
AGUIRRE_PANCREATIC_CANCER_COPY_NUMBER_UP 	0	50	269	16719	0.0	1.0	1	
AIGNER_ZEB1_TARGETS 	0	50	32	16956	0.0	1.0	1	
AIYAR_COBRA1_TARGETS_UP 	0	50	36	16952	0.0	1.0	1	
AKL_HTLV1_INFECTION_DN 	0	50	58	16930	0.0	1.0	1	
ALCALAY_AML_BY_NPM1_LOCALIZATION_DN 	0	50	166	16822	0.0	1.0	1	
ALCALAY_AML_BY_NPM1_LOCALIZATION_UP 	0	50	111	16877	0.0	1.0	1	
ALFANO_MYC_TARGETS 	0	50	225	16763	0.0	1.0	1	
ALONSO_METASTASIS_EMT_UP 	0	50	33	16955	0.0	1.0	1	
ALONSO_METASTASIS_UP 	0	50	175	16813	0.0	1.0	1	
ALTEMEIER_RESPONSE_TO_LPS_WITH_MECHANICAL_VENTILATION 	0	50	112	16876	0.0	1.0	1	
AMBROSINI_FLAVOPIRIDOL_TREATMENT_TP53 	0	50	98	16890	0.0	1.0	1	
AMIT_EGF_RESPONSE_120_HELA 	0	50	65	16923	0.0	1.0	1	
AMIT_EGF_RESPONSE_240_HELA 	0	50	58	16930	0.0	1.0	1	
AMIT_EGF_RESPONSE_40_HELA 	0	50	42	16946	0.0	1.0	1	
AMIT_EGF_RESPONSE_480_HELA 	0	50	156	16832	0.0	1.0	1	
AMIT_EGF_RESPONSE_60_HELA 	0	50	43	16945	0.0	1.0	1	
AMIT_EGF_RESPONSE_60_MCF10A 	0	50	36	16952	0.0	1.0	1	
AMIT_SERUM_RESPONSE_120_MCF10A 	0	50	61	16927	0.0	1.0	1	
AMIT_SERUM_RESPONSE_240_MCF10A 	0	50	51	16937	0.0	1.0	1	
AMIT_SERUM_RESPONSE_40_MCF10A 	0	50	31	16957	0.0	1.0	1	
AMIT_SERUM_RESPONSE_60_MCF10A 	0	50	52	16936	0.0	1.0	1	
AMUNDSON_GAMMA_RADIATION_RESPONSE 	0	50	31	16957	0.0	1.0	1	
AMUNDSON_GENOTOXIC_SIGNATURE 	0	50	94	16894	0.0	1.0	1	
AMUNDSON_POOR_SURVIVAL_AFTER_GAMMA_RADIATION_2G 	0	50	159	16829	0.0	1.0	1	
AMUNDSON_POOR_SURVIVAL_AFTER_GAMMA_RADIATION_8G 	0	50	92	16896	0.0	1.0	1	
AMUNDSON_RESPONSE_TO_ARSENITE 	0	50	208	16780	0.0	1.0	1	
ANASTASSIOU_MULTICANCER_INVASIVENESS_SIGNATURE 	0	50	60	16928	0.0	1.0	1	
APPEL_IMATINIB_RESPONSE 	0	50	32	16956	0.0	1.0	1	
APPIERTO_RESPONSE_TO_FENRETINIDE_UP 	0	50	35	16953	0.0	1.0	1	
APRELIKOVA_BRCA1_TARGETS 	0	50	46	16942	0.0	1.0	1	
ASGHARZADEH_NEUROBLASTOMA_POOR_SURVIVAL_DN 	0	50	38	16950	0.0	1.0	1	
ASTON_MAJOR_DEPRESSIVE_DISORDER_DN 	0	50	153	16835	0.0	1.0	1	
BACOLOD_RESISTANCE_TO_ALKYLATING_AGENTS_DN 	0	50	56	16932	0.0	1.0	1	
BAE_BRCA1_TARGETS_DN 	0	50	32	16956	0.0	1.0	1	
BAE_BRCA1_TARGETS_UP 	0	50	69	16919	0.0	1.0	1	
BAELDE_DIABETIC_NEPHROPATHY_UP 	0	50	76	16912	0.0	1.0	1	
BAKKER_FOXO3_TARGETS_UP 	0	50	55	16933	0.0	1.0	1	
BALDWIN_PRKCI_TARGETS_UP 	0	50	33	16955	0.0	1.0	1	
BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_24HR_DN 	0	50	30	16958	0.0	1.0	1	
BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_48HR_DN 	0	50	128	16860	0.0	1.0	1	
BANDRES_RESPONSE_TO_CARMUSTIN_WITHOUT_MGMT_48HR_DN 	0	50	29	16959	0.0	1.0	1	
BARIS_THYROID_CANCER_DN 	0	50	54	16934	0.0	1.0	1	
BARRIER_CANCER_RELAPSE_NORMAL_SAMPLE_DN 	0	50	28	16960	0.0	1.0	1	
BARRIER_CANCER_RELAPSE_NORMAL_SAMPLE_UP 	0	50	26	16962	0.0	1.0	1	
BARRIER_COLON_CANCER_RECURRENCE_UP 	0	50	38	16950	0.0	1.0	1	
BASSO_CD40_SIGNALING_DN 	0	50	60	16928	0.0	1.0	1	
BASSO_CD40_SIGNALING_UP 	0	50	89	16899	0.0	1.0	1	
BASSO_HAIRY_CELL_LEUKEMIA_UP 	0	50	79	16909	0.0	1.0	1	
BAUS_TFF2_TARGETS_UP 	0	50	21	16967	0.0	1.0	1	
BECKER_TAMOXIFEN_RESISTANCE_DN 	0	50	46	16942	0.0	1.0	1	
BECKER_TAMOXIFEN_RESISTANCE_UP 	0	50	45	16943	0.0	1.0	1	
BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_DN 	0	50	44	16944	0.0	1.0	1	
BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_UP 	0	50	57	16931	0.0	1.0	1	
BEIER_GLIOMA_STEM_CELL_DN 	0	50	62	16926	0.0	1.0	1	
BEIER_GLIOMA_STEM_CELL_UP 	0	50	33	16955	0.0	1.0	1	
BENNETT_SYSTEMIC_LUPUS_ERYTHEMATOSUS 	0	50	28	16960	0.0	1.0	1	
BENPORATH_ES_2 	0	50	30	16958	0.0	1.0	1	
BENPORATH_ES_CORE_NINE_CORRELATED 	0	50	91	16897	0.0	1.0	1	
BERENJENO_TRANSFORMED_BY_RHOA_FOREVER_DN 	0	50	27	16961	0.0	1.0	1	
BERNARD_PPAPDC1B_TARGETS_DN 	0	50	49	16939	0.0	1.0	1	
BERTUCCI_INVASIVE_CARCINOMA_DUCTAL_VS_LOBULAR_DN 	0	50	41	16947	0.0	1.0	1	
BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN 	0	50	155	16833	0.0	1.0	1	
BHAT_ESR1_TARGETS_NOT_VIA_AKT1_DN 	0	50	83	16905	0.0	1.0	1	
BHAT_ESR1_TARGETS_VIA_AKT1_DN 	0	50	77	16911	0.0	1.0	1	
BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN 	0	50	115	16873	0.0	1.0	1	
BHATTACHARYA_EMBRYONIC_STEM_CELL 	0	50	81	16907	0.0	1.0	1	
BIDUS_METASTASIS_DN 	0	50	145	16843	0.0	1.0	1	
BIDUS_METASTASIS_UP 	0	50	193	16795	0.0	1.0	1	
BILANGES_RAPAMYCIN_SENSITIVE_GENES 	0	50	38	16950	0.0	1.0	1	
BILANGES_SERUM_AND_RAPAMYCIN_SENSITIVE_GENES 	0	50	66	16922	0.0	1.0	1	
BILANGES_SERUM_RESPONSE_TRANSLATION 	0	50	33	16955	0.0	1.0	1	
BILANGES_SERUM_SENSITIVE_VIA_TSC2 	0	50	35	16953	0.0	1.0	1	
BILBAN_B_CLL_LPL_DN 	0	50	41	16947	0.0	1.0	1	
BILBAN_B_CLL_LPL_UP 	0	50	53	16935	0.0	1.0	1	
BILD_CTNNB1_ONCOGENIC_SIGNATURE 	0	50	76	16912	0.0	1.0	1	
BILD_E2F3_ONCOGENIC_SIGNATURE 	0	50	220	16768	0.0	1.0	1	
BILD_HRAS_ONCOGENIC_SIGNATURE 	0	50	228	16760	0.0	1.0	1	
BILD_MYC_ONCOGENIC_SIGNATURE 	0	50	185	16803	0.0	1.0	1	
BILD_SRC_ONCOGENIC_SIGNATURE 	0	50	58	16930	0.0	1.0	1	
BIOCARTA_AGR_PATHWAY 	0	50	33	16955	0.0	1.0	1	
BIOCARTA_ALK_PATHWAY 	0	50	32	16956	0.0	1.0	1	
BIOCARTA_AT1R_PATHWAY 	0	50	32	16956	0.0	1.0	1	
BIOCARTA_BCR_PATHWAY 	0	50	33	16955	0.0	1.0	1	
BIOCARTA_BIOPEPTIDES_PATHWAY 	0	50	38	16950	0.0	1.0	1	
BIOCARTA_CARM_ER_PATHWAY 	0	50	35	16953	0.0	1.0	1	
BIOCARTA_EGF_PATHWAY 	0	50	31	16957	0.0	1.0	1	
BIOCARTA_FCER1_PATHWAY 	0	50	37	16951	0.0	1.0	1	
BIOCARTA_FMLP_PATHWAY 	0	50	33	16955	0.0	1.0	1	
BIOCARTA_GPCR_PATHWAY 	0	50	32	16956	0.0	1.0	1	
BIOCARTA_HDAC_PATHWAY 	0	50	26	16962	0.0	1.0	1	
BIOCARTA_IL1R_PATHWAY 	0	50	29	16959	0.0	1.0	1	
BIOCARTA_IL2RB_PATHWAY 	0	50	36	16952	0.0	1.0	1	
BIOCARTA_INTEGRIN_PATHWAY 	0	50	36	16952	0.0	1.0	1	
BIOCARTA_KERATINOCYTE_PATHWAY 	0	50	43	16945	0.0	1.0	1	
BIOCARTA_MET_PATHWAY 	0	50	37	16951	0.0	1.0	1	
BIOCARTA_MPR_PATHWAY 	0	50	31	16957	0.0	1.0	1	
BIOCARTA_MYOSIN_PATHWAY 	0	50	30	16958	0.0	1.0	1	
BIOCARTA_NFAT_PATHWAY 	0	50	45	16943	0.0	1.0	1	
BIOCARTA_NO1_PATHWAY 	0	50	27	16961	0.0	1.0	1	
BIOCARTA_P38MAPK_PATHWAY 	0	50	39	16949	0.0	1.0	1	
BIOCARTA_PAR1_PATHWAY 	0	50	34	16954	0.0	1.0	1	
BIOCARTA_PDGF_PATHWAY 	0	50	32	16956	0.0	1.0	1	
BIOCARTA_PPARA_PATHWAY 	0	50	51	16937	0.0	1.0	1	
BIOCARTA_PYK2_PATHWAY 	0	50	28	16960	0.0	1.0	1	
BIOCARTA_RHO_PATHWAY 	0	50	32	16956	0.0	1.0	1	
BIOCARTA_TCR_PATHWAY 	0	50	42	16946	0.0	1.0	1	
BIOCARTA_TOLL_PATHWAY 	0	50	36	16952	0.0	1.0	1	
BLUM_RESPONSE_TO_SALIRASIB_UP 	0	50	232	16756	0.0	1.0	1	
BOGNI_TREATMENT_RELATED_MYELOID_LEUKEMIA_DN 	0	50	31	16957	0.0	1.0	1	
BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_DN 	0	50	38	16950	0.0	1.0	1	
BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_UP 	0	50	41	16947	0.0	1.0	1	
BONCI_TARGETS_OF_MIR15A_AND_MIR16_1 	0	50	83	16905	0.0	1.0	1	
BONOME_OVARIAN_CANCER_POOR_SURVIVAL_UP 	0	50	31	16957	0.0	1.0	1	
BONOME_OVARIAN_CANCER_SURVIVAL_OPTIMAL_DEBULKING 	0	50	217	16771	0.0	1.0	1	
BOQUEST_STEM_CELL_CULTURED_VS_FRESH_DN 	0	50	29	16959	0.0	1.0	1	
BOQUEST_STEM_CELL_DN 	0	50	204	16784	0.0	1.0	1	
BOQUEST_STEM_CELL_UP 	0	50	245	16743	0.0	1.0	1	
BORCZUK_MALIGNANT_MESOTHELIOMA_DN 	0	50	81	16907	0.0	1.0	1	
BORLAK_LIVER_CANCER_EGF_UP 	0	50	52	16936	0.0	1.0	1	
BOSCO_ALLERGEN_INDUCED_TH2_ASSOCIATED_MODULE 	0	50	125	16863	0.0	1.0	1	
BOSCO_EPITHELIAL_DIFFERENTIATION_MODULE 	0	50	34	16954	0.0	1.0	1	
BOSCO_INTERFERON_INDUCED_ANTIVIRAL_MODULE 	0	50	68	16920	0.0	1.0	1	
BOUDOUKHA_BOUND_BY_IGF2BP2 	0	50	101	16887	0.0	1.0	1	
BOYAULT_LIVER_CANCER_SUBCLASS_G123_DN 	0	50	43	16945	0.0	1.0	1	
BOYAULT_LIVER_CANCER_SUBCLASS_G123_UP 	0	50	42	16946	0.0	1.0	1	
BOYAULT_LIVER_CANCER_SUBCLASS_G12_UP 	0	50	35	16953	0.0	1.0	1	
BOYAULT_LIVER_CANCER_SUBCLASS_G1_DN 	0	50	40	16948	0.0	1.0	1	
BOYAULT_LIVER_CANCER_SUBCLASS_G1_UP 	0	50	105	16883	0.0	1.0	1	
BOYAULT_LIVER_CANCER_SUBCLASS_G23_UP 	0	50	44	16944	0.0	1.0	1	
BOYAULT_LIVER_CANCER_SUBCLASS_G3_DN 	0	50	44	16944	0.0	1.0	1	
BOYAULT_LIVER_CANCER_SUBCLASS_G6_UP 	0	50	59	16929	0.0	1.0	1	
BOYLAN_MULTIPLE_MYELOMA_C_CLUSTER_DN 	0	50	28	16960	0.0	1.0	1	
BOYLAN_MULTIPLE_MYELOMA_C_CLUSTER_UP 	0	50	35	16953	0.0	1.0	1	
BOYLAN_MULTIPLE_MYELOMA_C_D_DN 	0	50	207	16781	0.0	1.0	1	
BOYLAN_MULTIPLE_MYELOMA_C_DN 	0	50	52	16936	0.0	1.0	1	
BOYLAN_MULTIPLE_MYELOMA_C_D_UP 	0	50	128	16860	0.0	1.0	1	
BOYLAN_MULTIPLE_MYELOMA_C_UP 	0	50	42	16946	0.0	1.0	1	
BOYLAN_MULTIPLE_MYELOMA_D_UP 	0	50	81	16907	0.0	1.0	1	
BOYLAN_MULTIPLE_MYELOMA_PCA1_UP 	0	50	78	16910	0.0	1.0	1	
BRACHAT_RESPONSE_TO_CAMPTOTHECIN_DN 	0	50	43	16945	0.0	1.0	1	
BREDEMEYER_RAG_SIGNALING_NOT_VIA_ATM_DN 	0	50	52	16936	0.0	1.0	1	
BREDEMEYER_RAG_SIGNALING_NOT_VIA_ATM_UP 	0	50	52	16936	0.0	1.0	1	
BREDEMEYER_RAG_SIGNALING_VIA_ATM_NOT_VIA_NFKB_DN 	0	50	35	16953	0.0	1.0	1	
BREDEMEYER_RAG_SIGNALING_VIA_ATM_NOT_VIA_NFKB_UP 	0	50	46	16942	0.0	1.0	1	
BRIDEAU_IMPRINTED_GENES 	0	50	56	16932	0.0	1.0	1	
BROCKE_APOPTOSIS_REVERSED_BY_IL6 	0	50	139	16849	0.0	1.0	1	
BROWNE_HCMV_INFECTION_10HR_DN 	0	50	49	16939	0.0	1.0	1	
BROWNE_HCMV_INFECTION_10HR_UP 	0	50	88	16900	0.0	1.0	1	
BROWNE_HCMV_INFECTION_12HR_DN 	0	50	90	16898	0.0	1.0	1	
BROWNE_HCMV_INFECTION_12HR_UP 	0	50	99	16889	0.0	1.0	1	
BROWNE_HCMV_INFECTION_14HR_DN 	0	50	265	16723	0.0	1.0	1	
BROWNE_HCMV_INFECTION_14HR_UP 	0	50	145	16843	0.0	1.0	1	
BROWNE_HCMV_INFECTION_16HR_DN 	0	50	78	16910	0.0	1.0	1	
BROWNE_HCMV_INFECTION_18HR_DN 	0	50	156	16832	0.0	1.0	1	
BROWNE_HCMV_INFECTION_18HR_UP 	0	50	169	16819	0.0	1.0	1	
BROWNE_HCMV_INFECTION_1HR_UP 	0	50	49	16939	0.0	1.0	1	
BROWNE_HCMV_INFECTION_20HR_DN 	0	50	88	16900	0.0	1.0	1	
BROWNE_HCMV_INFECTION_24HR_DN 	0	50	139	16849	0.0	1.0	1	
BROWNE_HCMV_INFECTION_24HR_UP 	0	50	135	16853	0.0	1.0	1	
BROWNE_HCMV_INFECTION_2HR_DN 	0	50	45	16943	0.0	1.0	1	
BROWNE_HCMV_INFECTION_2HR_UP 	0	50	35	16953	0.0	1.0	1	
BROWNE_HCMV_INFECTION_30MIN_DN 	0	50	120	16868	0.0	1.0	1	
BROWNE_HCMV_INFECTION_30MIN_UP 	0	50	43	16945	0.0	1.0	1	
BROWNE_HCMV_INFECTION_4HR_UP 	0	50	47	16941	0.0	1.0	1	
BROWNE_HCMV_INFECTION_6HR_DN 	0	50	145	16843	0.0	1.0	1	
BROWNE_HCMV_INFECTION_6HR_UP 	0	50	60	16928	0.0	1.0	1	
BROWNE_HCMV_INFECTION_8HR_DN 	0	50	41	16947	0.0	1.0	1	
BROWNE_HCMV_INFECTION_8HR_UP 	0	50	95	16893	0.0	1.0	1	
BROWNE_INTERFERON_RESPONSIVE_GENES 	0	50	64	16924	0.0	1.0	1	
BROWN_MYELOID_CELL_DEVELOPMENT_UP 	0	50	130	16858	0.0	1.0	1	
BRUECKNER_TARGETS_OF_MIRLET7A3_DN 	0	50	69	16919	0.0	1.0	1	
BRUECKNER_TARGETS_OF_MIRLET7A3_UP 	0	50	96	16892	0.0	1.0	1	
BRUINS_UVC_RESPONSE_MIDDLE 	0	50	84	16904	0.0	1.0	1	
BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_C 	0	50	80	16908	0.0	1.0	1	
BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_D 	0	50	221	16767	0.0	1.0	1	
BRUNO_HEMATOPOIESIS 	0	50	58	16930	0.0	1.0	1	
BURTON_ADIPOGENESIS_1 	0	50	33	16955	0.0	1.0	1	
BURTON_ADIPOGENESIS_11 	0	50	51	16937	0.0	1.0	1	
BURTON_ADIPOGENESIS_12 	0	50	30	16958	0.0	1.0	1	
BURTON_ADIPOGENESIS_2 	0	50	70	16918	0.0	1.0	1	
BURTON_ADIPOGENESIS_3 	0	50	87	16901	0.0	1.0	1	
BURTON_ADIPOGENESIS_7 	0	50	48	16940	0.0	1.0	1	
BURTON_ADIPOGENESIS_9 	0	50	87	16901	0.0	1.0	1	
BURTON_ADIPOGENESIS_PEAK_AT_0HR 	0	50	59	16929	0.0	1.0	1	
BURTON_ADIPOGENESIS_PEAK_AT_16HR 	0	50	37	16951	0.0	1.0	1	
BURTON_ADIPOGENESIS_PEAK_AT_24HR 	0	50	34	16954	0.0	1.0	1	
BURTON_ADIPOGENESIS_PEAK_AT_2HR 	0	50	50	16938	0.0	1.0	1	
BURTON_ADIPOGENESIS_PEAK_AT_8HR 	0	50	37	16951	0.0	1.0	1	
BYSTROEM_CORRELATED_WITH_IL5_UP 	0	50	44	16944	0.0	1.0	1	
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_CIS 	0	50	57	16931	0.0	1.0	1	
CADWELL_ATG16L1_TARGETS_DN 	0	50	59	16929	0.0	1.0	1	
CADWELL_ATG16L1_TARGETS_UP 	0	50	69	16919	0.0	1.0	1	
CAFFAREL_RESPONSE_TO_THC_24HR_5_UP 	0	50	30	16958	0.0	1.0	1	
CAFFAREL_RESPONSE_TO_THC_DN 	0	50	26	16962	0.0	1.0	1	
CAFFAREL_RESPONSE_TO_THC_UP 	0	50	32	16956	0.0	1.0	1	
CAIRO_HEPATOBLASTOMA_CLASSES_DN 	0	50	178	16810	0.0	1.0	1	
CAIRO_HEPATOBLASTOMA_DN 	0	50	211	16777	0.0	1.0	1	
CAIRO_LIVER_DEVELOPMENT_DN 	0	50	172	16816	0.0	1.0	1	
CAIRO_LIVER_DEVELOPMENT_UP 	0	50	148	16840	0.0	1.0	1	
CAMPS_COLON_CANCER_COPY_NUMBER_DN 	0	50	36	16952	0.0	1.0	1	
CAMPS_COLON_CANCER_COPY_NUMBER_UP 	0	50	70	16918	0.0	1.0	1	
CARD_MIR302A_TARGETS 	0	50	76	16912	0.0	1.0	1	
CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_UP 	0	50	153	16835	0.0	1.0	1	
CASORELLI_APL_SECONDARY_VS_DE_NOVO_UP 	0	50	37	16951	0.0	1.0	1	
CAVARD_LIVER_CANCER_MALIGNANT_VS_BENIGN 	0	50	22	16966	0.0	1.0	1	
CEBALLOS_TARGETS_OF_TP53_AND_MYC_DN 	0	50	32	16956	0.0	1.0	1	
CERIBELLI_GENES_INACTIVE_AND_BOUND_BY_NFY 	0	50	24	16964	0.0	1.0	1	
CERIBELLI_PROMOTERS_INACTIVE_AND_BOUND_BY_NFY 	0	50	21	16967	0.0	1.0	1	
CERVERA_SDHB_TARGETS_1_DN 	0	50	27	16961	0.0	1.0	1	
CERVERA_SDHB_TARGETS_1_UP 	0	50	97	16891	0.0	1.0	1	
CHANDRAN_METASTASIS_TOP50_DN 	0	50	43	16945	0.0	1.0	1	
CHANDRAN_METASTASIS_TOP50_UP 	0	50	35	16953	0.0	1.0	1	
CHANDRAN_METASTASIS_UP 	0	50	188	16800	0.0	1.0	1	
CHANG_CORE_SERUM_RESPONSE_DN 	0	50	195	16793	0.0	1.0	1	
CHANG_CYCLING_GENES 	0	50	124	16864	0.0	1.0	1	
CHANG_IMMORTALIZED_BY_HPV31_DN 	0	50	51	16937	0.0	1.0	1	
CHANG_IMMORTALIZED_BY_HPV31_UP 	0	50	75	16913	0.0	1.0	1	
CHANGOLKAR_H2AFY_TARGETS_DN 	0	50	34	16954	0.0	1.0	1	
CHANGOLKAR_H2AFY_TARGETS_UP 	0	50	42	16946	0.0	1.0	1	
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_DN 	0	50	47	16941	0.0	1.0	1	
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP 	0	50	93	16895	0.0	1.0	1	
CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_DN 	0	50	94	16894	0.0	1.0	1	
CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_UP 	0	50	50	16938	0.0	1.0	1	
CHEBOTAEV_GR_TARGETS_DN 	0	50	109	16879	0.0	1.0	1	
CHEBOTAEV_GR_TARGETS_UP 	0	50	69	16919	0.0	1.0	1	
CHEMELLO_SOLEUS_VS_EDL_MYOFIBERS_UP 	0	50	29	16959	0.0	1.0	1	
CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_UP 	0	50	119	16869	0.0	1.0	1	
CHENG_IMPRINTED_BY_ESTRADIOL 	0	50	96	16892	0.0	1.0	1	
CHENG_RESPONSE_TO_NICKEL_ACETATE 	0	50	41	16947	0.0	1.0	1	
CHEN_HOXA5_TARGETS_9HR_DN 	0	50	37	16951	0.0	1.0	1	
CHEN_LIVER_METABOLISM_QTL_CIS 	0	50	80	16908	0.0	1.0	1	
CHEN_LVAD_SUPPORT_OF_FAILING_HEART_DN 	0	50	39	16949	0.0	1.0	1	
CHEN_LVAD_SUPPORT_OF_FAILING_HEART_UP 	0	50	98	16890	0.0	1.0	1	
CHEN_NEUROBLASTOMA_COPY_NUMBER_GAINS 	0	50	46	16942	0.0	1.0	1	
CHESLER_BRAIN_HIGHEST_EXPRESSION 	0	50	38	16950	0.0	1.0	1	
CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_DN 	0	50	145	16843	0.0	1.0	1	
CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_UP 	0	50	139	16849	0.0	1.0	1	
CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_DN 	0	50	41	16947	0.0	1.0	1	
CHIANG_LIVER_CANCER_SUBCLASS_POLYSOMY7_UP 	0	50	60	16928	0.0	1.0	1	
CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_DN 	0	50	126	16862	0.0	1.0	1	
CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP 	0	50	140	16848	0.0	1.0	1	
CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_UP 	0	50	67	16921	0.0	1.0	1	
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_DN 	0	50	145	16843	0.0	1.0	1	
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_UP 	0	50	110	16878	0.0	1.0	1	
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_CDC25_DN 	0	50	47	16941	0.0	1.0	1	
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_CDC25_UP 	0	50	52	16936	0.0	1.0	1	
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN 	0	50	137	16851	0.0	1.0	1	
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_UP 	0	50	111	16877	0.0	1.0	1	
CHIARETTI_ACUTE_LYMPHOBLASTIC_LEUKEMIA_ZAP70 	0	50	56	16932	0.0	1.0	1	
CHIBA_RESPONSE_TO_TSA 	0	50	44	16944	0.0	1.0	1	
CHIBA_RESPONSE_TO_TSA_UP 	0	50	49	16939	0.0	1.0	1	
CHICAS_RB1_TARGETS_LOW_SERUM 	0	50	79	16909	0.0	1.0	1	
CHNG_MULTIPLE_MYELOMA_HYPERPLOID_UP 	0	50	51	16937	0.0	1.0	1	
CHO_NR4A1_TARGETS 	0	50	26	16962	0.0	1.0	1	
CHUNG_BLISTER_CYTOTOXICITY_DN 	0	50	40	16948	0.0	1.0	1	
CHYLA_CBFA2T3_TARGETS_DN 	0	50	199	16789	0.0	1.0	1	
CLASPER_LYMPHATIC_VESSELS_DURING_METASTASIS_DN 	0	50	35	16953	0.0	1.0	1	
COATES_MACROPHAGE_M1_VS_M2_DN 	0	50	65	16923	0.0	1.0	1	
COATES_MACROPHAGE_M1_VS_M2_UP 	0	50	75	16913	0.0	1.0	1	
COLDREN_GEFITINIB_RESISTANCE_DN 	0	50	183	16805	0.0	1.0	1	
COLDREN_GEFITINIB_RESISTANCE_UP 	0	50	74	16914	0.0	1.0	1	
COLIN_PILOCYTIC_ASTROCYTOMA_VS_GLIOBLASTOMA_UP 	0	50	34	16954	0.0	1.0	1	
CONCANNON_APOPTOSIS_BY_EPOXOMICIN_DN 	0	50	143	16845	0.0	1.0	1	
CONRAD_STEM_CELL 	0	50	32	16956	0.0	1.0	1	
CORRE_MULTIPLE_MYELOMA_UP 	0	50	58	16930	0.0	1.0	1	
COULOUARN_TEMPORAL_TGFB1_SIGNATURE_DN 	0	50	120	16868	0.0	1.0	1	
COULOUARN_TEMPORAL_TGFB1_SIGNATURE_UP 	0	50	102	16886	0.0	1.0	1	
COWLING_MYCN_TARGETS 	0	50	37	16951	0.0	1.0	1	
CREIGHTON_AKT1_SIGNALING_VIA_MTOR_UP 	0	50	32	16956	0.0	1.0	1	
CROMER_METASTASIS_DN 	0	50	78	16910	0.0	1.0	1	
CROMER_TUMORIGENESIS_DN 	0	50	38	16950	0.0	1.0	1	
CROMER_TUMORIGENESIS_UP 	0	50	50	16938	0.0	1.0	1	
CROONQUIST_IL6_DEPRIVATION_DN 	0	50	83	16905	0.0	1.0	1	
CROONQUIST_NRAS_SIGNALING_DN 	0	50	61	16927	0.0	1.0	1	
CROONQUIST_NRAS_SIGNALING_UP 	0	50	33	16955	0.0	1.0	1	
CROONQUIST_NRAS_VS_STROMAL_STIMULATION_DN 	0	50	89	16899	0.0	1.0	1	
CROONQUIST_NRAS_VS_STROMAL_STIMULATION_UP 	0	50	35	16953	0.0	1.0	1	
CROONQUIST_STROMAL_STIMULATION_UP 	0	50	58	16930	0.0	1.0	1	
CUI_GLUCOSE_DEPRIVATION 	0	50	52	16936	0.0	1.0	1	
CUI_TCF21_TARGETS_DN 	0	50	28	16960	0.0	1.0	1	
DACOSTA_ERCC3_ALLELE_XPCS_VS_TTD_DN 	0	50	32	16956	0.0	1.0	1	
DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_UP 	0	50	71	16917	0.0	1.0	1	
DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_DN 	0	50	78	16910	0.0	1.0	1	
DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_UP 	0	50	62	16926	0.0	1.0	1	
DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_DN 	0	50	82	16906	0.0	1.0	1	
DAIRKEE_CANCER_PRONE_RESPONSE_BPA 	0	50	46	16942	0.0	1.0	1	
DAIRKEE_CANCER_PRONE_RESPONSE_BPA_E2 	0	50	106	16882	0.0	1.0	1	
DAIRKEE_TERT_TARGETS_DN 	0	50	109	16879	0.0	1.0	1	
DANG_MYC_TARGETS_DN 	0	50	28	16960	0.0	1.0	1	
DANG_REGULATED_BY_MYC_DN 	0	50	235	16753	0.0	1.0	1	
DANG_REGULATED_BY_MYC_UP 	0	50	70	16918	0.0	1.0	1	
DARWICHE_PAPILLOMA_PROGRESSION_RISK 	0	50	59	16929	0.0	1.0	1	
DARWICHE_PAPILLOMA_RISK_HIGH_DN 	0	50	149	16839	0.0	1.0	1	
DARWICHE_PAPILLOMA_RISK_HIGH_VS_LOW_DN 	0	50	26	16962	0.0	1.0	1	
DARWICHE_PAPILLOMA_RISK_LOW_DN 	0	50	140	16848	0.0	1.0	1	
DARWICHE_SKIN_TUMOR_PROMOTER_DN 	0	50	153	16835	0.0	1.0	1	
DARWICHE_SQUAMOUS_CELL_CARCINOMA_DN 	0	50	149	16839	0.0	1.0	1	
DAUER_STAT3_TARGETS_DN 	0	50	49	16939	0.0	1.0	1	
DAUER_STAT3_TARGETS_UP 	0	50	42	16946	0.0	1.0	1	
DAVICIONI_MOLECULAR_ARMS_VS_ERMS_DN 	0	50	162	16826	0.0	1.0	1	
DAVICIONI_PAX_FOXO1_SIGNATURE_IN_ARMS_UP 	0	50	53	16935	0.0	1.0	1	
DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_UP 	0	50	57	16931	0.0	1.0	1	
DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_DN 	0	50	63	16925	0.0	1.0	1	
DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_UP 	0	50	238	16750	0.0	1.0	1	
DAWSON_METHYLATED_IN_LYMPHOMA_TCL1 	0	50	52	16936	0.0	1.0	1	
DAZARD_RESPONSE_TO_UV_SCC_DN 	0	50	117	16871	0.0	1.0	1	
DAZARD_RESPONSE_TO_UV_SCC_UP 	0	50	108	16880	0.0	1.0	1	
DAZARD_UV_RESPONSE_CLUSTER_G1 	0	50	56	16932	0.0	1.0	1	
DAZARD_UV_RESPONSE_CLUSTER_G6 	0	50	135	16853	0.0	1.0	1	
DELACROIX_RAR_TARGETS_UP 	0	50	42	16946	0.0	1.0	1	
DELASERNA_MYOD_TARGETS_DN 	0	50	53	16935	0.0	1.0	1	
DELASERNA_MYOD_TARGETS_UP 	0	50	75	16913	0.0	1.0	1	
DELPUECH_FOXO3_TARGETS_DN 	0	50	36	16952	0.0	1.0	1	
DEMAGALHAES_AGING_UP 	0	50	51	16937	0.0	1.0	1	
DER_IFN_ALPHA_RESPONSE_UP 	0	50	72	16916	0.0	1.0	1	
DER_IFN_BETA_RESPONSE_UP 	0	50	100	16888	0.0	1.0	1	
DER_IFN_GAMMA_RESPONSE_UP 	0	50	68	16920	0.0	1.0	1	
DE_YY1_TARGETS_DN 	0	50	88	16900	0.0	1.0	1	
DIAZ_CHRONIC_MEYLOGENOUS_LEUKEMIA_DN 	0	50	108	16880	0.0	1.0	1	
DING_LUNG_CANCER_EXPRESSION_BY_COPY_NUMBER 	0	50	96	16892	0.0	1.0	1	
DIRMEIER_LMP1_RESPONSE_EARLY 	0	50	58	16930	0.0	1.0	1	
DIRMEIER_LMP1_RESPONSE_LATE_DN 	0	50	30	16958	0.0	1.0	1	
DITTMER_PTHLH_TARGETS_DN 	0	50	70	16918	0.0	1.0	1	
DITTMER_PTHLH_TARGETS_UP 	0	50	107	16881	0.0	1.0	1	
DOANE_BREAST_CANCER_CLASSES_DN 	0	50	31	16957	0.0	1.0	1	
DOANE_BREAST_CANCER_ESR1_DN 	0	50	37	16951	0.0	1.0	1	
DOANE_BREAST_CANCER_ESR1_UP 	0	50	97	16891	0.0	1.0	1	
DORN_ADENOVIRUS_INFECTION_12HR_DN 	0	50	31	16957	0.0	1.0	1	
DORN_ADENOVIRUS_INFECTION_24HR_DN 	0	50	41	16947	0.0	1.0	1	
DORN_ADENOVIRUS_INFECTION_32HR_DN 	0	50	37	16951	0.0	1.0	1	
DORN_ADENOVIRUS_INFECTION_48HR_DN 	0	50	38	16950	0.0	1.0	1	
DORSAM_HOXA9_TARGETS_DN 	0	50	31	16957	0.0	1.0	1	
DORSAM_HOXA9_TARGETS_UP 	0	50	34	16954	0.0	1.0	1	
DORSEY_GAB2_TARGETS 	0	50	27	16961	0.0	1.0	1	
DUAN_PRDM5_TARGETS 	0	50	70	16918	0.0	1.0	1	
DUNNE_TARGETS_OF_AML1_MTG8_FUSION_UP 	0	50	45	16943	0.0	1.0	1	
DURAND_STROMA_S_UP 	0	50	269	16719	0.0	1.0	1	
DURCHDEWALD_SKIN_CARCINOGENESIS_DN 	0	50	242	16746	0.0	1.0	1	
DURCHDEWALD_SKIN_CARCINOGENESIS_UP 	0	50	70	16918	0.0	1.0	1	
DUTERTRE_ESTRADIOL_RESPONSE_6HR_DN 	0	50	89	16899	0.0	1.0	1	
DUTERTRE_ESTRADIOL_RESPONSE_6HR_UP 	0	50	214	16774	0.0	1.0	1	
DUTTA_APOPTOSIS_VIA_NFKB 	0	50	30	16958	0.0	1.0	1	
EBAUER_MYOGENIC_TARGETS_OF_PAX3_FOXO1_FUSION 	0	50	41	16947	0.0	1.0	1	
EBAUER_TARGETS_OF_PAX3_FOXO1_FUSION_DN 	0	50	44	16944	0.0	1.0	1	
EHLERS_ANEUPLOIDY_UP 	0	50	40	16948	0.0	1.0	1	
ELLWOOD_MYC_TARGETS_DN 	0	50	37	16951	0.0	1.0	1	
ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN 	0	50	99	16889	0.0	1.0	1	
ELVIDGE_HIF1A_AND_HIF2A_TARGETS_UP 	0	50	38	16950	0.0	1.0	1	
ELVIDGE_HIF1A_TARGETS_DN 	0	50	86	16902	0.0	1.0	1	
ELVIDGE_HIF1A_TARGETS_UP 	0	50	63	16925	0.0	1.0	1	
ELVIDGE_HYPOXIA_BY_DMOG_DN 	0	50	55	16933	0.0	1.0	1	
ELVIDGE_HYPOXIA_BY_DMOG_UP 	0	50	124	16864	0.0	1.0	1	
ELVIDGE_HYPOXIA_UP 	0	50	160	16828	0.0	1.0	1	
ENGELMANN_CANCER_PROGENITORS_DN 	0	50	58	16930	0.0	1.0	1	
ENGELMANN_CANCER_PROGENITORS_UP 	0	50	45	16943	0.0	1.0	1	
EPPERT_CE_HSC_LSC 	0	50	35	16953	0.0	1.0	1	
EPPERT_HSC_R 	0	50	108	16880	0.0	1.0	1	
EPPERT_LSC_R 	0	50	38	16950	0.0	1.0	1	
EPPERT_PROGENITOR 	0	50	119	16869	0.0	1.0	1	
FAELT_B_CLL_WITH_VH3_21_DN 	0	50	49	16939	0.0	1.0	1	
FAELT_B_CLL_WITH_VH3_21_UP 	0	50	42	16946	0.0	1.0	1	
FAELT_B_CLL_WITH_VH_REARRANGEMENTS_DN 	0	50	46	16942	0.0	1.0	1	
FAELT_B_CLL_WITH_VH_REARRANGEMENTS_UP 	0	50	47	16941	0.0	1.0	1	
FALVELLA_SMOKERS_WITH_LUNG_CANCER 	0	50	68	16920	0.0	1.0	1	
FARDIN_HYPOXIA_11 	0	50	32	16956	0.0	1.0	1	
FARMER_BREAST_CANCER_CLUSTER_1 	0	50	30	16958	0.0	1.0	1	
FERRANDO_T_ALL_WITH_MLL_ENL_FUSION_DN 	0	50	76	16912	0.0	1.0	1	
FERRANDO_T_ALL_WITH_MLL_ENL_FUSION_UP 	0	50	80	16908	0.0	1.0	1	
FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_DN 	0	50	83	16905	0.0	1.0	1	
FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_UP 	0	50	140	16848	0.0	1.0	1	
FIGUEROA_AML_METHYLATION_CLUSTER_1_DN 	0	50	38	16950	0.0	1.0	1	
FIGUEROA_AML_METHYLATION_CLUSTER_3_DN 	0	50	35	16953	0.0	1.0	1	
FIGUEROA_AML_METHYLATION_CLUSTER_5_DN 	0	50	38	16950	0.0	1.0	1	
FIGUEROA_AML_METHYLATION_CLUSTER_6_DN 	0	50	26	16962	0.0	1.0	1	
FIRESTEIN_CTNNB1_PATHWAY 	0	50	32	16956	0.0	1.0	1	
FISCHER_DIRECT_P53_TARGETS_META_ANALYSIS 	0	50	282	16706	0.0	1.0	1	
FISCHER_G2_M_CELL_CYCLE 	0	50	196	16792	0.0	1.0	1	
FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP 	0	50	81	16907	0.0	1.0	1	
FLECHNER_PBL_KIDNEY_TRANSPLANT_OK_VS_DONOR_DN 	0	50	41	16947	0.0	1.0	1	
FLECHNER_PBL_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP 	0	50	144	16844	0.0	1.0	1	
FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN 	0	50	50	16938	0.0	1.0	1	
FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP 	0	50	62	16926	0.0	1.0	1	
FLOTHO_PEDIATRIC_ALL_THERAPY_RESPONSE_UP 	0	50	53	16935	0.0	1.0	1	
FONTAINE_FOLLICULAR_THYROID_ADENOMA_UP 	0	50	66	16922	0.0	1.0	1	
FONTAINE_PAPILLARY_THYROID_CARCINOMA_UP 	0	50	54	16934	0.0	1.0	1	
FONTAINE_THYROID_TUMOR_UNCERTAIN_MALIGNANCY_UP 	0	50	32	16956	0.0	1.0	1	
FOSTER_TOLERANT_MACROPHAGE_UP 	0	50	131	16857	0.0	1.0	1	
FRASOR_RESPONSE_TO_ESTRADIOL_DN 	0	50	76	16912	0.0	1.0	1	
FRASOR_RESPONSE_TO_ESTRADIOL_UP 	0	50	33	16955	0.0	1.0	1	
FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_DN 	0	50	48	16940	0.0	1.0	1	
FRIDMAN_IMMORTALIZATION_DN 	0	50	33	16955	0.0	1.0	1	
FRIDMAN_SENESCENCE_UP 	0	50	73	16915	0.0	1.0	1	
FUJII_YBX1_TARGETS_UP 	0	50	36	16952	0.0	1.0	1	
FURUKAWA_DUSP6_TARGETS_PCI35_DN 	0	50	59	16929	0.0	1.0	1	
FURUKAWA_DUSP6_TARGETS_PCI35_UP 	0	50	62	16926	0.0	1.0	1	
GAJATE_RESPONSE_TO_TRABECTEDIN_UP 	0	50	63	16925	0.0	1.0	1	
GALE_APL_WITH_FLT3_MUTATED_UP 	0	50	51	16937	0.0	1.0	1	
GALINDO_IMMUNE_RESPONSE_TO_ENTEROTOXIN 	0	50	78	16910	0.0	1.0	1	
GAL_LEUKEMIC_STEM_CELL_DN 	0	50	195	16793	0.0	1.0	1	
GAL_LEUKEMIC_STEM_CELL_UP 	0	50	116	16872	0.0	1.0	1	
GALLUZZI_PERMEABILIZE_MITOCHONDRIA 	0	50	41	16947	0.0	1.0	1	
GARCIA_TARGETS_OF_FLI1_AND_DAX1_UP 	0	50	53	16935	0.0	1.0	1	
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLACK_UP 	0	50	33	16955	0.0	1.0	1	
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_DN 	0	50	53	16935	0.0	1.0	1	
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP 	0	50	120	16868	0.0	1.0	1	
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREY_DN 	0	50	60	16928	0.0	1.0	1	
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_DN 	0	50	45	16943	0.0	1.0	1	
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_UP 	0	50	74	16914	0.0	1.0	1	
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_YELLOW_UP 	0	50	31	16957	0.0	1.0	1	
GAURNIER_PSMD4_TARGETS 	0	50	50	16938	0.0	1.0	1	
GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_DN 	0	50	82	16906	0.0	1.0	1	
GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP 	0	50	167	16821	0.0	1.0	1	
GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP 	0	50	160	16828	0.0	1.0	1	
GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP 	0	50	84	16904	0.0	1.0	1	
GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_DN 	0	50	27	16961	0.0	1.0	1	
GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_UP 	0	50	167	16821	0.0	1.0	1	
GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_DN 	0	50	31	16957	0.0	1.0	1	
GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_UP 	0	50	191	16797	0.0	1.0	1	
GAVIN_FOXP3_TARGETS_CLUSTER_P2 	0	50	69	16919	0.0	1.0	1	
GAVIN_FOXP3_TARGETS_CLUSTER_P3 	0	50	142	16846	0.0	1.0	1	
GAVIN_FOXP3_TARGETS_CLUSTER_P6 	0	50	77	16911	0.0	1.0	1	
GAVIN_FOXP3_TARGETS_CLUSTER_P7 	0	50	77	16911	0.0	1.0	1	
GAVIN_FOXP3_TARGETS_CLUSTER_T7 	0	50	94	16894	0.0	1.0	1	
GAZDA_DIAMOND_BLACKFAN_ANEMIA_MYELOID_DN 	0	50	34	16954	0.0	1.0	1	
GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_DN 	0	50	60	16928	0.0	1.0	1	
GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_UP 	0	50	38	16950	0.0	1.0	1	
GEISS_RESPONSE_TO_DSRNA_UP 	0	50	37	16951	0.0	1.0	1	
GENTILE_RESPONSE_CLUSTER_D3 	0	50	60	16928	0.0	1.0	1	
GENTILE_UV_LOW_DOSE_DN 	0	50	64	16924	0.0	1.0	1	
GENTILE_UV_RESPONSE_CLUSTER_D2 	0	50	38	16950	0.0	1.0	1	
GENTILE_UV_RESPONSE_CLUSTER_D4 	0	50	53	16935	0.0	1.0	1	
GENTILE_UV_RESPONSE_CLUSTER_D5 	0	50	35	16953	0.0	1.0	1	
GENTILE_UV_RESPONSE_CLUSTER_D6 	0	50	34	16954	0.0	1.0	1	
GENTILE_UV_RESPONSE_CLUSTER_D7 	0	50	37	16951	0.0	1.0	1	
GENTILE_UV_RESPONSE_CLUSTER_D8 	0	50	38	16950	0.0	1.0	1	
GEORGANTAS_HSC_MARKERS 	0	50	61	16927	0.0	1.0	1	
GEORGES_CELL_CYCLE_MIR192_TARGETS 	0	50	56	16932	0.0	1.0	1	
GERHOLD_ADIPOGENESIS_DN 	0	50	61	16927	0.0	1.0	1	
GERY_CEBP_TARGETS 	0	50	115	16873	0.0	1.0	1	
GHANDHI_BYSTANDER_IRRADIATION_UP 	0	50	72	16916	0.0	1.0	1	
GHANDHI_DIRECT_IRRADIATION_DN 	0	50	31	16957	0.0	1.0	1	
GHANDHI_DIRECT_IRRADIATION_UP 	0	50	89	16899	0.0	1.0	1	
GINESTIER_BREAST_CANCER_20Q13_AMPLIFICATION_DN 	0	50	149	16839	0.0	1.0	1	
GINESTIER_BREAST_CANCER_20Q13_AMPLIFICATION_UP 	0	50	106	16882	0.0	1.0	1	
GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_UP 	0	50	69	16919	0.0	1.0	1	
GNATENKO_PLATELET_SIGNATURE 	0	50	41	16947	0.0	1.0	1	
GOBERT_CORE_OLIGODENDROCYTE_DIFFERENTIATION 	0	50	37	16951	0.0	1.0	1	
GOLDRATH_HOMEOSTATIC_PROLIFERATION 	0	50	162	16826	0.0	1.0	1	
GOLDRATH_IMMUNE_MEMORY 	0	50	62	16926	0.0	1.0	1	
GOTTWEIN_TARGETS_OF_KSHV_MIR_K12_11 	0	50	62	16926	0.0	1.0	1	
GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_UP 	0	50	64	16924	0.0	1.0	1	
GOZGIT_ESR1_TARGETS_UP 	0	50	122	16866	0.0	1.0	1	
GRABARCZYK_BCL11B_TARGETS_DN 	0	50	45	16943	0.0	1.0	1	
GRABARCZYK_BCL11B_TARGETS_UP 	0	50	70	16918	0.0	1.0	1	
GRADE_COLON_AND_RECTAL_CANCER_DN 	0	50	88	16900	0.0	1.0	1	
GRADE_COLON_AND_RECTAL_CANCER_UP 	0	50	263	16725	0.0	1.0	1	
GRADE_COLON_CANCER_DN 	0	50	28	16960	0.0	1.0	1	
GRADE_COLON_VS_RECTAL_CANCER_DN 	0	50	49	16939	0.0	1.0	1	
GRADE_METASTASIS_DN 	0	50	41	16947	0.0	1.0	1	
GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN 	0	50	208	16780	0.0	1.0	1	
GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_DN 	0	50	76	16912	0.0	1.0	1	
GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_DN 	0	50	85	16903	0.0	1.0	1	
GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_UP 	0	50	147	16841	0.0	1.0	1	
GRAHAM_CML_QUIESCENT_VS_NORMAL_DIVIDING_UP 	0	50	43	16945	0.0	1.0	1	
GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_DN 	0	50	40	16948	0.0	1.0	1	
GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_UP 	0	50	63	16925	0.0	1.0	1	
GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_UP 	0	50	61	16927	0.0	1.0	1	
GREENBAUM_E2A_TARGETS_UP 	0	50	28	16960	0.0	1.0	1	
GREGORY_SYNTHETIC_LETHAL_WITH_IMATINIB 	0	50	129	16859	0.0	1.0	1	
GROSS_ELK3_TARGETS_DN 	0	50	29	16959	0.0	1.0	1	
GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_DN 	0	50	94	16894	0.0	1.0	1	
GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP 	0	50	135	16853	0.0	1.0	1	
GROSS_HYPOXIA_VIA_ELK3_ONLY_UP 	0	50	32	16956	0.0	1.0	1	
GROSS_HYPOXIA_VIA_HIF1A_DN 	0	50	100	16888	0.0	1.0	1	
GROSS_HYPOXIA_VIA_HIF1A_UP 	0	50	73	16915	0.0	1.0	1	
GRUETZMANN_PANCREATIC_CANCER_DN 	0	50	180	16808	0.0	1.0	1	
GUO_HEX_TARGETS_DN 	0	50	55	16933	0.0	1.0	1	
GUO_HEX_TARGETS_UP 	0	50	81	16907	0.0	1.0	1	
GUO_TARGETS_OF_IRS1_AND_IRS2 	0	50	89	16899	0.0	1.0	1	
GU_PDEF_TARGETS_DN 	0	50	28	16960	0.0	1.0	1	
GU_PDEF_TARGETS_UP 	0	50	69	16919	0.0	1.0	1	
GUTIERREZ_CHRONIC_LYMPHOCYTIC_LEUKEMIA_DN 	0	50	50	16938	0.0	1.0	1	
GUTIERREZ_MULTIPLE_MYELOMA_UP 	0	50	31	16957	0.0	1.0	1	
GYORFFY_DOXORUBICIN_RESISTANCE 	0	50	44	16944	0.0	1.0	1	
GYORFFY_MITOXANTRONE_RESISTANCE 	0	50	48	16940	0.0	1.0	1	
HADDAD_B_LYMPHOCYTE_PROGENITOR 	0	50	241	16747	0.0	1.0	1	
HADDAD_T_LYMPHOCYTE_AND_NK_PROGENITOR_DN 	0	50	50	16938	0.0	1.0	1	
HAHTOLA_MYCOSIS_FUNGOIDES_CD4_DN 	0	50	111	16877	0.0	1.0	1	
HAHTOLA_MYCOSIS_FUNGOIDES_CD4_UP 	0	50	58	16930	0.0	1.0	1	
HAHTOLA_SEZARY_SYNDROM_DN 	0	50	32	16956	0.0	1.0	1	
HAHTOLA_SEZARY_SYNDROM_UP 	0	50	82	16906	0.0	1.0	1	
HALMOS_CEBPA_TARGETS_DN 	0	50	41	16947	0.0	1.0	1	
HALMOS_CEBPA_TARGETS_UP 	0	50	45	16943	0.0	1.0	1	
HAN_JNK_SINGALING_DN 	0	50	32	16956	0.0	1.0	1	
HAN_JNK_SINGALING_UP 	0	50	34	16954	0.0	1.0	1	
HANN_RESISTANCE_TO_BCL2_INHIBITOR_DN 	0	50	40	16948	0.0	1.0	1	
HANN_RESISTANCE_TO_BCL2_INHIBITOR_UP 	0	50	30	16958	0.0	1.0	1	
HARRIS_HYPOXIA 	0	50	71	16917	0.0	1.0	1	
HATADA_METHYLATED_IN_LUNG_CANCER_DN 	0	50	18	16970	0.0	1.0	1	
HECKER_IFNB1_TARGETS 	0	50	78	16910	0.0	1.0	1	
HEDENFALK_BREAST_CANCER_HEREDITARY_VS_SPORADIC 	0	50	46	16942	0.0	1.0	1	
HEIDENBLAD_AMPLICON_12P11_12_UP 	0	50	30	16958	0.0	1.0	1	
HEIDENBLAD_AMPLICON_8Q24_UP 	0	50	30	16958	0.0	1.0	1	
HEIDENBLAD_AMPLIFIED_IN_PANCREATIC_CANCER 	0	50	30	16958	0.0	1.0	1	
HELLEBREKERS_SILENCED_DURING_TUMOR_ANGIOGENESIS 	0	50	76	16912	0.0	1.0	1	
HELLER_HDAC_TARGETS_DN 	0	50	265	16723	0.0	1.0	1	
HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_DN 	0	50	256	16732	0.0	1.0	1	
HELLER_SILENCED_BY_METHYLATION_DN 	0	50	95	16893	0.0	1.0	1	
HELLER_SILENCED_BY_METHYLATION_UP 	0	50	235	16753	0.0	1.0	1	
HENDRICKS_SMARCA4_TARGETS_DN 	0	50	42	16946	0.0	1.0	1	
HENDRICKS_SMARCA4_TARGETS_UP 	0	50	49	16939	0.0	1.0	1	
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_UP 	0	50	27	16961	0.0	1.0	1	
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_UP 	0	50	56	16932	0.0	1.0	1	
HESS_TARGETS_OF_HOXA9_AND_MEIS1_DN 	0	50	70	16918	0.0	1.0	1	
HILLION_HMGA1B_TARGETS 	0	50	84	16904	0.0	1.0	1	
HILLION_HMGA1_TARGETS 	0	50	82	16906	0.0	1.0	1	
HINATA_NFKB_TARGETS_FIBROBLAST_UP 	0	50	76	16912	0.0	1.0	1	
HINATA_NFKB_TARGETS_KERATINOCYTE_UP 	0	50	78	16910	0.0	1.0	1	
HIRSCH_CELLULAR_TRANSFORMATION_SIGNATURE_DN 	0	50	97	16891	0.0	1.0	1	
HIRSCH_CELLULAR_TRANSFORMATION_SIGNATURE_UP 	0	50	226	16762	0.0	1.0	1	
HOEBEKE_LYMPHOID_STEM_CELL_DN 	0	50	82	16906	0.0	1.0	1	
HOEBEKE_LYMPHOID_STEM_CELL_UP 	0	50	85	16903	0.0	1.0	1	
HOELZEL_NF1_TARGETS_DN 	0	50	98	16890	0.0	1.0	1	
HOELZEL_NF1_TARGETS_UP 	0	50	122	16866	0.0	1.0	1	
HOFFMANN_IMMATURE_TO_MATURE_B_LYMPHOCYTE_DN 	0	50	44	16944	0.0	1.0	1	
HOFFMANN_IMMATURE_TO_MATURE_B_LYMPHOCYTE_UP 	0	50	37	16951	0.0	1.0	1	
HOFFMANN_LARGE_TO_SMALL_PRE_BII_LYMPHOCYTE_DN 	0	50	63	16925	0.0	1.0	1	
HOFFMANN_LARGE_TO_SMALL_PRE_BII_LYMPHOCYTE_UP 	0	50	137	16851	0.0	1.0	1	
HOFFMANN_PRE_BI_TO_LARGE_PRE_BII_LYMPHOCYTE_UP 	0	50	32	16956	0.0	1.0	1	
HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHOCYTE_DN 	0	50	44	16944	0.0	1.0	1	
HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHOCYTE_UP 	0	50	61	16927	0.0	1.0	1	
HOFMANN_CELL_LYMPHOMA_DN 	0	50	37	16951	0.0	1.0	1	
HOFMANN_CELL_LYMPHOMA_UP 	0	50	43	16945	0.0	1.0	1	
HOLLEMAN_VINCRISTINE_RESISTANCE_B_ALL_UP 	0	50	35	16953	0.0	1.0	1	
HONMA_DOCETAXEL_RESISTANCE 	0	50	31	16957	0.0	1.0	1	
HOOI_ST7_TARGETS_UP 	0	50	78	16910	0.0	1.0	1	
HOQUE_METHYLATED_IN_CANCER 	0	50	48	16940	0.0	1.0	1	
HOSHIDA_LIVER_CANCER_SUBCLASS_S1 	0	50	229	16759	0.0	1.0	1	
HOSHIDA_LIVER_CANCER_SUBCLASS_S2 	0	50	109	16879	0.0	1.0	1	
HOSHIDA_LIVER_CANCER_SUBCLASS_S3 	0	50	228	16760	0.0	1.0	1	
HOSHIDA_LIVER_CANCER_SURVIVAL_UP 	0	50	65	16923	0.0	1.0	1	
HOUSTIS_ROS 	0	50	34	16954	0.0	1.0	1	
HOWLIN_CITED1_TARGETS_1_DN 	0	50	34	16954	0.0	1.0	1	
HOWLIN_CITED1_TARGETS_1_UP 	0	50	28	16960	0.0	1.0	1	
HSIAO_LIVER_SPECIFIC_GENES 	0	50	166	16822	0.0	1.0	1	
HUANG_DASATINIB_RESISTANCE_DN 	0	50	65	16923	0.0	1.0	1	
HUANG_DASATINIB_RESISTANCE_UP 	0	50	77	16911	0.0	1.0	1	
HUANG_FOXA2_TARGETS_DN 	0	50	35	16953	0.0	1.0	1	
HUANG_FOXA2_TARGETS_UP 	0	50	41	16947	0.0	1.0	1	
HUANG_GATA2_TARGETS_DN 	0	50	63	16925	0.0	1.0	1	
HUANG_GATA2_TARGETS_UP 	0	50	135	16853	0.0	1.0	1	
HU_ANGIOGENESIS_DN 	0	50	35	16953	0.0	1.0	1	
HU_GENOTOXIC_DAMAGE_24HR 	0	50	30	16958	0.0	1.0	1	
HU_GENOTOXIN_ACTION_DIRECT_VS_INDIRECT_4HR 	0	50	31	16957	0.0	1.0	1	
HUMMEL_BURKITTS_LYMPHOMA_UP 	0	50	37	16951	0.0	1.0	1	
HUMMERICH_SKIN_CANCER_PROGRESSION_UP 	0	50	79	16909	0.0	1.0	1	
HUNSBERGER_EXERCISE_REGULATED_GENES 	0	50	29	16959	0.0	1.0	1	
HUPER_BREAST_BASAL_VS_LUMINAL_DN 	0	50	52	16936	0.0	1.0	1	
HUPER_BREAST_BASAL_VS_LUMINAL_UP 	0	50	41	16947	0.0	1.0	1	
HUTTMANN_B_CLL_POOR_SURVIVAL_DN 	0	50	51	16937	0.0	1.0	1	
HUTTMANN_B_CLL_POOR_SURVIVAL_UP 	0	50	240	16748	0.0	1.0	1	
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_DN 	0	50	38	16950	0.0	1.0	1	
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_UP 	0	50	115	16873	0.0	1.0	1	
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_D7_DN 	0	50	28	16960	0.0	1.0	1	
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_D7_UP 	0	50	95	16893	0.0	1.0	1	
IGLESIAS_E2F_TARGETS_UP 	0	50	144	16844	0.0	1.0	1	
IKEDA_MIR133_TARGETS_UP 	0	50	43	16945	0.0	1.0	1	
IKEDA_MIR1_TARGETS_UP 	0	50	53	16935	0.0	1.0	1	
IKEDA_MIR30_TARGETS_UP 	0	50	112	16876	0.0	1.0	1	
INGRAM_SHH_TARGETS_DN 	0	50	55	16933	0.0	1.0	1	
IRITANI_MAD1_TARGETS_DN 	0	50	45	16943	0.0	1.0	1	
ISHIDA_E2F_TARGETS 	0	50	41	16947	0.0	1.0	1	
ISSAEVA_MLL2_TARGETS 	0	50	54	16934	0.0	1.0	1	
IVANOVA_HEMATOPOIESIS_MATURE_CELL 	0	50	251	16737	0.0	1.0	1	
IVANOVA_HEMATOPOIESIS_STEM_CELL_SHORT_TERM 	0	50	29	16959	0.0	1.0	1	
IVANOVSKA_MIR106B_TARGETS 	0	50	84	16904	0.0	1.0	1	
IWANAGA_CARCINOGENESIS_BY_KRAS_DN 	0	50	110	16878	0.0	1.0	1	
IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_UP 	0	50	146	16842	0.0	1.0	1	
IWANAGA_E2F1_TARGETS_INDUCED_BY_SERUM 	0	50	28	16960	0.0	1.0	1	
IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_DN 	0	50	97	16891	0.0	1.0	1	
IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP 	0	50	114	16874	0.0	1.0	1	
JAATINEN_HEMATOPOIETIC_STEM_CELL_DN 	0	50	180	16808	0.0	1.0	1	
JACKSON_DNMT1_TARGETS_UP 	0	50	72	16916	0.0	1.0	1	
JAEGER_METASTASIS_DN 	0	50	198	16790	0.0	1.0	1	
JAEGER_METASTASIS_UP 	0	50	38	16950	0.0	1.0	1	
JAERVINEN_AMPLIFIED_IN_LARYNGEAL_CANCER 	0	50	37	16951	0.0	1.0	1	
JAZAERI_BREAST_CANCER_BRCA1_VS_BRCA2_DN 	0	50	37	16951	0.0	1.0	1	
JAZAERI_BREAST_CANCER_BRCA1_VS_BRCA2_UP 	0	50	45	16943	0.0	1.0	1	
JAZAG_TGFB1_SIGNALING_DN 	0	50	28	16960	0.0	1.0	1	
JAZAG_TGFB1_SIGNALING_UP 	0	50	100	16888	0.0	1.0	1	
JAZAG_TGFB1_SIGNALING_VIA_SMAD4_DN 	0	50	58	16930	0.0	1.0	1	
JAZAG_TGFB1_SIGNALING_VIA_SMAD4_UP 	0	50	89	16899	0.0	1.0	1	
JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN 	0	50	62	16926	0.0	1.0	1	
JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_UP 	0	50	64	16924	0.0	1.0	1	
JEPSEN_SMRT_TARGETS 	0	50	33	16955	0.0	1.0	1	
JIANG_AGING_CEREBRAL_CORTEX_DN 	0	50	54	16934	0.0	1.0	1	
JIANG_AGING_CEREBRAL_CORTEX_UP 	0	50	34	16954	0.0	1.0	1	
JIANG_AGING_HYPOTHALAMUS_DN 	0	50	40	16948	0.0	1.0	1	
JIANG_AGING_HYPOTHALAMUS_UP 	0	50	47	16941	0.0	1.0	1	
JIANG_HYPOXIA_CANCER 	0	50	77	16911	0.0	1.0	1	
JIANG_TIP30_TARGETS_UP 	0	50	41	16947	0.0	1.0	1	
JI_RESPONSE_TO_FSH_DN 	0	50	54	16934	0.0	1.0	1	
JOHANSSON_BRAIN_CANCER_EARLY_VS_LATE_DN 	0	50	44	16944	0.0	1.0	1	
JOHANSSON_GLIOMAGENESIS_BY_PDGFB_UP 	0	50	53	16935	0.0	1.0	1	
JOHNSTONE_PARVB_TARGETS_1_DN 	0	50	57	16931	0.0	1.0	1	
JOSEPH_RESPONSE_TO_SODIUM_BUTYRATE_DN 	0	50	58	16930	0.0	1.0	1	
JUBAN_TARGETS_OF_SPI1_AND_FLI1_DN 	0	50	85	16903	0.0	1.0	1	
JUBAN_TARGETS_OF_SPI1_AND_FLI1_UP 	0	50	109	16879	0.0	1.0	1	
KAAB_FAILED_HEART_ATRIUM_DN 	0	50	135	16853	0.0	1.0	1	
KAAB_FAILED_HEART_ATRIUM_UP 	0	50	30	16958	0.0	1.0	1	
KAAB_FAILED_HEART_VENTRICLE_DN 	0	50	40	16948	0.0	1.0	1	
KAAB_HEART_ATRIUM_VS_VENTRICLE_DN 	0	50	251	16737	0.0	1.0	1	
KAAB_HEART_ATRIUM_VS_VENTRICLE_UP 	0	50	239	16749	0.0	1.0	1	
KAMMINGA_EZH2_TARGETS 	0	50	36	16952	0.0	1.0	1	
KAMMINGA_SENESCENCE 	0	50	37	16951	0.0	1.0	1	
KANG_DOXORUBICIN_RESISTANCE_UP 	0	50	42	16946	0.0	1.0	1	
KANG_GIST_WITH_PDGFRA_UP 	0	50	46	16942	0.0	1.0	1	
KANG_IMMORTALIZED_BY_TERT_DN 	0	50	83	16905	0.0	1.0	1	
KANG_IMMORTALIZED_BY_TERT_UP 	0	50	79	16909	0.0	1.0	1	
KANNAN_TP53_TARGETS_UP 	0	50	55	16933	0.0	1.0	1	
KAN_RESPONSE_TO_ARSENIC_TRIOXIDE 	0	50	110	16878	0.0	1.0	1	
KARLSSON_TGFB1_TARGETS_DN 	0	50	198	16790	0.0	1.0	1	
KARLSSON_TGFB1_TARGETS_UP 	0	50	116	16872	0.0	1.0	1	
KASLER_HDAC7_TARGETS_2_DN 	0	50	31	16957	0.0	1.0	1	
KATSANOU_ELAVL1_TARGETS_DN 	0	50	129	16859	0.0	1.0	1	
KATSANOU_ELAVL1_TARGETS_UP 	0	50	145	16843	0.0	1.0	1	
KAYO_AGING_MUSCLE_DN 	0	50	114	16874	0.0	1.0	1	
KAYO_CALORIE_RESTRICTION_MUSCLE_DN 	0	50	75	16913	0.0	1.0	1	
KAYO_CALORIE_RESTRICTION_MUSCLE_UP 	0	50	88	16900	0.0	1.0	1	
KEEN_RESPONSE_TO_ROSIGLITAZONE_DN 	0	50	98	16890	0.0	1.0	1	
KEEN_RESPONSE_TO_ROSIGLITAZONE_UP 	0	50	37	16951	0.0	1.0	1	
KEGG_ABC_TRANSPORTERS 	0	50	41	16947	0.0	1.0	1	
KEGG_ACUTE_MYELOID_LEUKEMIA 	0	50	57	16931	0.0	1.0	1	
KEGG_ADHERENS_JUNCTION 	0	50	67	16921	0.0	1.0	1	
KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY 	0	50	60	16928	0.0	1.0	1	
KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM 	0	50	30	16958	0.0	1.0	1	
KEGG_ALDOSTERONE_REGULATED_SODIUM_REABSORPTION 	0	50	38	16950	0.0	1.0	1	
KEGG_ALLOGRAFT_REJECTION 	0	50	23	16965	0.0	1.0	1	
KEGG_AMINOACYL_TRNA_BIOSYNTHESIS 	0	50	41	16947	0.0	1.0	1	
KEGG_AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM 	0	50	43	16945	0.0	1.0	1	
KEGG_AMYOTROPHIC_LATERAL_SCLEROSIS_ALS 	0	50	50	16938	0.0	1.0	1	
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 	0	50	57	16931	0.0	1.0	1	
KEGG_ARGININE_AND_PROLINE_METABOLISM 	0	50	49	16939	0.0	1.0	1	
KEGG_AUTOIMMUNE_THYROID_DISEASE 	0	50	25	16963	0.0	1.0	1	
KEGG_AXON_GUIDANCE 	0	50	125	16863	0.0	1.0	1	
KEGG_BASAL_CELL_CARCINOMA 	0	50	53	16935	0.0	1.0	1	
KEGG_BASAL_TRANSCRIPTION_FACTORS 	0	50	32	16956	0.0	1.0	1	
KEGG_BASE_EXCISION_REPAIR 	0	50	32	16956	0.0	1.0	1	
KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY 	0	50	70	16918	0.0	1.0	1	
KEGG_BLADDER_CANCER 	0	50	38	16950	0.0	1.0	1	
KEGG_BUTANOATE_METABOLISM 	0	50	27	16961	0.0	1.0	1	
KEGG_CELL_ADHESION_MOLECULES_CAMS 	0	50	111	16877	0.0	1.0	1	
KEGG_CHEMOKINE_SIGNALING_PATHWAY 	0	50	143	16845	0.0	1.0	1	
KEGG_CHRONIC_MYELOID_LEUKEMIA 	0	50	71	16917	0.0	1.0	1	
KEGG_CITRATE_CYCLE_TCA_CYCLE 	0	50	29	16959	0.0	1.0	1	
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 	0	50	48	16940	0.0	1.0	1	
KEGG_CYSTEINE_AND_METHIONINE_METABOLISM 	0	50	29	16959	0.0	1.0	1	
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 	0	50	155	16833	0.0	1.0	1	
KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY 	0	50	40	16948	0.0	1.0	1	
KEGG_DNA_REPLICATION 	0	50	35	16953	0.0	1.0	1	
KEGG_DRUG_METABOLISM_CYTOCHROME_P450 	0	50	30	16958	0.0	1.0	1	
KEGG_DRUG_METABOLISM_OTHER_ENZYMES 	0	50	25	16963	0.0	1.0	1	
KEGG_ECM_RECEPTOR_INTERACTION 	0	50	77	16911	0.0	1.0	1	
KEGG_ENDOCYTOSIS 	0	50	170	16818	0.0	1.0	1	
KEGG_ENDOMETRIAL_CANCER 	0	50	52	16936	0.0	1.0	1	
KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION 	0	50	64	16924	0.0	1.0	1	
KEGG_ERBB_SIGNALING_PATHWAY 	0	50	83	16905	0.0	1.0	1	
KEGG_ETHER_LIPID_METABOLISM 	0	50	20	16968	0.0	1.0	1	
KEGG_FATTY_ACID_METABOLISM 	0	50	37	16951	0.0	1.0	1	
KEGG_FC_EPSILON_RI_SIGNALING_PATHWAY 	0	50	61	16927	0.0	1.0	1	
KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS 	0	50	91	16897	0.0	1.0	1	
KEGG_FOCAL_ADHESION 	0	50	188	16800	0.0	1.0	1	
KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM 	0	50	31	16957	0.0	1.0	1	
KEGG_GAP_JUNCTION 	0	50	83	16905	0.0	1.0	1	
KEGG_GLIOMA 	0	50	63	16925	0.0	1.0	1	
KEGG_GLUTATHIONE_METABOLISM 	0	50	40	16948	0.0	1.0	1	
KEGG_GLYCEROLIPID_METABOLISM 	0	50	37	16951	0.0	1.0	1	
KEGG_GLYCEROPHOSPHOLIPID_METABOLISM 	0	50	60	16928	0.0	1.0	1	
KEGG_GLYCINE_SERINE_AND_THREONINE_METABOLISM 	0	50	29	16959	0.0	1.0	1	
KEGG_GLYCOLYSIS_GLUCONEOGENESIS 	0	50	46	16942	0.0	1.0	1	
KEGG_GNRH_SIGNALING_PATHWAY 	0	50	84	16904	0.0	1.0	1	
KEGG_GRAFT_VERSUS_HOST_DISEASE 	0	50	25	16963	0.0	1.0	1	
KEGG_HEDGEHOG_SIGNALING_PATHWAY 	0	50	49	16939	0.0	1.0	1	
KEGG_HEMATOPOIETIC_CELL_LINEAGE 	0	50	59	16929	0.0	1.0	1	
KEGG_HUNTINGTONS_DISEASE 	0	50	167	16821	0.0	1.0	1	
KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION 	0	50	31	16957	0.0	1.0	1	
KEGG_JAK_STAT_SIGNALING_PATHWAY 	0	50	100	16888	0.0	1.0	1	
KEGG_LEISHMANIA_INFECTION 	0	50	64	16924	0.0	1.0	1	
KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION 	0	50	102	16886	0.0	1.0	1	
KEGG_LONG_TERM_DEPRESSION 	0	50	60	16928	0.0	1.0	1	
KEGG_LONG_TERM_POTENTIATION 	0	50	66	16922	0.0	1.0	1	
KEGG_LYSINE_DEGRADATION 	0	50	39	16949	0.0	1.0	1	
KEGG_LYSOSOME 	0	50	113	16875	0.0	1.0	1	
KEGG_MELANOGENESIS 	0	50	95	16893	0.0	1.0	1	
KEGG_MELANOMA 	0	50	62	16926	0.0	1.0	1	
KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450 	0	50	30	16958	0.0	1.0	1	
KEGG_MTOR_SIGNALING_PATHWAY 	0	50	50	16938	0.0	1.0	1	
KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY 	0	50	96	16892	0.0	1.0	1	
KEGG_N_GLYCAN_BIOSYNTHESIS 	0	50	46	16942	0.0	1.0	1	
KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY 	0	50	53	16935	0.0	1.0	1	
KEGG_NON_SMALL_CELL_LUNG_CANCER 	0	50	53	16935	0.0	1.0	1	
KEGG_NOTCH_SIGNALING_PATHWAY 	0	50	45	16943	0.0	1.0	1	
KEGG_OOCYTE_MEIOSIS 	0	50	98	16890	0.0	1.0	1	
KEGG_OXIDATIVE_PHOSPHORYLATION 	0	50	109	16879	0.0	1.0	1	
KEGG_P53_SIGNALING_PATHWAY 	0	50	62	16926	0.0	1.0	1	
KEGG_PANCREATIC_CANCER 	0	50	67	16921	0.0	1.0	1	
KEGG_PARKINSONS_DISEASE 	0	50	107	16881	0.0	1.0	1	
KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION 	0	50	51	16937	0.0	1.0	1	
KEGG_PEROXISOME 	0	50	74	16914	0.0	1.0	1	
KEGG_PORPHYRIN_AND_CHLOROPHYLL_METABOLISM 	0	50	22	16966	0.0	1.0	1	
KEGG_PPAR_SIGNALING_PATHWAY 	0	50	57	16931	0.0	1.0	1	
KEGG_PRIMARY_IMMUNODEFICIENCY 	0	50	26	16962	0.0	1.0	1	
KEGG_PRION_DISEASES 	0	50	29	16959	0.0	1.0	1	
KEGG_PROGESTERONE_MEDIATED_OOCYTE_MATURATION 	0	50	79	16909	0.0	1.0	1	
KEGG_PROPANOATE_METABOLISM 	0	50	29	16959	0.0	1.0	1	
KEGG_PROSTATE_CANCER 	0	50	85	16903	0.0	1.0	1	
KEGG_PROTEASOME 	0	50	40	16948	0.0	1.0	1	
KEGG_PURINE_METABOLISM 	0	50	142	16846	0.0	1.0	1	
KEGG_PYRIMIDINE_METABOLISM 	0	50	93	16895	0.0	1.0	1	
KEGG_PYRUVATE_METABOLISM 	0	50	34	16954	0.0	1.0	1	
KEGG_REGULATION_OF_ACTIN_CYTOSKELETON 	0	50	191	16797	0.0	1.0	1	
KEGG_REGULATION_OF_AUTOPHAGY 	0	50	19	16969	0.0	1.0	1	
KEGG_RENAL_CELL_CARCINOMA 	0	50	66	16922	0.0	1.0	1	
KEGG_RETINOL_METABOLISM 	0	50	26	16962	0.0	1.0	1	
KEGG_RIBOSOME 	0	50	85	16903	0.0	1.0	1	
KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY 	0	50	50	16938	0.0	1.0	1	
KEGG_SMALL_CELL_LUNG_CANCER 	0	50	82	16906	0.0	1.0	1	
KEGG_SNARE_INTERACTIONS_IN_VESICULAR_TRANSPORT 	0	50	37	16951	0.0	1.0	1	
KEGG_SPHINGOLIPID_METABOLISM 	0	50	33	16955	0.0	1.0	1	
KEGG_STARCH_AND_SUCROSE_METABOLISM 	0	50	26	16962	0.0	1.0	1	
KEGG_STEROID_HORMONE_BIOSYNTHESIS 	0	50	24	16964	0.0	1.0	1	
KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS 	0	50	74	16914	0.0	1.0	1	
KEGG_TASTE_TRANSDUCTION 	0	50	24	16964	0.0	1.0	1	
KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY 	0	50	91	16897	0.0	1.0	1	
KEGG_TGF_BETA_SIGNALING_PATHWAY 	0	50	78	16910	0.0	1.0	1	
KEGG_TIGHT_JUNCTION 	0	50	113	16875	0.0	1.0	1	
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 	0	50	82	16906	0.0	1.0	1	
KEGG_TRYPTOPHAN_METABOLISM 	0	50	33	16955	0.0	1.0	1	
KEGG_TYPE_I_DIABETES_MELLITUS 	0	50	31	16957	0.0	1.0	1	
KEGG_TYPE_II_DIABETES_MELLITUS 	0	50	41	16947	0.0	1.0	1	
KEGG_TYROSINE_METABOLISM 	0	50	33	16955	0.0	1.0	1	
KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS 	0	50	128	16860	0.0	1.0	1	
KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION 	0	50	43	16945	0.0	1.0	1	
KEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION 	0	50	102	16886	0.0	1.0	1	
KEGG_VASOPRESSIN_REGULATED_WATER_REABSORPTION 	0	50	40	16948	0.0	1.0	1	
KEGG_VEGF_SIGNALING_PATHWAY 	0	50	64	16924	0.0	1.0	1	
KEGG_VIBRIO_CHOLERAE_INFECTION 	0	50	48	16940	0.0	1.0	1	
KEGG_VIRAL_MYOCARDITIS 	0	50	61	16927	0.0	1.0	1	
KEGG_WNT_SIGNALING_PATHWAY 	0	50	140	16848	0.0	1.0	1	
KENNY_CTNNB1_TARGETS_DN 	0	50	50	16938	0.0	1.0	1	
KENNY_CTNNB1_TARGETS_UP 	0	50	46	16942	0.0	1.0	1	
KERLEY_RESPONSE_TO_CISPLATIN_UP 	0	50	42	16946	0.0	1.0	1	
KESHELAVA_MULTIPLE_DRUG_RESISTANCE 	0	50	76	16912	0.0	1.0	1	
KHETCHOUMIAN_TRIM24_TARGETS_UP 	0	50	45	16943	0.0	1.0	1	
KIM_ALL_DISORDERS_CALB1_CORR_DN 	0	50	22	16966	0.0	1.0	1	
KIM_ALL_DISORDERS_DURATION_CORR_DN 	0	50	142	16846	0.0	1.0	1	
KIM_ALL_DISORDERS_OLIGODENDROCYTE_NUMBER_CORR_DN 	0	50	22	16966	0.0	1.0	1	
KIM_BIPOLAR_DISORDER_OLIGODENDROCYTE_DENSITY_CORR_DN 	0	50	42	16946	0.0	1.0	1	
KIM_GASTRIC_CANCER_CHEMOSENSITIVITY 	0	50	82	16906	0.0	1.0	1	
KIM_GERMINAL_CENTER_T_HELPER_UP 	0	50	61	16927	0.0	1.0	1	
KIM_GLIS2_TARGETS_UP 	0	50	76	16912	0.0	1.0	1	
KIM_MYC_AMPLIFICATION_TARGETS_DN 	0	50	85	16903	0.0	1.0	1	
KIM_MYC_AMPLIFICATION_TARGETS_UP 	0	50	185	16803	0.0	1.0	1	
KIM_MYCN_AMPLIFICATION_TARGETS_UP 	0	50	80	16908	0.0	1.0	1	
KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP 	0	50	107	16881	0.0	1.0	1	
KIM_TIAL1_TARGETS 	0	50	30	16958	0.0	1.0	1	
KIM_WT1_TARGETS_12HR_UP 	0	50	153	16835	0.0	1.0	1	
KIM_WT1_TARGETS_8HR_DN 	0	50	104	16884	0.0	1.0	1	
KIM_WT1_TARGETS_8HR_UP 	0	50	159	16829	0.0	1.0	1	
KIM_WT1_TARGETS_UP 	0	50	202	16786	0.0	1.0	1	
KLEIN_PRIMARY_EFFUSION_LYMPHOMA_DN 	0	50	51	16937	0.0	1.0	1	
KLEIN_TARGETS_OF_BCR_ABL1_FUSION 	0	50	36	16952	0.0	1.0	1	
KOBAYASHI_EGFR_SIGNALING_24HR_UP 	0	50	88	16900	0.0	1.0	1	
KOHOUTEK_CCNT1_TARGETS 	0	50	45	16943	0.0	1.0	1	
KOHOUTEK_CCNT2_TARGETS 	0	50	47	16941	0.0	1.0	1	
KONDO_EZH2_TARGETS 	0	50	201	16787	0.0	1.0	1	
KONDO_PROSTATE_CANCER_HCP_WITH_H3K27ME3 	0	50	75	16913	0.0	1.0	1	
KONDO_PROSTATE_CANCER_WITH_H3K27ME3 	0	50	85	16903	0.0	1.0	1	
KONG_E2F3_TARGETS 	0	50	76	16912	0.0	1.0	1	
KORKOLA_CORRELATED_WITH_POU5F1 	0	50	21	16967	0.0	1.0	1	
KORKOLA_EMBRYONAL_CARCINOMA_UP 	0	50	37	16951	0.0	1.0	1	
KORKOLA_SEMINOMA_UP 	0	50	38	16950	0.0	1.0	1	
KORKOLA_TERATOMA 	0	50	32	16956	0.0	1.0	1	
KRASNOSELSKAYA_ILF3_TARGETS_DN 	0	50	42	16946	0.0	1.0	1	
KRASNOSELSKAYA_ILF3_TARGETS_UP 	0	50	36	16952	0.0	1.0	1	
KRIEG_HYPOXIA_VIA_KDM3A 	0	50	46	16942	0.0	1.0	1	
KRIEG_KDM3A_TARGETS_NOT_HYPOXIA 	0	50	178	16810	0.0	1.0	1	
KUMAR_AUTOPHAGY_NETWORK 	0	50	58	16930	0.0	1.0	1	
KUNINGER_IGF1_VS_PDGFB_TARGETS_DN 	0	50	39	16949	0.0	1.0	1	
KUNINGER_IGF1_VS_PDGFB_TARGETS_UP 	0	50	63	16925	0.0	1.0	1	
KUROKAWA_LIVER_CANCER_CHEMOTHERAPY_DN 	0	50	36	16952	0.0	1.0	1	
KUROZUMI_RESPONSE_TO_ONCOCYTIC_VIRUS 	0	50	27	16961	0.0	1.0	1	
KUUSELO_PANCREATIC_CANCER_19Q13_AMPLIFICATION 	0	50	24	16964	0.0	1.0	1	
KYNG_DNA_DAMAGE_BY_4NQO 	0	50	36	16952	0.0	1.0	1	
KYNG_DNA_DAMAGE_BY_GAMMA_AND_UV_RADIATION 	0	50	81	16907	0.0	1.0	1	
KYNG_DNA_DAMAGE_BY_GAMMA_RADIATION 	0	50	73	16915	0.0	1.0	1	
KYNG_DNA_DAMAGE_BY_UV 	0	50	58	16930	0.0	1.0	1	
KYNG_DNA_DAMAGE_DN 	0	50	184	16804	0.0	1.0	1	
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_4NQO_IN_WS 	0	50	39	16949	0.0	1.0	1	
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_GAMMA_IN_OLD 	0	50	30	16958	0.0	1.0	1	
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_GAMMA_IN_WS 	0	50	32	16956	0.0	1.0	1	
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_UP 	0	50	54	16934	0.0	1.0	1	
KYNG_RESPONSE_TO_H2O2 	0	50	67	16921	0.0	1.0	1	
KYNG_RESPONSE_TO_H2O2_VIA_ERCC6_DN 	0	50	44	16944	0.0	1.0	1	
KYNG_RESPONSE_TO_H2O2_VIA_ERCC6_UP 	0	50	37	16951	0.0	1.0	1	
LABBE_TARGETS_OF_TGFB1_AND_WNT3A_DN 	0	50	87	16901	0.0	1.0	1	
LABBE_TGFB1_TARGETS_DN 	0	50	78	16910	0.0	1.0	1	
LABBE_WNT3A_TARGETS_UP 	0	50	95	16893	0.0	1.0	1	
LAIHO_COLORECTAL_CANCER_SERRATED_DN 	0	50	74	16914	0.0	1.0	1	
LANDIS_BREAST_CANCER_PROGRESSION_UP 	0	50	42	16946	0.0	1.0	1	
LANDIS_ERBB2_BREAST_TUMORS_324_UP 	0	50	139	16849	0.0	1.0	1	
LASTOWSKA_COAMPLIFIED_WITH_MYCN 	0	50	38	16950	0.0	1.0	1	
LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_UP 	0	50	163	16825	0.0	1.0	1	
LAU_APOPTOSIS_CDKN2A_UP 	0	50	54	16934	0.0	1.0	1	
LEE_AGING_CEREBELLUM_DN 	0	50	72	16916	0.0	1.0	1	
LEE_AGING_CEREBELLUM_UP 	0	50	75	16913	0.0	1.0	1	
LEE_AGING_MUSCLE_DN 	0	50	43	16945	0.0	1.0	1	
LEE_AGING_MUSCLE_UP 	0	50	42	16946	0.0	1.0	1	
LEE_AGING_NEOCORTEX_DN 	0	50	61	16927	0.0	1.0	1	
LEE_AGING_NEOCORTEX_UP 	0	50	84	16904	0.0	1.0	1	
LEE_CALORIE_RESTRICTION_MUSCLE_DN 	0	50	45	16943	0.0	1.0	1	
LEE_CALORIE_RESTRICTION_NEOCORTEX_DN 	0	50	77	16911	0.0	1.0	1	
LEE_DIFFERENTIATING_T_LYMPHOCYTE 	0	50	171	16817	0.0	1.0	1	
LEE_EARLY_T_LYMPHOCYTE_DN 	0	50	50	16938	0.0	1.0	1	
LEE_EARLY_T_LYMPHOCYTE_UP 	0	50	69	16919	0.0	1.0	1	
LE_EGR2_TARGETS_DN 	0	50	103	16885	0.0	1.0	1	
LE_EGR2_TARGETS_UP 	0	50	97	16891	0.0	1.0	1	
LEE_LIVER_CANCER_ACOX1_DN 	0	50	50	16938	0.0	1.0	1	
LEE_LIVER_CANCER_ACOX1_UP 	0	50	51	16937	0.0	1.0	1	
LEE_LIVER_CANCER_CIPROFIBRATE_DN 	0	50	45	16943	0.0	1.0	1	
LEE_LIVER_CANCER_CIPROFIBRATE_UP 	0	50	50	16938	0.0	1.0	1	
LEE_LIVER_CANCER_DENA_DN 	0	50	53	16935	0.0	1.0	1	
LEE_LIVER_CANCER_DENA_UP 	0	50	50	16938	0.0	1.0	1	
LEE_LIVER_CANCER_E2F1_DN 	0	50	45	16943	0.0	1.0	1	
LEE_LIVER_CANCER_E2F1_UP 	0	50	52	16936	0.0	1.0	1	
LEE_LIVER_CANCER_MYC_DN 	0	50	44	16944	0.0	1.0	1	
LEE_LIVER_CANCER_MYC_E2F1_DN 	0	50	44	16944	0.0	1.0	1	
LEE_LIVER_CANCER_MYC_E2F1_UP 	0	50	49	16939	0.0	1.0	1	
LEE_LIVER_CANCER_MYC_TGFA_DN 	0	50	47	16941	0.0	1.0	1	
LEE_LIVER_CANCER_MYC_TGFA_UP 	0	50	55	16933	0.0	1.0	1	
LEE_LIVER_CANCER_MYC_UP 	0	50	46	16942	0.0	1.0	1	
LEE_LIVER_CANCER_SURVIVAL_UP 	0	50	140	16848	0.0	1.0	1	
LEE_METASTASIS_AND_ALTERNATIVE_SPLICING_DN 	0	50	45	16943	0.0	1.0	1	
LEE_METASTASIS_AND_ALTERNATIVE_SPLICING_UP 	0	50	69	16919	0.0	1.0	1	
LEE_NEURAL_CREST_STEM_CELL_DN 	0	50	111	16877	0.0	1.0	1	
LEE_NEURAL_CREST_STEM_CELL_UP 	0	50	133	16855	0.0	1.0	1	
LEE_TARGETS_OF_PTCH1_AND_SUFU_UP 	0	50	48	16940	0.0	1.0	1	
LEIN_ASTROCYTE_MARKERS 	0	50	40	16948	0.0	1.0	1	
LEIN_CEREBELLUM_MARKERS 	0	50	75	16913	0.0	1.0	1	
LEIN_CHOROID_PLEXUS_MARKERS 	0	50	92	16896	0.0	1.0	1	
LEIN_LOCALIZED_TO_PROXIMAL_DENDRITES 	0	50	33	16955	0.0	1.0	1	
LEIN_MEDULLA_MARKERS 	0	50	68	16920	0.0	1.0	1	
LEIN_MIDBRAIN_MARKERS 	0	50	75	16913	0.0	1.0	1	
LEIN_NEURON_MARKERS 	0	50	64	16924	0.0	1.0	1	
LEIN_OLIGODENDROCYTE_MARKERS 	0	50	71	16917	0.0	1.0	1	
LEIN_PONS_MARKERS 	0	50	82	16906	0.0	1.0	1	
LENAOUR_DENDRITIC_CELL_MATURATION_DN 	0	50	118	16870	0.0	1.0	1	
LENAOUR_DENDRITIC_CELL_MATURATION_UP 	0	50	101	16887	0.0	1.0	1	
LEONARD_HYPOXIA 	0	50	45	16943	0.0	1.0	1	
LI_AMPLIFIED_IN_LUNG_CANCER 	0	50	158	16830	0.0	1.0	1	
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_LARGE_VS_TINY_DN 	0	50	38	16950	0.0	1.0	1	
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_LARGE_VS_TINY_UP 	0	50	38	16950	0.0	1.0	1	
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_SMALL_VS_HUGE_DN 	0	50	30	16958	0.0	1.0	1	
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_SMALL_VS_HUGE_UP 	0	50	35	16953	0.0	1.0	1	
LIANG_SILENCED_BY_METHYLATION_2 	0	50	40	16948	0.0	1.0	1	
LIAN_LIPA_TARGETS_3M 	0	50	46	16942	0.0	1.0	1	
LIAN_LIPA_TARGETS_6M 	0	50	56	16932	0.0	1.0	1	
LIAO_HAVE_SOX4_BINDING_SITES 	0	50	38	16950	0.0	1.0	1	
LI_CISPLATIN_RESISTANCE_DN 	0	50	25	16963	0.0	1.0	1	
LIEN_BREAST_CARCINOMA_METAPLASTIC 	0	50	34	16954	0.0	1.0	1	
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_DN 	0	50	86	16902	0.0	1.0	1	
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_UP 	0	50	71	16917	0.0	1.0	1	
LI_INDUCED_T_TO_NATURAL_KILLER_DN 	0	50	104	16884	0.0	1.0	1	
LI_LUNG_CANCER 	0	50	39	16949	0.0	1.0	1	
LIM_MAMMARY_LUMINAL_MATURE_DN 	0	50	96	16892	0.0	1.0	1	
LIM_MAMMARY_LUMINAL_MATURE_UP 	0	50	94	16894	0.0	1.0	1	
LIM_MAMMARY_LUMINAL_PROGENITOR_UP 	0	50	43	16945	0.0	1.0	1	
LIN_APC_TARGETS 	0	50	75	16913	0.0	1.0	1	
LINDGREN_BLADDER_CANCER_CLUSTER_1_UP 	0	50	103	16885	0.0	1.0	1	
LINDGREN_BLADDER_CANCER_CLUSTER_2A_DN 	0	50	130	16858	0.0	1.0	1	
LINDGREN_BLADDER_CANCER_CLUSTER_3_DN 	0	50	208	16780	0.0	1.0	1	
LINDGREN_BLADDER_CANCER_HIGH_RECURRENCE 	0	50	46	16942	0.0	1.0	1	
LINDGREN_BLADDER_CANCER_WITH_LOH_IN_CHR9Q 	0	50	106	16882	0.0	1.0	1	
LINDSTEDT_DENDRITIC_CELL_MATURATION_A 	0	50	56	16932	0.0	1.0	1	
LINDSTEDT_DENDRITIC_CELL_MATURATION_C 	0	50	63	16925	0.0	1.0	1	
LINDSTEDT_DENDRITIC_CELL_MATURATION_D 	0	50	61	16927	0.0	1.0	1	
LINDVALL_IMMORTALIZED_BY_TERT_DN 	0	50	73	16915	0.0	1.0	1	
LINDVALL_IMMORTALIZED_BY_TERT_UP 	0	50	72	16916	0.0	1.0	1	
LIN_MELANOMA_COPY_NUMBER_DN 	0	50	41	16947	0.0	1.0	1	
LIN_MELANOMA_COPY_NUMBER_UP 	0	50	62	16926	0.0	1.0	1	
LIN_NPAS4_TARGETS_DN 	0	50	60	16928	0.0	1.0	1	
LIN_NPAS4_TARGETS_UP 	0	50	148	16840	0.0	1.0	1	
LIN_SILENCED_BY_TUMOR_MICROENVIRONMENT 	0	50	75	16913	0.0	1.0	1	
LIU_CDX2_TARGETS_UP 	0	50	23	16965	0.0	1.0	1	
LIU_CMYB_TARGETS_UP 	0	50	155	16833	0.0	1.0	1	
LIU_COMMON_CANCER_GENES 	0	50	66	16922	0.0	1.0	1	
LIU_LIVER_CANCER 	0	50	33	16955	0.0	1.0	1	
LIU_NASOPHARYNGEAL_CARCINOMA 	0	50	61	16927	0.0	1.0	1	
LIU_PROSTATE_CANCER_UP 	0	50	84	16904	0.0	1.0	1	
LIU_SMARCA4_TARGETS 	0	50	54	16934	0.0	1.0	1	
LIU_SOX4_TARGETS_UP 	0	50	123	16865	0.0	1.0	1	
LIU_TARGETS_OF_VMYB_VS_CMYB_DN 	0	50	35	16953	0.0	1.0	1	
LIU_VAV3_PROSTATE_CARCINOGENESIS_UP 	0	50	77	16911	0.0	1.0	1	
LIU_VMYB_TARGETS_UP 	0	50	117	16871	0.0	1.0	1	
LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP 	0	50	175	16813	0.0	1.0	1	
LI_WILMS_TUMOR_VS_FETAL_KIDNEY_2_DN 	0	50	49	16939	0.0	1.0	1	
LOCKWOOD_AMPLIFIED_IN_LUNG_CANCER 	0	50	205	16783	0.0	1.0	1	
LOPEZ_TRANSLATION_VIA_FN1_SIGNALING 	0	50	33	16955	0.0	1.0	1	
LU_AGING_BRAIN_UP 	0	50	255	16733	0.0	1.0	1	
LUCAS_HNF4A_TARGETS_UP 	0	50	53	16935	0.0	1.0	1	
LU_IL4_SIGNALING 	0	50	88	16900	0.0	1.0	1	
LUI_TARGETS_OF_PAX8_PPARG_FUSION 	0	50	33	16955	0.0	1.0	1	
LUI_THYROID_CANCER_CLUSTER_1 	0	50	50	16938	0.0	1.0	1	
LUI_THYROID_CANCER_CLUSTER_2 	0	50	39	16949	0.0	1.0	1	
LUI_THYROID_CANCER_PAX8_PPARG_DN 	0	50	45	16943	0.0	1.0	1	
LUI_THYROID_CANCER_PAX8_PPARG_UP 	0	50	43	16945	0.0	1.0	1	
LY_AGING_OLD_DN 	0	50	50	16938	0.0	1.0	1	
MACAEVA_PBMC_RESPONSE_TO_IR 	0	50	85	16903	0.0	1.0	1	
MADAN_DPPA4_TARGETS 	0	50	33	16955	0.0	1.0	1	
MAGRANGEAS_MULTIPLE_MYELOMA_IGLL_VS_IGLK_UP 	0	50	39	16949	0.0	1.0	1	
MAHAJAN_RESPONSE_TO_IL1A_DN 	0	50	69	16919	0.0	1.0	1	
MAHAJAN_RESPONSE_TO_IL1A_UP 	0	50	71	16917	0.0	1.0	1	
MALONEY_RESPONSE_TO_17AAG_DN 	0	50	75	16913	0.0	1.0	1	
MALONEY_RESPONSE_TO_17AAG_UP 	0	50	39	16949	0.0	1.0	1	
MA_MYELOID_DIFFERENTIATION_DN 	0	50	35	16953	0.0	1.0	1	
MA_MYELOID_DIFFERENTIATION_UP 	0	50	37	16951	0.0	1.0	1	
MANALO_HYPOXIA_UP 	0	50	198	16790	0.0	1.0	1	
MANTOVANI_NFKB_TARGETS_UP 	0	50	38	16950	0.0	1.0	1	
MANTOVANI_VIRAL_GPCR_SIGNALING_DN 	0	50	42	16946	0.0	1.0	1	
MANTOVANI_VIRAL_GPCR_SIGNALING_UP 	0	50	70	16918	0.0	1.0	1	
MARCHINI_TRABECTEDIN_RESISTANCE_DN 	0	50	46	16942	0.0	1.0	1	
MARIADASON_REGULATED_BY_HISTONE_ACETYLATION_DN 	0	50	48	16940	0.0	1.0	1	
MARIADASON_REGULATED_BY_HISTONE_ACETYLATION_UP 	0	50	74	16914	0.0	1.0	1	
MARIADASON_RESPONSE_TO_BUTYRATE_SULINDAC_6 	0	50	46	16942	0.0	1.0	1	
MARKEY_RB1_CHRONIC_LOF_DN 	0	50	106	16882	0.0	1.0	1	
MARSON_FOXP3_TARGETS_DN 	0	50	45	16943	0.0	1.0	1	
MARSON_FOXP3_TARGETS_UP 	0	50	61	16927	0.0	1.0	1	
MARTINEZ_RESPONSE_TO_TRABECTEDIN 	0	50	48	16940	0.0	1.0	1	
MARTIN_INTERACT_WITH_HDAC 	0	50	41	16947	0.0	1.0	1	
MARZEC_IL2_SIGNALING_DN 	0	50	34	16954	0.0	1.0	1	
MARZEC_IL2_SIGNALING_UP 	0	50	100	16888	0.0	1.0	1	
MASSARWEH_RESPONSE_TO_ESTRADIOL 	0	50	56	16932	0.0	1.0	1	
MASSARWEH_TAMOXIFEN_RESISTANCE_DN 	0	50	218	16770	0.0	1.0	1	
MATTIOLI_MGUS_VS_PCL 	0	50	90	16898	0.0	1.0	1	
MATTIOLI_MULTIPLE_MYELOMA_WITH_14Q32_TRANSLOCATIONS 	0	50	32	16956	0.0	1.0	1	
MATZUK_MEIOTIC_AND_DNA_REPAIR 	0	50	34	16954	0.0	1.0	1	
MATZUK_SPERMATID_DIFFERENTIATION 	0	50	27	16961	0.0	1.0	1	
MATZUK_SPERMATOCYTE 	0	50	63	16925	0.0	1.0	1	
MATZUK_SPERMATOZOA 	0	50	86	16902	0.0	1.0	1	
MCBRYAN_PUBERTAL_BREAST_3_4WK_DN 	0	50	33	16955	0.0	1.0	1	
MCBRYAN_PUBERTAL_BREAST_3_4WK_UP 	0	50	186	16802	0.0	1.0	1	
MCBRYAN_PUBERTAL_BREAST_4_5WK_UP 	0	50	233	16755	0.0	1.0	1	
MCBRYAN_PUBERTAL_BREAST_5_6WK_DN 	0	50	127	16861	0.0	1.0	1	
MCBRYAN_PUBERTAL_BREAST_6_7WK_DN 	0	50	68	16920	0.0	1.0	1	
MCBRYAN_PUBERTAL_BREAST_6_7WK_UP 	0	50	181	16807	0.0	1.0	1	
MCBRYAN_PUBERTAL_TGFB1_TARGETS_DN 	0	50	55	16933	0.0	1.0	1	
MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP 	0	50	167	16821	0.0	1.0	1	
MCCABE_HOXC6_TARGETS_CANCER_UP 	0	50	27	16961	0.0	1.0	1	
MCCLUNG_COCAIN_REWARD_4WK 	0	50	58	16930	0.0	1.0	1	
MCCLUNG_CREB1_TARGETS_UP 	0	50	97	16891	0.0	1.0	1	
MCCLUNG_DELTA_FOSB_TARGETS_2WK 	0	50	44	16944	0.0	1.0	1	
MCCLUNG_DELTA_FOSB_TARGETS_8WK 	0	50	47	16941	0.0	1.0	1	
MCDOWELL_ACUTE_LUNG_INJURY_UP 	0	50	42	16946	0.0	1.0	1	
MCGARVEY_SILENCED_BY_METHYLATION_IN_COLON_CANCER 	0	50	35	16953	0.0	1.0	1	
MCLACHLAN_DENTAL_CARIES_DN 	0	50	75	16913	0.0	1.0	1	
MCLACHLAN_DENTAL_CARIES_UP 	0	50	211	16777	0.0	1.0	1	
MCMURRAY_TP53_HRAS_COOPERATION_RESPONSE_DN 	0	50	62	16926	0.0	1.0	1	
MEDINA_SMARCA4_TARGETS 	0	50	37	16951	0.0	1.0	1	
MEISSNER_BRAIN_HCP_WITH_H3K27ME3 	0	50	126	16862	0.0	1.0	1	
MEISSNER_BRAIN_HCP_WITH_H3K4ME2_AND_H3K27ME3 	0	50	40	16948	0.0	1.0	1	
MEISSNER_BRAIN_HCP_WITH_H3_UNMETHYLATED 	0	50	18	16970	0.0	1.0	1	
MEISSNER_BRAIN_ICP_WITH_H3K4ME3 	0	50	28	16960	0.0	1.0	1	
MEISSNER_ES_ICP_WITH_H3K4ME3 	0	50	29	16959	0.0	1.0	1	
MEISSNER_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3 	0	50	127	16861	0.0	1.0	1	
MELLMAN_TUT1_TARGETS_DN 	0	50	45	16943	0.0	1.0	1	
MENSE_HYPOXIA_UP 	0	50	95	16893	0.0	1.0	1	
MIKKELSEN_ES_HCP_WITH_H3K27ME3 	0	50	30	16958	0.0	1.0	1	
MIKKELSEN_ES_HCP_WITH_H3_UNMETHYLATED 	0	50	40	16948	0.0	1.0	1	
MIKKELSEN_ES_ICP_WITH_H3K27ME3 	0	50	29	16959	0.0	1.0	1	
MIKKELSEN_ES_ICP_WITH_H3K4ME3_AND_H3K27ME3 	0	50	106	16882	0.0	1.0	1	
MIKKELSEN_ES_LCP_WITH_H3K4ME3 	0	50	103	16885	0.0	1.0	1	
MIKKELSEN_IPS_HCP_WITH_H3_UNMETHYLATED 	0	50	52	16936	0.0	1.0	1	
MIKKELSEN_IPS_ICP_WITH_H3K27ME3 	0	50	38	16950	0.0	1.0	1	
MIKKELSEN_IPS_ICP_WITH_H3K4ME3_AND_H327ME3 	0	50	101	16887	0.0	1.0	1	
MIKKELSEN_IPS_LCP_WITH_H3K4ME3 	0	50	134	16854	0.0	1.0	1	
MIKKELSEN_IPS_WITH_HCP_H3K27ME3 	0	50	63	16925	0.0	1.0	1	
MIKKELSEN_MCV6_ICP_WITH_H3K27ME3 	0	50	44	16944	0.0	1.0	1	
MIKKELSEN_MCV6_ICP_WITH_H3K4ME3_AND_H3K27ME3 	0	50	28	16960	0.0	1.0	1	
MIKKELSEN_MCV6_LCP_WITH_H3K4ME3 	0	50	130	16858	0.0	1.0	1	
MIKKELSEN_MEF_ICP_WITH_H3K4ME3_AND_H3K27ME3 	0	50	34	16954	0.0	1.0	1	
MIKKELSEN_MEF_LCP_WITH_H3K27ME3 	0	50	42	16946	0.0	1.0	1	
MIKKELSEN_MEF_LCP_WITH_H3K4ME3 	0	50	107	16881	0.0	1.0	1	
MIKKELSEN_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3 	0	50	181	16807	0.0	1.0	1	
MIKKELSEN_NPC_LCP_WITH_H3K4ME3 	0	50	49	16939	0.0	1.0	1	
MILI_PSEUDOPODIA 	0	50	42	16946	0.0	1.0	1	
MISSIAGLIA_REGULATED_BY_METHYLATION_UP 	0	50	106	16882	0.0	1.0	1	
MMS_MOUSE_LYMPH_HIGH_4HRS_UP 	0	50	31	16957	0.0	1.0	1	
MODY_HIPPOCAMPUS_POSTNATAL 	0	50	62	16926	0.0	1.0	1	
MODY_HIPPOCAMPUS_PRENATAL 	0	50	39	16949	0.0	1.0	1	
MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN 	0	50	42	16946	0.0	1.0	1	
MOOTHA_GLUCONEOGENESIS 	0	50	28	16960	0.0	1.0	1	
MOOTHA_VOXPHOS 	0	50	84	16904	0.0	1.0	1	
MOREAUX_B_LYMPHOCYTE_MATURATION_BY_TACI_DN 	0	50	66	16922	0.0	1.0	1	
MORI_EMU_MYC_LYMPHOMA_BY_ONSET_TIME_UP 	0	50	98	16890	0.0	1.0	1	
MORI_IMMATURE_B_LYMPHOCYTE_DN 	0	50	75	16913	0.0	1.0	1	
MORI_IMMATURE_B_LYMPHOCYTE_UP 	0	50	47	16941	0.0	1.0	1	
MORI_LARGE_PRE_BII_LYMPHOCYTE_DN 	0	50	54	16934	0.0	1.0	1	
MORI_LARGE_PRE_BII_LYMPHOCYTE_UP 	0	50	71	16917	0.0	1.0	1	
MORI_MATURE_B_LYMPHOCYTE_DN 	0	50	66	16922	0.0	1.0	1	
MORI_MATURE_B_LYMPHOCYTE_UP 	0	50	82	16906	0.0	1.0	1	
MORI_PLASMA_CELL_DN 	0	50	27	16961	0.0	1.0	1	
MORI_PLASMA_CELL_UP 	0	50	47	16941	0.0	1.0	1	
MORI_PRE_BI_LYMPHOCYTE_DN 	0	50	68	16920	0.0	1.0	1	
MORI_SMALL_PRE_BII_LYMPHOCYTE_DN 	0	50	73	16915	0.0	1.0	1	
MORI_SMALL_PRE_BII_LYMPHOCYTE_UP 	0	50	74	16914	0.0	1.0	1	
MOSERLE_IFNA_RESPONSE 	0	50	31	16957	0.0	1.0	1	
MUELLER_METHYLATED_IN_GLIOBLASTOMA 	0	50	26	16962	0.0	1.0	1	
MULLIGHAN_MLL_SIGNATURE_1_DN 	0	50	215	16773	0.0	1.0	1	
MULLIGHAN_MLL_SIGNATURE_2_DN 	0	50	251	16737	0.0	1.0	1	
MULLIGHAN_NPM1_MUTATED_SIGNATURE_1_DN 	0	50	110	16878	0.0	1.0	1	
MULLIGHAN_NPM1_MUTATED_SIGNATURE_1_UP 	0	50	219	16769	0.0	1.0	1	
MULLIGHAN_NPM1_MUTATED_SIGNATURE_2_DN 	0	50	69	16919	0.0	1.0	1	
MULLIGHAN_NPM1_MUTATED_SIGNATURE_2_UP 	0	50	115	16873	0.0	1.0	1	
MULLIGHAN_NPM1_SIGNATURE_3_DN 	0	50	144	16844	0.0	1.0	1	
MUNSHI_MULTIPLE_MYELOMA_UP 	0	50	77	16911	0.0	1.0	1	
MURAKAMI_UV_RESPONSE_6HR_UP 	0	50	36	16952	0.0	1.0	1	
NABA_BASEMENT_MEMBRANES 	0	50	37	16951	0.0	1.0	1	
NABA_COLLAGENS 	0	50	43	16945	0.0	1.0	1	
NABA_CORE_MATRISOME 	0	50	231	16757	0.0	1.0	1	
NABA_ECM_AFFILIATED 	0	50	120	16868	0.0	1.0	1	
NABA_ECM_GLYCOPROTEINS 	0	50	160	16828	0.0	1.0	1	
NABA_ECM_REGULATORS 	0	50	160	16828	0.0	1.0	1	
NABA_PROTEOGLYCANS 	0	50	28	16960	0.0	1.0	1	
NADERI_BREAST_CANCER_PROGNOSIS_UP 	0	50	36	16952	0.0	1.0	1	
NADLER_HYPERGLYCEMIA_AT_OBESITY 	0	50	53	16935	0.0	1.0	1	
NADLER_OBESITY_DN 	0	50	44	16944	0.0	1.0	1	
NADLER_OBESITY_UP 	0	50	58	16930	0.0	1.0	1	
NAGASHIMA_EGF_SIGNALING_UP 	0	50	55	16933	0.0	1.0	1	
NAGASHIMA_NRG1_SIGNALING_DN 	0	50	48	16940	0.0	1.0	1	
NAGASHIMA_NRG1_SIGNALING_UP 	0	50	165	16823	0.0	1.0	1	
NAKAJIMA_MAST_CELL 	0	50	39	16949	0.0	1.0	1	
NAKAMURA_ADIPOGENESIS_EARLY_DN 	0	50	38	16950	0.0	1.0	1	
NAKAMURA_ADIPOGENESIS_EARLY_UP 	0	50	59	16929	0.0	1.0	1	
NAKAMURA_ADIPOGENESIS_LATE_DN 	0	50	37	16951	0.0	1.0	1	
NAKAMURA_CANCER_MICROENVIRONMENT_DN 	0	50	41	16947	0.0	1.0	1	
NAKAMURA_METASTASIS 	0	50	42	16946	0.0	1.0	1	
NAKAMURA_METASTASIS_MODEL_DN 	0	50	35	16953	0.0	1.0	1	
NAKAMURA_METASTASIS_MODEL_UP 	0	50	39	16949	0.0	1.0	1	
NAKAYAMA_FRA2_TARGETS 	0	50	39	16949	0.0	1.0	1	
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA1_DN 	0	50	66	16922	0.0	1.0	1	
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA1_UP 	0	50	67	16921	0.0	1.0	1	
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_DN 	0	50	72	16916	0.0	1.0	1	
NATSUME_RESPONSE_TO_INTERFERON_BETA_DN 	0	50	49	16939	0.0	1.0	1	
NELSON_RESPONSE_TO_ANDROGEN_UP 	0	50	79	16909	0.0	1.0	1	
NEMETH_INFLAMMATORY_RESPONSE_LPS_UP 	0	50	84	16904	0.0	1.0	1	
NEWMAN_ERCC6_TARGETS_DN 	0	50	31	16957	0.0	1.0	1	
NGUYEN_NOTCH1_TARGETS_DN 	0	50	84	16904	0.0	1.0	1	
NIKOLSKY_BREAST_CANCER_11Q12_Q14_AMPLICON 	0	50	127	16861	0.0	1.0	1	
NIKOLSKY_BREAST_CANCER_12Q13_Q21_AMPLICON 	0	50	41	16947	0.0	1.0	1	
NIKOLSKY_BREAST_CANCER_16P13_AMPLICON 	0	50	92	16896	0.0	1.0	1	
NIKOLSKY_BREAST_CANCER_16Q24_AMPLICON 	0	50	42	16946	0.0	1.0	1	
NIKOLSKY_BREAST_CANCER_1Q21_AMPLICON 	0	50	35	16953	0.0	1.0	1	
NIKOLSKY_BREAST_CANCER_20Q11_AMPLICON 	0	50	27	16961	0.0	1.0	1	
NIKOLSKY_BREAST_CANCER_20Q12_Q13_AMPLICON 	0	50	112	16876	0.0	1.0	1	
NIKOLSKY_BREAST_CANCER_7P22_AMPLICON 	0	50	31	16957	0.0	1.0	1	
NIKOLSKY_BREAST_CANCER_7Q21_Q22_AMPLICON 	0	50	60	16928	0.0	1.0	1	
NIKOLSKY_BREAST_CANCER_8P12_P11_AMPLICON 	0	50	38	16950	0.0	1.0	1	
NIKOLSKY_BREAST_CANCER_8Q23_Q24_AMPLICON 	0	50	132	16856	0.0	1.0	1	
NIKOLSKY_MUTATED_AND_AMPLIFIED_IN_BREAST_CANCER 	0	50	78	16910	0.0	1.0	1	
NING_CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE_DN 	0	50	114	16874	0.0	1.0	1	
NOJIMA_SFRP2_TARGETS_UP 	0	50	27	16961	0.0	1.0	1	
NOUSHMEHR_GBM_SILENCED_BY_METHYLATION 	0	50	46	16942	0.0	1.0	1	
NOUZOVA_METHYLATED_IN_APL 	0	50	52	16936	0.0	1.0	1	
NOUZOVA_TRETINOIN_AND_H4_ACETYLATION 	0	50	127	16861	0.0	1.0	1	
NUTT_GBM_VS_AO_GLIOMA_DN 	0	50	44	16944	0.0	1.0	1	
NUTT_GBM_VS_AO_GLIOMA_UP 	0	50	46	16942	0.0	1.0	1	
ODONNELL_METASTASIS_UP 	0	50	62	16926	0.0	1.0	1	
ODONNELL_TARGETS_OF_MYC_AND_TFRC_DN 	0	50	38	16950	0.0	1.0	1	
ODONNELL_TARGETS_OF_MYC_AND_TFRC_UP 	0	50	74	16914	0.0	1.0	1	
OHGUCHI_LIVER_HNF4A_TARGETS_DN 	0	50	91	16897	0.0	1.0	1	
OHGUCHI_LIVER_HNF4A_TARGETS_UP 	0	50	38	16950	0.0	1.0	1	
OKUMURA_INFLAMMATORY_RESPONSE_LPS 	0	50	162	16826	0.0	1.0	1	
OLSSON_E2F3_TARGETS_DN 	0	50	40	16948	0.0	1.0	1	
ONDER_CDH1_TARGETS_1_DN 	0	50	142	16846	0.0	1.0	1	
ONDER_CDH1_TARGETS_1_UP 	0	50	129	16859	0.0	1.0	1	
ONDER_CDH1_TARGETS_3_DN 	0	50	36	16952	0.0	1.0	1	
ONGUSAHA_TP53_TARGETS 	0	50	33	16955	0.0	1.0	1	
ONO_AML1_TARGETS_DN 	0	50	25	16963	0.0	1.0	1	
ONO_FOXP3_TARGETS_DN 	0	50	29	16959	0.0	1.0	1	
OSADA_ASCL1_TARGETS_UP 	0	50	40	16948	0.0	1.0	1	
OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_DN 	0	50	239	16749	0.0	1.0	1	
OUELLET_CULTURED_OVARIAN_CANCER_INVASIVE_VS_LMP_DN 	0	50	25	16963	0.0	1.0	1	
OUELLET_CULTURED_OVARIAN_CANCER_INVASIVE_VS_LMP_UP 	0	50	63	16925	0.0	1.0	1	
OUELLET_OVARIAN_CANCER_INVASIVE_VS_LMP_UP 	0	50	115	16873	0.0	1.0	1	
OUILLETTE_CLL_13Q14_DELETION_DN 	0	50	51	16937	0.0	1.0	1	
OUILLETTE_CLL_13Q14_DELETION_UP 	0	50	67	16921	0.0	1.0	1	
OXFORD_RALA_OR_RALB_TARGETS_UP 	0	50	42	16946	0.0	1.0	1	
PACHER_TARGETS_OF_IGF1_AND_IGF2_UP 	0	50	34	16954	0.0	1.0	1	
PANGAS_TUMOR_SUPPRESSION_BY_SMAD1_AND_SMAD5_DN 	0	50	137	16851	0.0	1.0	1	
PANGAS_TUMOR_SUPPRESSION_BY_SMAD1_AND_SMAD5_UP 	0	50	124	16864	0.0	1.0	1	
PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_DN 	0	50	42	16946	0.0	1.0	1	
PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_UP 	0	50	48	16940	0.0	1.0	1	
PARENT_MTOR_SIGNALING_DN 	0	50	38	16950	0.0	1.0	1	
PARK_APL_PATHOGENESIS_DN 	0	50	45	16943	0.0	1.0	1	
PARK_HSC_AND_MULTIPOTENT_PROGENITORS 	0	50	48	16940	0.0	1.0	1	
PARK_HSC_MARKERS 	0	50	42	16946	0.0	1.0	1	
PASINI_SUZ12_TARGETS_UP 	0	50	90	16898	0.0	1.0	1	
PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_DN 	0	50	150	16838	0.0	1.0	1	
PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_UP 	0	50	258	16730	0.0	1.0	1	
PEART_HDAC_PROLIFERATION_CLUSTER_DN 	0	50	70	16918	0.0	1.0	1	
PECE_MAMMARY_STEM_CELL_DN 	0	50	131	16857	0.0	1.0	1	
PECE_MAMMARY_STEM_CELL_UP 	0	50	131	16857	0.0	1.0	1	
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_1 	0	50	39	16949	0.0	1.0	1	
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_4 	0	50	96	16892	0.0	1.0	1	
PEDERSEN_TARGETS_OF_611CTF_ISOFORM_OF_ERBB2 	0	50	66	16922	0.0	1.0	1	
PELLICCIOTTA_HDAC_IN_ANTIGEN_PRESENTATION_DN 	0	50	49	16939	0.0	1.0	1	
PELLICCIOTTA_HDAC_IN_ANTIGEN_PRESENTATION_UP 	0	50	61	16927	0.0	1.0	1	
PENG_GLUCOSE_DEPRIVATION_UP 	0	50	42	16946	0.0	1.0	1	
PENG_GLUTAMINE_DEPRIVATION_UP 	0	50	34	16954	0.0	1.0	1	
PENG_LEUCINE_DEPRIVATION_UP 	0	50	131	16857	0.0	1.0	1	
PENG_RAPAMYCIN_RESPONSE_UP 	0	50	182	16806	0.0	1.0	1	
PEPPER_CHRONIC_LYMPHOCYTIC_LEUKEMIA_UP 	0	50	30	16958	0.0	1.0	1	
PEREZ_TP53_AND_TP63_TARGETS 	0	50	185	16803	0.0	1.0	1	
PETRETTO_CARDIAC_HYPERTROPHY 	0	50	33	16955	0.0	1.0	1	
PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN 	0	50	152	16836	0.0	1.0	1	
PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_UP 	0	50	114	16874	0.0	1.0	1	
PETROVA_PROX1_TARGETS_DN 	0	50	59	16929	0.0	1.0	1	
PHONG_TNF_RESPONSE_VIA_P38_COMPLETE 	0	50	218	16770	0.0	1.0	1	
PHONG_TNF_RESPONSE_VIA_P38_PARTIAL 	0	50	147	16841	0.0	1.0	1	
PHONG_TNF_TARGETS_UP 	0	50	57	16931	0.0	1.0	1	
PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_DN 	0	50	124	16864	0.0	1.0	1	
PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP 	0	50	195	16793	0.0	1.0	1	
PID_AJDISS_2PATHWAY 	0	50	45	16943	0.0	1.0	1	
PID_ALPHA_SYNUCLEIN_PATHWAY 	0	50	31	16957	0.0	1.0	1	
PID_AMB2_NEUTROPHILS_PATHWAY 	0	50	37	16951	0.0	1.0	1	
PID_ANGIOPOIETIN_RECEPTOR_PATHWAY 	0	50	46	16942	0.0	1.0	1	
PID_ARF6_PATHWAY 	0	50	34	16954	0.0	1.0	1	
PID_ARF6_TRAFFICKING_PATHWAY 	0	50	46	16942	0.0	1.0	1	
PID_AR_NONGENOMIC_PATHWAY 	0	50	31	16957	0.0	1.0	1	
PID_AR_PATHWAY 	0	50	57	16931	0.0	1.0	1	
PID_AR_TF_PATHWAY 	0	50	47	16941	0.0	1.0	1	
PID_ATF2_PATHWAY 	0	50	53	16935	0.0	1.0	1	
PID_ATM_PATHWAY 	0	50	32	16956	0.0	1.0	1	
PID_ATR_PATHWAY 	0	50	37	16951	0.0	1.0	1	
PID_AURORA_A_PATHWAY 	0	50	27	16961	0.0	1.0	1	
PID_AURORA_B_PATHWAY 	0	50	34	16954	0.0	1.0	1	
PID_AVB3_INTEGRIN_PATHWAY 	0	50	73	16915	0.0	1.0	1	
PID_AVB3_OPN_PATHWAY 	0	50	31	16957	0.0	1.0	1	
PID_BCR_5PATHWAY 	0	50	63	16925	0.0	1.0	1	
PID_BETA_CATENIN_NUC_PATHWAY 	0	50	68	16920	0.0	1.0	1	
PID_BMP_PATHWAY 	0	50	39	16949	0.0	1.0	1	
PID_CD40_PATHWAY 	0	50	27	16961	0.0	1.0	1	
PID_CD8_TCR_DOWNSTREAM_PATHWAY 	0	50	44	16944	0.0	1.0	1	
PID_CD8_TCR_PATHWAY 	0	50	49	16939	0.0	1.0	1	
PID_CDC42_PATHWAY 	0	50	70	16918	0.0	1.0	1	
PID_CERAMIDE_PATHWAY 	0	50	47	16941	0.0	1.0	1	
PID_CMYB_PATHWAY 	0	50	77	16911	0.0	1.0	1	
PID_CXCR3_PATHWAY 	0	50	38	16950	0.0	1.0	1	
PID_CXCR4_PATHWAY 	0	50	96	16892	0.0	1.0	1	
PID_ECADHERIN_NASCENT_AJ_PATHWAY 	0	50	38	16950	0.0	1.0	1	
PID_ECADHERIN_STABILIZATION_PATHWAY 	0	50	40	16948	0.0	1.0	1	
PID_ENDOTHELIN_PATHWAY 	0	50	61	16927	0.0	1.0	1	
PID_EPHA_FWDPATHWAY 	0	50	33	16955	0.0	1.0	1	
PID_EPHB_FWD_PATHWAY 	0	50	40	16948	0.0	1.0	1	
PID_EPO_PATHWAY 	0	50	33	16955	0.0	1.0	1	
PID_ERA_GENOMIC_PATHWAY 	0	50	60	16928	0.0	1.0	1	
PID_ERBB1_INTERNALIZATION_PATHWAY 	0	50	41	16947	0.0	1.0	1	
PID_ERBB1_RECEPTOR_PROXIMAL_PATHWAY 	0	50	35	16953	0.0	1.0	1	
PID_ERBB2_ERBB3_PATHWAY 	0	50	44	16944	0.0	1.0	1	
PID_ERBB4_PATHWAY 	0	50	36	16952	0.0	1.0	1	
PID_ER_NONGENOMIC_PATHWAY 	0	50	41	16947	0.0	1.0	1	
PID_FAK_PATHWAY 	0	50	57	16931	0.0	1.0	1	
PID_FANCONI_PATHWAY 	0	50	42	16946	0.0	1.0	1	
PID_FAS_PATHWAY 	0	50	37	16951	0.0	1.0	1	
PID_FCER1_PATHWAY 	0	50	57	16931	0.0	1.0	1	
PID_FGF_PATHWAY 	0	50	51	16937	0.0	1.0	1	
PID_FOXM1_PATHWAY 	0	50	35	16953	0.0	1.0	1	
PID_FOXO_PATHWAY 	0	50	47	16941	0.0	1.0	1	
PID_FRA_PATHWAY 	0	50	33	16955	0.0	1.0	1	
PID_GMCSF_PATHWAY 	0	50	35	16953	0.0	1.0	1	
PID_HDAC_CLASSII_PATHWAY 	0	50	32	16956	0.0	1.0	1	
PID_HDAC_CLASSI_PATHWAY 	0	50	63	16925	0.0	1.0	1	
PID_HEDGEHOG_GLI_PATHWAY 	0	50	47	16941	0.0	1.0	1	
PID_HES_HEY_PATHWAY 	0	50	42	16946	0.0	1.0	1	
PID_HIF1_TFPATHWAY 	0	50	60	16928	0.0	1.0	1	
PID_HIF2PATHWAY 	0	50	31	16957	0.0	1.0	1	
PID_HNF3A_PATHWAY 	0	50	33	16955	0.0	1.0	1	
PID_HNF3B_PATHWAY 	0	50	31	16957	0.0	1.0	1	
PID_IL12_2PATHWAY 	0	50	52	16936	0.0	1.0	1	
PID_IL12_STAT4_PATHWAY 	0	50	24	16964	0.0	1.0	1	
PID_IL1_PATHWAY 	0	50	32	16956	0.0	1.0	1	
PID_IL2_1PATHWAY 	0	50	52	16936	0.0	1.0	1	
PID_IL23_PATHWAY 	0	50	26	16962	0.0	1.0	1	
PID_IL2_PI3K_PATHWAY 	0	50	32	16956	0.0	1.0	1	
PID_IL4_2PATHWAY 	0	50	47	16941	0.0	1.0	1	
PID_IL6_7_PATHWAY 	0	50	43	16945	0.0	1.0	1	
PID_IL8_CXCR2_PATHWAY 	0	50	33	16955	0.0	1.0	1	
PID_ILK_PATHWAY 	0	50	45	16943	0.0	1.0	1	
PID_INSULIN_PATHWAY 	0	50	44	16944	0.0	1.0	1	
PID_INTEGRIN1_PATHWAY 	0	50	63	16925	0.0	1.0	1	
PID_INTEGRIN3_PATHWAY 	0	50	39	16949	0.0	1.0	1	
PID_INTEGRIN_A4B1_PATHWAY 	0	50	32	16956	0.0	1.0	1	
PID_KIT_PATHWAY 	0	50	50	16938	0.0	1.0	1	
PID_LKB1_PATHWAY 	0	50	46	16942	0.0	1.0	1	
PID_LYSOPHOSPHOLIPID_PATHWAY 	0	50	65	16923	0.0	1.0	1	
PID_MAPK_TRK_PATHWAY 	0	50	33	16955	0.0	1.0	1	
PID_MET_PATHWAY 	0	50	80	16908	0.0	1.0	1	
PID_MTOR_4PATHWAY 	0	50	69	16919	0.0	1.0	1	
PID_MYC_ACTIV_PATHWAY 	0	50	77	16911	0.0	1.0	1	
PID_MYC_REPRESS_PATHWAY 	0	50	58	16930	0.0	1.0	1	
PID_NCADHERIN_PATHWAY 	0	50	33	16955	0.0	1.0	1	
PID_NEPHRIN_NEPH1_PATHWAY 	0	50	30	16958	0.0	1.0	1	
PID_NETRIN_PATHWAY 	0	50	32	16956	0.0	1.0	1	
PID_NFAT_3PATHWAY 	0	50	53	16935	0.0	1.0	1	
PID_NFAT_TFPATHWAY 	0	50	33	16955	0.0	1.0	1	
PID_NOTCH_PATHWAY 	0	50	55	16933	0.0	1.0	1	
PID_P38_ALPHA_BETA_PATHWAY 	0	50	30	16958	0.0	1.0	1	
PID_P53_REGULATION_PATHWAY 	0	50	57	16931	0.0	1.0	1	
PID_P75_NTR_PATHWAY 	0	50	62	16926	0.0	1.0	1	
PID_PDGFRB_PATHWAY 	0	50	127	16861	0.0	1.0	1	
PID_PI3KCI_AKT_PATHWAY 	0	50	35	16953	0.0	1.0	1	
PID_PI3KCI_PATHWAY 	0	50	48	16940	0.0	1.0	1	
PID_PI3K_PLC_TRK_PATHWAY 	0	50	36	16952	0.0	1.0	1	
PID_PLK1_PATHWAY 	0	50	39	16949	0.0	1.0	1	
PID_PS1_PATHWAY 	0	50	45	16943	0.0	1.0	1	
PID_PTP1B_PATHWAY 	0	50	47	16941	0.0	1.0	1	
PID_RAC1_REG_PATHWAY 	0	50	38	16950	0.0	1.0	1	
PID_RB_1PATHWAY 	0	50	59	16929	0.0	1.0	1	
PID_REG_GR_PATHWAY 	0	50	65	16923	0.0	1.0	1	
PID_RET_PATHWAY 	0	50	39	16949	0.0	1.0	1	
PID_RHOA_PATHWAY 	0	50	45	16943	0.0	1.0	1	
PID_RHOA_REG_PATHWAY 	0	50	44	16944	0.0	1.0	1	
PID_SHP2_PATHWAY 	0	50	52	16936	0.0	1.0	1	
PID_SMAD2_3NUCLEAR_PATHWAY 	0	50	74	16914	0.0	1.0	1	
PID_SYNDECAN_1_PATHWAY 	0	50	44	16944	0.0	1.0	1	
PID_SYNDECAN_2_PATHWAY 	0	50	28	16960	0.0	1.0	1	
PID_SYNDECAN_4_PATHWAY 	0	50	28	16960	0.0	1.0	1	
PID_TAP63_PATHWAY 	0	50	53	16935	0.0	1.0	1	
PID_TCPTP_PATHWAY 	0	50	42	16946	0.0	1.0	1	
PID_TCR_PATHWAY 	0	50	62	16926	0.0	1.0	1	
PID_TELOMERASE_PATHWAY 	0	50	65	16923	0.0	1.0	1	
PID_TGFBR_PATHWAY 	0	50	55	16933	0.0	1.0	1	
PID_THROMBIN_PAR1_PATHWAY 	0	50	41	16947	0.0	1.0	1	
PID_TNF_PATHWAY 	0	50	43	16945	0.0	1.0	1	
PID_TRKR_PATHWAY 	0	50	60	16928	0.0	1.0	1	
PID_TXA2PATHWAY 	0	50	53	16935	0.0	1.0	1	
PID_UPA_UPAR_PATHWAY 	0	50	31	16957	0.0	1.0	1	
PID_VEGFR1_2_PATHWAY 	0	50	69	16919	0.0	1.0	1	
PID_WNT_NONCANONICAL_PATHWAY 	0	50	32	16956	0.0	1.0	1	
PIONTEK_PKD1_TARGETS_UP 	0	50	32	16956	0.0	1.0	1	
PLASARI_TGFB1_SIGNALING_VIA_NFIC_10HR_UP 	0	50	48	16940	0.0	1.0	1	
PLASARI_TGFB1_SIGNALING_VIA_NFIC_1HR_DN 	0	50	98	16890	0.0	1.0	1	
PLASARI_TGFB1_SIGNALING_VIA_NFIC_1HR_UP 	0	50	31	16957	0.0	1.0	1	
PLASARI_TGFB1_TARGETS_10HR_UP 	0	50	183	16805	0.0	1.0	1	
PLASARI_TGFB1_TARGETS_1HR_UP 	0	50	33	16955	0.0	1.0	1	
PODAR_RESPONSE_TO_ADAPHOSTIN_UP 	0	50	138	16850	0.0	1.0	1	
POMEROY_MEDULLOBLASTOMA_DESMOPLASIC_VS_CLASSIC_UP 	0	50	58	16930	0.0	1.0	1	
POMEROY_MEDULLOBLASTOMA_PROGNOSIS_DN 	0	50	42	16946	0.0	1.0	1	
POMEROY_MEDULLOBLASTOMA_PROGNOSIS_UP 	0	50	41	16947	0.0	1.0	1	
POOLA_INVASIVE_BREAST_CANCER_DN 	0	50	120	16868	0.0	1.0	1	
POOLA_INVASIVE_BREAST_CANCER_UP 	0	50	215	16773	0.0	1.0	1	
POS_HISTAMINE_RESPONSE_NETWORK 	0	50	29	16959	0.0	1.0	1	
PRAMOONJAGO_SOX4_TARGETS_DN 	0	50	47	16941	0.0	1.0	1	
PRAMOONJAGO_SOX4_TARGETS_UP 	0	50	51	16937	0.0	1.0	1	
PROVENZANI_METASTASIS_DN 	0	50	129	16859	0.0	1.0	1	
PROVENZANI_METASTASIS_UP 	0	50	179	16809	0.0	1.0	1	
PUIFFE_INVASION_INHIBITED_BY_ASCITES_UP 	0	50	75	16913	0.0	1.0	1	
PURBEY_TARGETS_OF_CTBP1_AND_SATB1_UP 	0	50	75	16913	0.0	1.0	1	
PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP 	0	50	163	16825	0.0	1.0	1	
PYEON_HPV_POSITIVE_TUMORS_UP 	0	50	85	16903	0.0	1.0	1	
QI_HYPOXIA 	0	50	135	16853	0.0	1.0	1	
QI_HYPOXIA_TARGETS_OF_HIF1A_AND_FOXA2 	0	50	36	16952	0.0	1.0	1	
QI_PLASMACYTOMA_DN 	0	50	91	16897	0.0	1.0	1	
RADMACHER_AML_PROGNOSIS 	0	50	68	16920	0.0	1.0	1	
RAGHAVACHARI_PLATELET_SPECIFIC_GENES 	0	50	63	16925	0.0	1.0	1	
RAMALHO_STEMNESS_DN 	0	50	67	16921	0.0	1.0	1	
RAMASWAMY_METASTASIS_DN 	0	50	56	16932	0.0	1.0	1	
RAO_BOUND_BY_SALL4 	0	50	195	16793	0.0	1.0	1	
RASHI_RESPONSE_TO_IONIZING_RADIATION_1 	0	50	38	16950	0.0	1.0	1	
RASHI_RESPONSE_TO_IONIZING_RADIATION_2 	0	50	119	16869	0.0	1.0	1	
RASHI_RESPONSE_TO_IONIZING_RADIATION_3 	0	50	44	16944	0.0	1.0	1	
RASHI_RESPONSE_TO_IONIZING_RADIATION_4 	0	50	54	16934	0.0	1.0	1	
RASHI_RESPONSE_TO_IONIZING_RADIATION_5 	0	50	134	16854	0.0	1.0	1	
RASHI_RESPONSE_TO_IONIZING_RADIATION_6 	0	50	70	16918	0.0	1.0	1	
RAY_TUMORIGENESIS_BY_ERBB2_CDC25A_DN 	0	50	145	16843	0.0	1.0	1	
RAY_TUMORIGENESIS_BY_ERBB2_CDC25A_UP 	0	50	86	16902	0.0	1.0	1	
REACTOME_3_UTR_MEDIATED_TRANSLATIONAL_REGULATION 	0	50	104	16884	0.0	1.0	1	
REACTOME_ABC_FAMILY_PROTEINS_MEDIATED_TRANSPORT 	0	50	31	16957	0.0	1.0	1	
REACTOME_ACTIVATED_TLR4_SIGNALLING 	0	50	89	16899	0.0	1.0	1	
REACTOME_ACTIVATION_OF_CHAPERONE_GENES_BY_XBP1S 	0	50	43	16945	0.0	1.0	1	
REACTOME_ACTIVATION_OF_KAINATE_RECEPTORS_UPON_GLUTAMATE_BINDING 	0	50	29	16959	0.0	1.0	1	
REACTOME_ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS 	0	50	60	16928	0.0	1.0	1	
REACTOME_ACTIVATION_OF_NMDA_RECEPTOR_UPON_GLUTAMATE_BINDING_AND_POSTSYNAPTIC_EVENTS 	0	50	37	16951	0.0	1.0	1	
REACTOME_ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S 	0	50	56	16932	0.0	1.0	1	
REACTOME_AMINE_LIGAND_BINDING_RECEPTORS 	0	50	28	16960	0.0	1.0	1	
REACTOME_AMINO_ACID_AND_OLIGOPEPTIDE_SLC_TRANSPORTERS 	0	50	41	16947	0.0	1.0	1	
REACTOME_AMINO_ACID_TRANSPORT_ACROSS_THE_PLASMA_MEMBRANE 	0	50	26	16962	0.0	1.0	1	
REACTOME_AMYLOIDS 	0	50	39	16949	0.0	1.0	1	
REACTOME_ANTIGEN_PROCESSING_CROSS_PRESENTATION 	0	50	69	16919	0.0	1.0	1	
REACTOME_ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES 	0	50	64	16924	0.0	1.0	1	
REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_MITOTIC_PROTEINS 	0	50	63	16925	0.0	1.0	1	
REACTOME_APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY_G1 	0	50	61	16927	0.0	1.0	1	
REACTOME_AQUAPORIN_MEDIATED_TRANSPORT 	0	50	42	16946	0.0	1.0	1	
REACTOME_ASPARAGINE_N_LINKED_GLYCOSYLATION 	0	50	80	16908	0.0	1.0	1	
REACTOME_AUTODEGRADATION_OF_CDH1_BY_CDH1_APC_C 	0	50	55	16933	0.0	1.0	1	
REACTOME_AUTODEGRADATION_OF_THE_E3_UBIQUITIN_LIGASE_COP1 	0	50	46	16942	0.0	1.0	1	
REACTOME_BETA_DEFENSINS 	0	50	3	16985	0.0	1.0	1	
REACTOME_BIOLOGICAL_OXIDATIONS 	0	50	87	16901	0.0	1.0	1	
REACTOME_BMAL1_CLOCK_NPAS2_ACTIVATES_CIRCADIAN_EXPRESSION 	0	50	33	16955	0.0	1.0	1	
REACTOME_CD28_CO_STIMULATION 	0	50	29	16959	0.0	1.0	1	
REACTOME_CDK_MEDIATED_PHOSPHORYLATION_AND_REMOVAL_OF_CDC6 	0	50	45	16943	0.0	1.0	1	
REACTOME_CELL_CELL_COMMUNICATION 	0	50	101	16887	0.0	1.0	1	
REACTOME_CELL_CELL_JUNCTION_ORGANIZATION 	0	50	41	16947	0.0	1.0	1	
REACTOME_CELL_DEATH_SIGNALLING_VIA_NRAGE_NRIF_AND_NADE 	0	50	57	16931	0.0	1.0	1	
REACTOME_CELL_JUNCTION_ORGANIZATION 	0	50	61	16927	0.0	1.0	1	
REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL 	0	50	75	16913	0.0	1.0	1	
REACTOME_CHEMOKINE_RECEPTORS_BIND_CHEMOKINES 	0	50	24	16964	0.0	1.0	1	
REACTOME_CHONDROITIN_SULFATE_DERMATAN_SULFATE_METABOLISM 	0	50	47	16941	0.0	1.0	1	
REACTOME_CHROMOSOME_MAINTENANCE 	0	50	86	16902	0.0	1.0	1	
REACTOME_CIRCADIAN_CLOCK 	0	50	49	16939	0.0	1.0	1	
REACTOME_CLASS_B_2_SECRETIN_FAMILY_RECEPTORS 	0	50	65	16923	0.0	1.0	1	
REACTOME_CLEAVAGE_OF_GROWING_TRANSCRIPT_IN_THE_TERMINATION_REGION_ 	0	50	42	16946	0.0	1.0	1	
REACTOME_COLLAGEN_FORMATION 	0	50	54	16934	0.0	1.0	1	
REACTOME_COMPLEMENT_CASCADE 	0	50	19	16969	0.0	1.0	1	
REACTOME_COSTIMULATION_BY_THE_CD28_FAMILY 	0	50	54	16934	0.0	1.0	1	
REACTOME_CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIGENS_ENDOSOMES 	0	50	45	16943	0.0	1.0	1	
REACTOME_CYCLIN_E_ASSOCIATED_EVENTS_DURING_G1_S_TRANSITION_ 	0	50	62	16926	0.0	1.0	1	
REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE 	0	50	31	16957	0.0	1.0	1	
REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM 	0	50	230	16758	0.0	1.0	1	
REACTOME_DAG_AND_IP3_SIGNALING 	0	50	29	16959	0.0	1.0	1	
REACTOME_DEFENSINS 	0	50	5	16983	0.0	1.0	1	
REACTOME_DEPOSITION_OF_NEW_CENPA_CONTAINING_NUCLEOSOMES_AT_THE_CENTROMERE 	0	50	35	16953	0.0	1.0	1	
REACTOME_DESTABILIZATION_OF_MRNA_BY_AUF1_HNRNP_D0 	0	50	49	16939	0.0	1.0	1	
REACTOME_DIABETES_PATHWAYS 	0	50	110	16878	0.0	1.0	1	
REACTOME_DNA_REPAIR 	0	50	98	16890	0.0	1.0	1	
REACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR 	0	50	91	16897	0.0	1.0	1	
REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR 	0	50	89	16899	0.0	1.0	1	
REACTOME_DOWNSTREAM_SIGNAL_TRANSDUCTION 	0	50	89	16899	0.0	1.0	1	
REACTOME_DOWNSTREAM_TCR_SIGNALING 	0	50	30	16958	0.0	1.0	1	
REACTOME_ELONGATION_ARREST_AND_RECOVERY 	0	50	24	16964	0.0	1.0	1	
REACTOME_ER_PHAGOSOME_PATHWAY 	0	50	56	16932	0.0	1.0	1	
REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION 	0	50	68	16920	0.0	1.0	1	
REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPMENT_AND_PLATELET_PRODUCTION 	0	50	91	16897	0.0	1.0	1	
REACTOME_FORMATION_OF_FIBRIN_CLOT_CLOTTING_CASCADE 	0	50	19	16969	0.0	1.0	1	
REACTOME_FORMATION_OF_RNA_POL_II_ELONGATION_COMPLEX_ 	0	50	35	16953	0.0	1.0	1	
REACTOME_FORMATION_OF_THE_HIV1_EARLY_ELONGATION_COMPLEX 	0	50	28	16960	0.0	1.0	1	
REACTOME_FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSEQUENTLY_THE_43S_COMPLEX 	0	50	48	16940	0.0	1.0	1	
REACTOME_FRS2_MEDIATED_CASCADE 	0	50	30	16958	0.0	1.0	1	
REACTOME_G1_PHASE 	0	50	34	16954	0.0	1.0	1	
REACTOME_GAB1_SIGNALOSOME 	0	50	36	16952	0.0	1.0	1	
REACTOME_GABA_B_RECEPTOR_ACTIVATION 	0	50	35	16953	0.0	1.0	1	
REACTOME_GABA_RECEPTOR_ACTIVATION 	0	50	47	16941	0.0	1.0	1	
REACTOME_G_ALPHA1213_SIGNALLING_EVENTS 	0	50	71	16917	0.0	1.0	1	
REACTOME_G_ALPHA_S_SIGNALLING_EVENTS 	0	50	82	16906	0.0	1.0	1	
REACTOME_G_ALPHA_Z_SIGNALLING_EVENTS 	0	50	42	16946	0.0	1.0	1	
REACTOME_GLOBAL_GENOMIC_NER_GG_NER 	0	50	32	16956	0.0	1.0	1	
REACTOME_GLUCAGON_SIGNALING_IN_METABOLIC_REGULATION 	0	50	29	16959	0.0	1.0	1	
REACTOME_GLUCAGON_TYPE_LIGAND_RECEPTORS 	0	50	24	16964	0.0	1.0	1	
REACTOME_GLUCONEOGENESIS 	0	50	27	16961	0.0	1.0	1	
REACTOME_GLUCOSE_METABOLISM 	0	50	58	16930	0.0	1.0	1	
REACTOME_GLUCOSE_TRANSPORT 	0	50	34	16954	0.0	1.0	1	
REACTOME_GLYCEROPHOSPHOLIPID_BIOSYNTHESIS 	0	50	70	16918	0.0	1.0	1	
REACTOME_GLYCOSAMINOGLYCAN_METABOLISM 	0	50	101	16887	0.0	1.0	1	
REACTOME_GLYCOSPHINGOLIPID_METABOLISM 	0	50	33	16955	0.0	1.0	1	
REACTOME_GOLGI_ASSOCIATED_VESICLE_BIOGENESIS 	0	50	49	16939	0.0	1.0	1	
REACTOME_GPVI_MEDIATED_ACTIVATION_CASCADE 	0	50	31	16957	0.0	1.0	1	
REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM 	0	50	48	16940	0.0	1.0	1	
REACTOME_HIV_INFECTION 	0	50	181	16807	0.0	1.0	1	
REACTOME_HIV_LIFE_CYCLE 	0	50	105	16883	0.0	1.0	1	
REACTOME_HOST_INTERACTIONS_OF_HIV_FACTORS 	0	50	114	16874	0.0	1.0	1	
REACTOME_HS_GAG_BIOSYNTHESIS 	0	50	27	16961	0.0	1.0	1	
REACTOME_IL1_SIGNALING 	0	50	36	16952	0.0	1.0	1	
REACTOME_IL_2_SIGNALING 	0	50	35	16953	0.0	1.0	1	
REACTOME_IL_3_5_AND_GM_CSF_SIGNALING 	0	50	37	16951	0.0	1.0	1	
REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL 	0	50	42	16946	0.0	1.0	1	
REACTOME_INFLUENZA_LIFE_CYCLE 	0	50	133	16855	0.0	1.0	1	
REACTOME_INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REPLICATION 	0	50	100	16888	0.0	1.0	1	
REACTOME_INNATE_IMMUNE_SYSTEM 	0	50	195	16793	0.0	1.0	1	
REACTOME_INSULIN_RECEPTOR_SIGNALLING_CASCADE 	0	50	76	16912	0.0	1.0	1	
REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS 	0	50	72	16916	0.0	1.0	1	
REACTOME_INTERACTIONS_OF_VPR_WITH_HOST_CELLULAR_PROTEINS 	0	50	31	16957	0.0	1.0	1	
REACTOME_INTERFERON_ALPHA_BETA_SIGNALING 	0	50	47	16941	0.0	1.0	1	
REACTOME_INTERFERON_GAMMA_SIGNALING 	0	50	54	16934	0.0	1.0	1	
REACTOME_INTERFERON_SIGNALING 	0	50	134	16854	0.0	1.0	1	
REACTOME_INWARDLY_RECTIFYING_K_CHANNELS 	0	50	28	16960	0.0	1.0	1	
REACTOME_ION_CHANNEL_TRANSPORT 	0	50	49	16939	0.0	1.0	1	
REACTOME_ION_TRANSPORT_BY_P_TYPE_ATPASES 	0	50	31	16957	0.0	1.0	1	
REACTOME_IRON_UPTAKE_AND_TRANSPORT 	0	50	33	16955	0.0	1.0	1	
REACTOME_LATENT_INFECTION_OF_HOMO_SAPIENS_WITH_MYCOBACTERIUM_TUBERCULOSIS 	0	50	27	16961	0.0	1.0	1	
REACTOME_LATE_PHASE_OF_HIV_LIFE_CYCLE 	0	50	92	16896	0.0	1.0	1	
REACTOME_LIPID_DIGESTION_MOBILIZATION_AND_TRANSPORT 	0	50	38	16950	0.0	1.0	1	
REACTOME_MAP_KINASE_ACTIVATION_IN_TLR_CASCADE 	0	50	49	16939	0.0	1.0	1	
REACTOME_MEIOSIS 	0	50	70	16918	0.0	1.0	1	
REACTOME_MEIOTIC_RECOMBINATION 	0	50	46	16942	0.0	1.0	1	
REACTOME_MEIOTIC_SYNAPSIS 	0	50	45	16943	0.0	1.0	1	
REACTOME_MEMBRANE_TRAFFICKING 	0	50	117	16871	0.0	1.0	1	
REACTOME_METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES 	0	50	168	16820	0.0	1.0	1	
REACTOME_METABOLISM_OF_CARBOHYDRATES 	0	50	211	16777	0.0	1.0	1	
REACTOME_METABOLISM_OF_NON_CODING_RNA 	0	50	47	16941	0.0	1.0	1	
REACTOME_METABOLISM_OF_NUCLEOTIDES 	0	50	65	16923	0.0	1.0	1	
REACTOME_METABOLISM_OF_STEROID_HORMONES_AND_VITAMINS_A_AND_D 	0	50	22	16966	0.0	1.0	1	
REACTOME_MHC_CLASS_II_ANTIGEN_PRESENTATION 	0	50	83	16905	0.0	1.0	1	
REACTOME_MITOCHONDRIAL_PROTEIN_IMPORT 	0	50	48	16940	0.0	1.0	1	
REACTOME_MRNA_3_END_PROCESSING 	0	50	33	16955	0.0	1.0	1	
REACTOME_MRNA_PROCESSING 	0	50	149	16839	0.0	1.0	1	
REACTOME_MRNA_SPLICING 	0	50	104	16884	0.0	1.0	1	
REACTOME_MRNA_SPLICING_MINOR_PATHWAY 	0	50	40	16948	0.0	1.0	1	
REACTOME_MUSCLE_CONTRACTION 	0	50	41	16947	0.0	1.0	1	
REACTOME_MYD88_MAL_CASCADE_INITIATED_ON_PLASMA_MEMBRANE 	0	50	79	16909	0.0	1.0	1	
REACTOME_NEGATIVE_REGULATION_OF_FGFR_SIGNALING 	0	50	30	16958	0.0	1.0	1	
REACTOME_NEGATIVE_REGULATORS_OF_RIG_I_MDA5_SIGNALING 	0	50	30	16958	0.0	1.0	1	
REACTOME_NETRIN1_SIGNALING 	0	50	35	16953	0.0	1.0	1	
REACTOME_NEUROTRANSMITTER_RECEPTOR_BINDING_AND_DOWNSTREAM_TRANSMISSION_IN_THE_POSTSYNAPTIC_CELL 	0	50	124	16864	0.0	1.0	1	
REACTOME_NFKB_AND_MAP_KINASES_ACTIVATION_MEDIATED_BY_TLR4_SIGNALING_REPERTOIRE 	0	50	69	16919	0.0	1.0	1	
REACTOME_NGF_SIGNALLING_VIA_TRKA_FROM_THE_PLASMA_MEMBRANE 	0	50	132	16856	0.0	1.0	1	
REACTOME_NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_EXON_JUNCTION_COMPLEX 	0	50	105	16883	0.0	1.0	1	
REACTOME_NOTCH1_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION 	0	50	44	16944	0.0	1.0	1	
REACTOME_NRAGE_SIGNALS_DEATH_THROUGH_JNK 	0	50	43	16945	0.0	1.0	1	
REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY 	0	50	42	16946	0.0	1.0	1	
REACTOME_NUCLEAR_SIGNALING_BY_ERBB4 	0	50	32	16956	0.0	1.0	1	
REACTOME_NUCLEOTIDE_BINDING_DOMAIN_LEUCINE_RICH_REPEAT_CONTAINING_RECEPTOR_NLR_SIGNALING_PATHWAYS 	0	50	43	16945	0.0	1.0	1	
REACTOME_NUCLEOTIDE_EXCISION_REPAIR 	0	50	48	16940	0.0	1.0	1	
REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS 	0	50	37	16951	0.0	1.0	1	
REACTOME_OPIOID_SIGNALLING 	0	50	71	16917	0.0	1.0	1	
REACTOME_P53_DEPENDENT_G1_DNA_DAMAGE_RESPONSE 	0	50	52	16936	0.0	1.0	1	
REACTOME_P53_INDEPENDENT_G1_S_DNA_DAMAGE_CHECKPOINT 	0	50	47	16941	0.0	1.0	1	
REACTOME_P75_NTR_RECEPTOR_MEDIATED_SIGNALLING 	0	50	78	16910	0.0	1.0	1	
REACTOME_PACKAGING_OF_TELOMERE_ENDS 	0	50	26	16962	0.0	1.0	1	
REACTOME_PEPTIDE_CHAIN_ELONGATION 	0	50	84	16904	0.0	1.0	1	
REACTOME_PHASE1_FUNCTIONALIZATION_OF_COMPOUNDS 	0	50	44	16944	0.0	1.0	1	
REACTOME_PHASE_II_CONJUGATION 	0	50	43	16945	0.0	1.0	1	
REACTOME_PHOSPHOLIPASE_C_MEDIATED_CASCADE 	0	50	45	16943	0.0	1.0	1	
REACTOME_PHOSPHOLIPID_METABOLISM 	0	50	173	16815	0.0	1.0	1	
REACTOME_PI3K_AKT_ACTIVATION 	0	50	36	16952	0.0	1.0	1	
REACTOME_PI_3K_CASCADE 	0	50	48	16940	0.0	1.0	1	
REACTOME_PI3K_CASCADE 	0	50	60	16928	0.0	1.0	1	
REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING 	0	50	41	16947	0.0	1.0	1	
REACTOME_PI3K_EVENTS_IN_ERBB4_SIGNALING 	0	50	35	16953	0.0	1.0	1	
REACTOME_PI_METABOLISM 	0	50	46	16942	0.0	1.0	1	
REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION 	0	50	179	16809	0.0	1.0	1	
REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION 	0	50	29	16959	0.0	1.0	1	
REACTOME_PLATELET_HOMEOSTASIS 	0	50	71	16917	0.0	1.0	1	
REACTOME_PLC_BETA_MEDIATED_EVENTS 	0	50	38	16950	0.0	1.0	1	
REACTOME_POST_NMDA_RECEPTOR_ACTIVATION_EVENTS 	0	50	33	16955	0.0	1.0	1	
REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION 	0	50	160	16828	0.0	1.0	1	
REACTOME_POTASSIUM_CHANNELS 	0	50	88	16900	0.0	1.0	1	
REACTOME_PPARA_ACTIVATES_GENE_EXPRESSION 	0	50	95	16893	0.0	1.0	1	
REACTOME_PRE_NOTCH_EXPRESSION_AND_PROCESSING 	0	50	38	16950	0.0	1.0	1	
REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA 	0	50	132	16856	0.0	1.0	1	
REACTOME_PROTEIN_FOLDING 	0	50	49	16939	0.0	1.0	1	
REACTOME_PURINE_METABOLISM 	0	50	30	16958	0.0	1.0	1	
REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_ACID_TCA_CYCLE 	0	50	40	16948	0.0	1.0	1	
REACTOME_REGULATION_OF_APOPTOSIS 	0	50	55	16933	0.0	1.0	1	
REACTOME_REGULATION_OF_INSULIN_SECRETION 	0	50	77	16911	0.0	1.0	1	
REACTOME_REGULATION_OF_INSULIN_SECRETION_BY_GLUCAGON_LIKE_PEPTIDE1 	0	50	38	16950	0.0	1.0	1	
REACTOME_REGULATION_OF_MITOTIC_CELL_CYCLE 	0	50	74	16914	0.0	1.0	1	
REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_BIND_AU_RICH_ELEMENTS 	0	50	80	16908	0.0	1.0	1	
REACTOME_REGULATION_OF_ORNITHINE_DECARBOXYLASE_ODC 	0	50	47	16941	0.0	1.0	1	
REACTOME_REGULATION_OF_WATER_BALANCE_BY_RENAL_AQUAPORINS 	0	50	37	16951	0.0	1.0	1	
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT 	0	50	64	16924	0.0	1.0	1	
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT_ATP_SYNTHESIS_BY_CHEMIOSMOTIC_COUPLING_AND_HEAT_PRODUCTION_BY_UNCOUPLING_PROTEINS_ 	0	50	79	16909	0.0	1.0	1	
REACTOME_RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2_ 	0	50	70	16918	0.0	1.0	1	
REACTOME_RIG_I_MDA5_MEDIATED_INDUCTION_OF_IFN_ALPHA_BETA_PATHWAYS 	0	50	57	16931	0.0	1.0	1	
REACTOME_RNA_POL_III_TRANSCRIPTION 	0	50	33	16955	0.0	1.0	1	
REACTOME_RNA_POL_II_PRE_TRANSCRIPTION_EVENTS 	0	50	51	16937	0.0	1.0	1	
REACTOME_RNA_POL_II_TRANSCRIPTION 	0	50	93	16895	0.0	1.0	1	
REACTOME_RNA_POL_II_TRANSCRIPTION_PRE_INITIATION_AND_PROMOTER_OPENING 	0	50	39	16949	0.0	1.0	1	
REACTOME_RNA_POL_I_PROMOTER_OPENING 	0	50	28	16960	0.0	1.0	1	
REACTOME_RNA_POL_I_RNA_POL_III_AND_MITOCHONDRIAL_TRANSCRIPTION 	0	50	84	16904	0.0	1.0	1	
REACTOME_RNA_POL_I_TRANSCRIPTION 	0	50	52	16936	0.0	1.0	1	
REACTOME_SCF_BETA_TRCP_MEDIATED_DEGRADATION_OF_EMI1 	0	50	48	16940	0.0	1.0	1	
REACTOME_SCFSKP2_MEDIATED_DEGRADATION_OF_P27_P21 	0	50	53	16935	0.0	1.0	1	
REACTOME_SEMA4D_IN_SEMAPHORIN_SIGNALING 	0	50	29	16959	0.0	1.0	1	
REACTOME_SEMAPHORIN_INTERACTIONS 	0	50	64	16924	0.0	1.0	1	
REACTOME_SIGNAL_AMPLIFICATION 	0	50	29	16959	0.0	1.0	1	
REACTOME_SIGNALING_BY_EGFR_IN_CANCER 	0	50	103	16885	0.0	1.0	1	
REACTOME_SIGNALING_BY_ERBB2 	0	50	94	16894	0.0	1.0	1	
REACTOME_SIGNALING_BY_ERBB4 	0	50	81	16907	0.0	1.0	1	
REACTOME_SIGNALING_BY_FGFR 	0	50	100	16888	0.0	1.0	1	
REACTOME_SIGNALING_BY_FGFR_IN_DISEASE 	0	50	114	16874	0.0	1.0	1	
REACTOME_SIGNALING_BY_FGFR_MUTANTS 	0	50	38	16950	0.0	1.0	1	
REACTOME_SIGNALING_BY_ILS 	0	50	96	16892	0.0	1.0	1	
REACTOME_SIGNALING_BY_INSULIN_RECEPTOR 	0	50	94	16894	0.0	1.0	1	
REACTOME_SIGNALING_BY_NOTCH 	0	50	95	16893	0.0	1.0	1	
REACTOME_SIGNALING_BY_NOTCH1 	0	50	67	16921	0.0	1.0	1	
REACTOME_SIGNALING_BY_PDGF 	0	50	115	16873	0.0	1.0	1	
REACTOME_SIGNALING_BY_RHO_GTPASES 	0	50	109	16879	0.0	1.0	1	
REACTOME_SIGNALING_BY_SCF_KIT 	0	50	74	16914	0.0	1.0	1	
REACTOME_SIGNALING_BY_TGF_BETA_RECEPTOR_COMPLEX 	0	50	60	16928	0.0	1.0	1	
REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR 	0	50	117	16871	0.0	1.0	1	
REACTOME_SIGNALING_BY_WNT 	0	50	61	16927	0.0	1.0	1	
REACTOME_SIGNALLING_BY_NGF 	0	50	209	16779	0.0	1.0	1	
REACTOME_SIGNALLING_TO_ERKS 	0	50	36	16952	0.0	1.0	1	
REACTOME_SLC_MEDIATED_TRANSMEMBRANE_TRANSPORT 	0	50	190	16798	0.0	1.0	1	
REACTOME_SPHINGOLIPID_DE_NOVO_BIOSYNTHESIS 	0	50	25	16963	0.0	1.0	1	
REACTOME_SPHINGOLIPID_METABOLISM 	0	50	58	16930	0.0	1.0	1	
REACTOME_SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE 	0	50	106	16882	0.0	1.0	1	
REACTOME_SYNTHESIS_OF_PIPS_AT_THE_PLASMA_MEMBRANE 	0	50	29	16959	0.0	1.0	1	
REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPORT 	0	50	115	16873	0.0	1.0	1	
REACTOME_TCR_SIGNALING 	0	50	47	16941	0.0	1.0	1	
REACTOME_TELOMERE_MAINTENANCE 	0	50	53	16935	0.0	1.0	1	
REACTOME_THROMBIN_SIGNALLING_THROUGH_PROTEINASE_ACTIVATED_RECEPTORS_PARS 	0	50	28	16960	0.0	1.0	1	
REACTOME_TOLL_RECEPTOR_CASCADES 	0	50	109	16879	0.0	1.0	1	
REACTOME_TRAF6_MEDIATED_INDUCTION_OF_NFKB_AND_MAP_KINASES_UPON_TLR7_8_OR_9_ACTIVATION 	0	50	73	16915	0.0	1.0	1	
REACTOME_TRANSCRIPTION 	0	50	162	16826	0.0	1.0	1	
REACTOME_TRANSCRIPTIONAL_ACTIVITY_OF_SMAD2_SMAD3_SMAD4_HETEROTRIMER 	0	50	36	16952	0.0	1.0	1	
REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION 	0	50	68	16920	0.0	1.0	1	
REACTOME_TRANSCRIPTION_COUPLED_NER_TC_NER 	0	50	43	16945	0.0	1.0	1	
REACTOME_TRANS_GOLGI_NETWORK_VESICLE_BUDDING 	0	50	56	16932	0.0	1.0	1	
REACTOME_TRANSLATION 	0	50	143	16845	0.0	1.0	1	
REACTOME_TRANSPORT_OF_GLUCOSE_AND_OTHER_SUGARS_BILE_SALTS_AND_ORGANIC_ACIDS_METAL_IONS_AND_AMINE_COMPOUNDS 	0	50	62	16926	0.0	1.0	1	
REACTOME_TRANSPORT_OF_INORGANIC_CATIONS_ANIONS_AND_AMINO_ACIDS_OLIGOPEPTIDES 	0	50	77	16911	0.0	1.0	1	
REACTOME_TRANSPORT_OF_MATURE_MRNA_DERIVED_FROM_AN_INTRONLESS_TRANSCRIPT 	0	50	31	16957	0.0	1.0	1	
REACTOME_TRANSPORT_OF_MATURE_TRANSCRIPT_TO_CYTOPLASM 	0	50	51	16937	0.0	1.0	1	
REACTOME_TRANSPORT_OF_VITAMINS_NUCLEOSIDES_AND_RELATED_MOLECULES 	0	50	24	16964	0.0	1.0	1	
REACTOME_TRANSPORT_TO_THE_GOLGI_AND_SUBSEQUENT_MODIFICATION 	0	50	33	16955	0.0	1.0	1	
REACTOME_TRIF_MEDIATED_TLR3_SIGNALING 	0	50	71	16917	0.0	1.0	1	
REACTOME_TRNA_AMINOACYLATION 	0	50	42	16946	0.0	1.0	1	
REACTOME_UNFOLDED_PROTEIN_RESPONSE 	0	50	73	16915	0.0	1.0	1	
REACTOME_VIF_MEDIATED_DEGRADATION_OF_APOBEC3G 	0	50	46	16942	0.0	1.0	1	
REACTOME_VOLTAGE_GATED_POTASSIUM_CHANNELS 	0	50	38	16950	0.0	1.0	1	
REN_ALVEOLAR_RHABDOMYOSARCOMA_UP 	0	50	85	16903	0.0	1.0	1	
RHEIN_ALL_GLUCOCORTICOID_THERAPY_UP 	0	50	67	16921	0.0	1.0	1	
RHODES_CANCER_META_SIGNATURE 	0	50	62	16926	0.0	1.0	1	
RHODES_UNDIFFERENTIATED_CANCER 	0	50	59	16929	0.0	1.0	1	
RICKMAN_HEAD_AND_NECK_CANCER_B 	0	50	34	16954	0.0	1.0	1	
RICKMAN_HEAD_AND_NECK_CANCER_C 	0	50	69	16919	0.0	1.0	1	
RICKMAN_HEAD_AND_NECK_CANCER_D 	0	50	20	16968	0.0	1.0	1	
RICKMAN_HEAD_AND_NECK_CANCER_F 	0	50	44	16944	0.0	1.0	1	
RICKMAN_TUMOR_DIFFERENTIATED_MODERATELY_VS_POORLY_UP 	0	50	110	16878	0.0	1.0	1	
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_MODERATELY_DN 	0	50	84	16904	0.0	1.0	1	
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_MODERATELY_UP 	0	50	100	16888	0.0	1.0	1	
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_UP 	0	50	219	16769	0.0	1.0	1	
RIGGI_EWING_SARCOMA_PROGENITOR_DN 	0	50	160	16828	0.0	1.0	1	
RIGGINS_TAMOXIFEN_RESISTANCE_DN 	0	50	208	16780	0.0	1.0	1	
RIZ_ERYTHROID_DIFFERENTIATION 	0	50	66	16922	0.0	1.0	1	
RIZ_ERYTHROID_DIFFERENTIATION_12HR 	0	50	35	16953	0.0	1.0	1	
RIZ_ERYTHROID_DIFFERENTIATION_6HR 	0	50	23	16965	0.0	1.0	1	
RIZ_ERYTHROID_DIFFERENTIATION_CCNE1 	0	50	35	16953	0.0	1.0	1	
RIZ_ERYTHROID_DIFFERENTIATION_HBZ 	0	50	30	16958	0.0	1.0	1	
RIZ_ERYTHROID_DIFFERENTIATION_HEMGN 	0	50	22	16966	0.0	1.0	1	
RIZKI_TUMOR_INVASIVENESS_2D_DN 	0	50	55	16933	0.0	1.0	1	
RIZKI_TUMOR_INVASIVENESS_2D_UP 	0	50	62	16926	0.0	1.0	1	
RODRIGUES_DCC_TARGETS_DN 	0	50	115	16873	0.0	1.0	1	
RODRIGUES_NTN1_AND_DCC_TARGETS 	0	50	31	16957	0.0	1.0	1	
RODRIGUES_NTN1_TARGETS_DN 	0	50	138	16850	0.0	1.0	1	
RODRIGUES_THYROID_CARCINOMA_DN 	0	50	71	16917	0.0	1.0	1	
RODWELL_AGING_KIDNEY_DN 	0	50	126	16862	0.0	1.0	1	
RODWELL_AGING_KIDNEY_NO_BLOOD_DN 	0	50	138	16850	0.0	1.0	1	
RODWELL_AGING_KIDNEY_NO_BLOOD_UP 	0	50	193	16795	0.0	1.0	1	
ROESSLER_LIVER_CANCER_METASTASIS_UP 	0	50	92	16896	0.0	1.0	1	
ROME_INSULIN_TARGETS_IN_MUSCLE_DN 	0	50	150	16838	0.0	1.0	1	
ROPERO_HDAC2_TARGETS 	0	50	89	16899	0.0	1.0	1	
ROSS_ACUTE_MYELOID_LEUKEMIA_CBF 	0	50	77	16911	0.0	1.0	1	
ROSS_AML_OF_FAB_M7_TYPE 	0	50	61	16927	0.0	1.0	1	
ROSS_AML_WITH_AML1_ETO_FUSION 	0	50	66	16922	0.0	1.0	1	
ROSS_AML_WITH_CBFB_MYH11_FUSION 	0	50	46	16942	0.0	1.0	1	
ROSS_AML_WITH_MLL_FUSIONS 	0	50	69	16919	0.0	1.0	1	
ROSS_AML_WITH_PML_RARA_FUSION 	0	50	71	16917	0.0	1.0	1	
ROSS_LEUKEMIA_WITH_MLL_FUSIONS 	0	50	68	16920	0.0	1.0	1	
ROVERSI_GLIOMA_COPY_NUMBER_DN 	0	50	49	16939	0.0	1.0	1	
ROVERSI_GLIOMA_LOH_REGIONS 	0	50	35	16953	0.0	1.0	1	
ROYLANCE_BREAST_CANCER_16Q_COPY_NUMBER_UP 	0	50	47	16941	0.0	1.0	1	
ROY_WOUND_BLOOD_VESSEL_UP 	0	50	48	16940	0.0	1.0	1	
ROZANOV_MMP14_TARGETS_DN 	0	50	29	16959	0.0	1.0	1	
ROZANOV_MMP14_TARGETS_SUBSET 	0	50	29	16959	0.0	1.0	1	
ROZANOV_MMP14_TARGETS_UP 	0	50	245	16743	0.0	1.0	1	
RUIZ_TNC_TARGETS_UP 	0	50	149	16839	0.0	1.0	1	
RUTELLA_RESPONSE_TO_HGF_DN 	0	50	224	16764	0.0	1.0	1	
RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_DN 	0	50	222	16766	0.0	1.0	1	
SABATES_COLORECTAL_ADENOMA_DN 	0	50	204	16784	0.0	1.0	1	
SABATES_COLORECTAL_ADENOMA_UP 	0	50	88	16900	0.0	1.0	1	
SAFFORD_T_LYMPHOCYTE_ANERGY 	0	50	76	16912	0.0	1.0	1	
SAGIV_CD24_TARGETS_DN 	0	50	41	16947	0.0	1.0	1	
SAKAI_CHRONIC_HEPATITIS_VS_LIVER_CANCER_DN 	0	50	29	16959	0.0	1.0	1	
SAKAI_CHRONIC_HEPATITIS_VS_LIVER_CANCER_UP 	0	50	78	16910	0.0	1.0	1	
SAKAI_TUMOR_INFILTRATING_MONOCYTES_DN 	0	50	76	16912	0.0	1.0	1	
SAMOLS_TARGETS_OF_KHSV_MIRNAS_DN 	0	50	58	16930	0.0	1.0	1	
SANA_RESPONSE_TO_IFNG_DN 	0	50	80	16908	0.0	1.0	1	
SANA_RESPONSE_TO_IFNG_UP 	0	50	70	16918	0.0	1.0	1	
SANA_TNF_SIGNALING_DN 	0	50	87	16901	0.0	1.0	1	
SANA_TNF_SIGNALING_UP 	0	50	73	16915	0.0	1.0	1	
SANSOM_APC_MYC_TARGETS 	0	50	191	16797	0.0	1.0	1	
SANSOM_APC_TARGETS_REQUIRE_MYC 	0	50	184	16804	0.0	1.0	1	
SANSOM_APC_TARGETS_UP 	0	50	107	16881	0.0	1.0	1	
SANSOM_WNT_PATHWAY_REQUIRE_MYC 	0	50	56	16932	0.0	1.0	1	
SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_DN 	0	50	135	16853	0.0	1.0	1	
SARTIPY_NORMAL_AT_INSULIN_RESISTANCE_UP 	0	50	31	16957	0.0	1.0	1	
SASAI_RESISTANCE_TO_NEOPLASTIC_TRANSFROMATION 	0	50	48	16940	0.0	1.0	1	
SASAKI_ADULT_T_CELL_LEUKEMIA 	0	50	155	16833	0.0	1.0	1	
SASSON_RESPONSE_TO_FORSKOLIN_DN 	0	50	87	16901	0.0	1.0	1	
SASSON_RESPONSE_TO_FORSKOLIN_UP 	0	50	84	16904	0.0	1.0	1	
SASSON_RESPONSE_TO_GONADOTROPHINS_DN 	0	50	86	16902	0.0	1.0	1	
SASSON_RESPONSE_TO_GONADOTROPHINS_UP 	0	50	84	16904	0.0	1.0	1	
SATO_SILENCED_BY_DEACETYLATION_IN_PANCREATIC_CANCER 	0	50	36	16952	0.0	1.0	1	
SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_CANCER_2 	0	50	39	16949	0.0	1.0	1	
SATO_SILENCED_EPIGENETICALLY_IN_PANCREATIC_CANCER 	0	50	38	16950	0.0	1.0	1	
SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_DN 	0	50	51	16937	0.0	1.0	1	
SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_UP 	0	50	154	16834	0.0	1.0	1	
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX4_DN 	0	50	32	16956	0.0	1.0	1	
SCHAEFFER_SOX9_TARGETS_IN_PROSTATE_DEVELOPMENT_DN 	0	50	41	16947	0.0	1.0	1	
SCHEIDEREIT_IKK_INTERACTING_PROTEINS 	0	50	55	16933	0.0	1.0	1	
SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER 	0	50	74	16914	0.0	1.0	1	
SCHLINGEMANN_SKIN_CARCINOGENESIS_TPA_UP 	0	50	33	16955	0.0	1.0	1	
SCHLOSSER_MYC_AND_SERUM_RESPONSE_SYNERGY 	0	50	32	16956	0.0	1.0	1	
SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP 	0	50	46	16942	0.0	1.0	1	
SCHLOSSER_MYC_TARGETS_REPRESSED_BY_SERUM 	0	50	151	16837	0.0	1.0	1	
SCHLOSSER_SERUM_RESPONSE_AUGMENTED_BY_MYC 	0	50	97	16891	0.0	1.0	1	
SCHLOSSER_SERUM_RESPONSE_UP 	0	50	116	16872	0.0	1.0	1	
SCHOEN_NFKB_SIGNALING 	0	50	31	16957	0.0	1.0	1	
SCHRAETS_MLL_TARGETS_DN 	0	50	26	16962	0.0	1.0	1	
SCHRAETS_MLL_TARGETS_UP 	0	50	32	16956	0.0	1.0	1	
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_DN 	0	50	75	16913	0.0	1.0	1	
SCIAN_INVERSED_TARGETS_OF_TP53_AND_TP73_DN 	0	50	29	16959	0.0	1.0	1	
SCIBETTA_KDM5B_TARGETS_DN 	0	50	70	16918	0.0	1.0	1	
SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_UP 	0	50	69	16919	0.0	1.0	1	
SEKI_INFLAMMATORY_RESPONSE_LPS_UP 	0	50	71	16917	0.0	1.0	1	
SEMENZA_HIF1_TARGETS 	0	50	32	16956	0.0	1.0	1	
SENESE_HDAC2_TARGETS_DN 	0	50	112	16876	0.0	1.0	1	
SENGUPTA_EBNA1_ANTICORRELATED 	0	50	132	16856	0.0	1.0	1	
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_UP 	0	50	257	16731	0.0	1.0	1	
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_DN 	0	50	107	16881	0.0	1.0	1	
SERVITJA_ISLET_HNF1A_TARGETS_DN 	0	50	77	16911	0.0	1.0	1	
SERVITJA_ISLET_HNF1A_TARGETS_UP 	0	50	154	16834	0.0	1.0	1	
SERVITJA_LIVER_HNF1A_TARGETS_DN 	0	50	104	16884	0.0	1.0	1	
SERVITJA_LIVER_HNF1A_TARGETS_UP 	0	50	114	16874	0.0	1.0	1	
SESTO_RESPONSE_TO_UV_C0 	0	50	100	16888	0.0	1.0	1	
SESTO_RESPONSE_TO_UV_C1 	0	50	65	16923	0.0	1.0	1	
SESTO_RESPONSE_TO_UV_C2 	0	50	52	16936	0.0	1.0	1	
SESTO_RESPONSE_TO_UV_C5 	0	50	45	16943	0.0	1.0	1	
SESTO_RESPONSE_TO_UV_C6 	0	50	39	16949	0.0	1.0	1	
SESTO_RESPONSE_TO_UV_C7 	0	50	58	16930	0.0	1.0	1	
SETLUR_PROSTATE_CANCER_TMPRSS2_ERG_FUSION_UP 	0	50	65	16923	0.0	1.0	1	
SHAFFER_IRF4_MULTIPLE_MYELOMA_PROGRAM 	0	50	31	16957	0.0	1.0	1	
SHAFFER_IRF4_TARGETS_IN_ACTIVATED_B_LYMPHOCYTE 	0	50	75	16913	0.0	1.0	1	
SHAFFER_IRF4_TARGETS_IN_ACTIVATED_DENDRITIC_CELL 	0	50	58	16930	0.0	1.0	1	
SHAFFER_IRF4_TARGETS_IN_MYELOMA_VS_MATURE_B_LYMPHOCYTE 	0	50	95	16893	0.0	1.0	1	
SHAFFER_IRF4_TARGETS_IN_PLASMA_CELL_VS_MATURE_B_LYMPHOCYTE 	0	50	61	16927	0.0	1.0	1	
SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A5 	0	50	60	16928	0.0	1.0	1	
SHEPARD_BMYB_TARGETS 	0	50	60	16928	0.0	1.0	1	
SHEPARD_CRUSH_AND_BURN_MUTANT_DN 	0	50	153	16835	0.0	1.0	1	
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM2 	0	50	135	16853	0.0	1.0	1	
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM3 	0	50	58	16930	0.0	1.0	1	
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4 	0	50	207	16781	0.0	1.0	1	
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM6 	0	50	42	16946	0.0	1.0	1	
SHIN_B_CELL_LYMPHOMA_CLUSTER_8 	0	50	30	16958	0.0	1.0	1	
SHIPP_DLBCL_CURED_VS_FATAL_DN 	0	50	41	16947	0.0	1.0	1	
SHIPP_DLBCL_CURED_VS_FATAL_UP 	0	50	30	16958	0.0	1.0	1	
SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_DN 	0	50	33	16955	0.0	1.0	1	
SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_UP 	0	50	41	16947	0.0	1.0	1	
SIG_BCR_SIGNALING_PATHWAY 	0	50	43	16945	0.0	1.0	1	
SIG_CD40PATHWAYMAP 	0	50	34	16954	0.0	1.0	1	
SIG_CHEMOTAXIS 	0	50	42	16946	0.0	1.0	1	
SIG_INSULIN_RECEPTOR_PATHWAY_IN_CARDIAC_MYOCYTES 	0	50	49	16939	0.0	1.0	1	
SIG_PIP3_SIGNALING_IN_B_LYMPHOCYTES 	0	50	33	16955	0.0	1.0	1	
SIG_PIP3_SIGNALING_IN_CARDIAC_MYOCTES 	0	50	65	16923	0.0	1.0	1	
SIG_REGULATION_OF_THE_ACTIN_CYTOSKELETON_BY_RHO_GTPASES 	0	50	32	16956	0.0	1.0	1	
SILIGAN_BOUND_BY_EWS_FLT1_FUSION 	0	50	43	16945	0.0	1.0	1	
SIMBULAN_PARP1_TARGETS_UP 	0	50	31	16957	0.0	1.0	1	
SIMBULAN_UV_RESPONSE_IMMORTALIZED_DN 	0	50	29	16959	0.0	1.0	1	
SIMBULAN_UV_RESPONSE_NORMAL_DN 	0	50	33	16955	0.0	1.0	1	
SLEBOS_HEAD_AND_NECK_CANCER_WITH_HPV_UP 	0	50	75	16913	0.0	1.0	1	
SMID_BREAST_CANCER_LUMINAL_A_UP 	0	50	70	16918	0.0	1.0	1	
SMID_BREAST_CANCER_LUMINAL_B_UP 	0	50	148	16840	0.0	1.0	1	
SMID_BREAST_CANCER_RELAPSE_IN_BONE_UP 	0	50	80	16908	0.0	1.0	1	
SMID_BREAST_CANCER_RELAPSE_IN_BRAIN_DN 	0	50	74	16914	0.0	1.0	1	
SMID_BREAST_CANCER_RELAPSE_IN_BRAIN_UP 	0	50	27	16961	0.0	1.0	1	
SMID_BREAST_CANCER_RELAPSE_IN_LUNG_DN 	0	50	28	16960	0.0	1.0	1	
SMIRNOV_CIRCULATING_ENDOTHELIOCYTES_IN_CANCER_UP 	0	50	149	16839	0.0	1.0	1	
SMIRNOV_RESPONSE_TO_IR_2HR_UP 	0	50	47	16941	0.0	1.0	1	
SMIRNOV_RESPONSE_TO_IR_6HR_DN 	0	50	96	16892	0.0	1.0	1	
SMIRNOV_RESPONSE_TO_IR_6HR_UP 	0	50	150	16838	0.0	1.0	1	
SMITH_LIVER_CANCER 	0	50	39	16949	0.0	1.0	1	
SMITH_TERT_TARGETS_DN 	0	50	83	16905	0.0	1.0	1	
SMITH_TERT_TARGETS_UP 	0	50	140	16848	0.0	1.0	1	
SNIJDERS_AMPLIFIED_IN_HEAD_AND_NECK_TUMORS 	0	50	34	16954	0.0	1.0	1	
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_DN 	0	50	49	16939	0.0	1.0	1	
SPIRA_SMOKERS_LUNG_CANCER_UP 	0	50	34	16954	0.0	1.0	1	
ST_ADRENERGIC 	0	50	30	16958	0.0	1.0	1	
STAEGE_EWING_FAMILY_TUMOR 	0	50	27	16961	0.0	1.0	1	
STAMBOLSKY_RESPONSE_TO_VITAMIN_D3_UP 	0	50	69	16919	0.0	1.0	1	
STAMBOLSKY_TARGETS_OF_MUTATED_TP53_DN 	0	50	45	16943	0.0	1.0	1	
STAMBOLSKY_TARGETS_OF_MUTATED_TP53_UP 	0	50	45	16943	0.0	1.0	1	
STARK_HYPPOCAMPUS_22Q11_DELETION_UP 	0	50	49	16939	0.0	1.0	1	
STARK_PREFRONTAL_CORTEX_22Q11_DELETION_UP 	0	50	186	16802	0.0	1.0	1	
ST_B_CELL_ANTIGEN_RECEPTOR 	0	50	37	16951	0.0	1.0	1	
ST_DIFFERENTIATION_PATHWAY_IN_PC12_CELLS 	0	50	41	16947	0.0	1.0	1	
STEARMAN_LUNG_CANCER_EARLY_VS_LATE_DN 	0	50	54	16934	0.0	1.0	1	
STEARMAN_LUNG_CANCER_EARLY_VS_LATE_UP 	0	50	119	16869	0.0	1.0	1	
STEARMAN_TUMOR_FIELD_EFFECT_UP 	0	50	32	16956	0.0	1.0	1	
STEIN_ESRRA_TARGETS_DN 	0	50	96	16892	0.0	1.0	1	
STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_UP 	0	50	28	16960	0.0	1.0	1	
ST_ERK1_ERK2_MAPK_PATHWAY 	0	50	31	16957	0.0	1.0	1	
ST_FAS_SIGNALING_PATHWAY 	0	50	63	16925	0.0	1.0	1	
ST_GA13_PATHWAY 	0	50	35	16953	0.0	1.0	1	
ST_G_ALPHA_I_PATHWAY 	0	50	33	16955	0.0	1.0	1	
ST_INTEGRIN_SIGNALING_PATHWAY 	0	50	80	16908	0.0	1.0	1	
ST_JNK_MAPK_PATHWAY 	0	50	39	16949	0.0	1.0	1	
STONER_ESOPHAGEAL_CARCINOGENESIS_UP 	0	50	35	16953	0.0	1.0	1	
STOSSI_RESPONSE_TO_ESTRADIOL 	0	50	38	16950	0.0	1.0	1	
ST_P38_MAPK_PATHWAY 	0	50	37	16951	0.0	1.0	1	
ST_PHOSPHOINOSITIDE_3_KINASE_PATHWAY 	0	50	36	16952	0.0	1.0	1	
STREICHER_LSM1_TARGETS_UP 	0	50	41	16947	0.0	1.0	1	
ST_T_CELL_SIGNAL_TRANSDUCTION 	0	50	41	16947	0.0	1.0	1	
ST_WNT_BETA_CATENIN_PATHWAY 	0	50	31	16957	0.0	1.0	1	
SUBTIL_PROGESTIN_TARGETS 	0	50	36	16952	0.0	1.0	1	
SU_LIVER 	0	50	27	16961	0.0	1.0	1	
SUMI_HNF4A_TARGETS 	0	50	19	16969	0.0	1.0	1	
SUNG_METASTASIS_STROMA_DN 	0	50	45	16943	0.0	1.0	1	
SUNG_METASTASIS_STROMA_UP 	0	50	103	16885	0.0	1.0	1	
SU_PANCREAS 	0	50	35	16953	0.0	1.0	1	
SU_TESTIS 	0	50	53	16935	0.0	1.0	1	
SWEET_KRAS_ONCOGENIC_SIGNATURE 	0	50	84	16904	0.0	1.0	1	
SWEET_KRAS_TARGETS_DN 	0	50	53	16935	0.0	1.0	1	
SWEET_KRAS_TARGETS_UP 	0	50	79	16909	0.0	1.0	1	
TAKAO_RESPONSE_TO_UVB_RADIATION_DN 	0	50	94	16894	0.0	1.0	1	
TAKAO_RESPONSE_TO_UVB_RADIATION_UP 	0	50	82	16906	0.0	1.0	1	
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_DN 	0	50	104	16884	0.0	1.0	1	
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_DN 	0	50	105	16883	0.0	1.0	1	
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_DN 	0	50	21	16967	0.0	1.0	1	
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_UP 	0	50	154	16834	0.0	1.0	1	
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_DN 	0	50	37	16951	0.0	1.0	1	
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP 	0	50	71	16917	0.0	1.0	1	
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_DN 	0	50	167	16821	0.0	1.0	1	
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_UP 	0	50	126	16862	0.0	1.0	1	
TANAKA_METHYLATED_IN_ESOPHAGEAL_CARCINOMA 	0	50	75	16913	0.0	1.0	1	
TANG_SENESCENCE_TP53_TARGETS_DN 	0	50	44	16944	0.0	1.0	1	
TANG_SENESCENCE_TP53_TARGETS_UP 	0	50	30	16958	0.0	1.0	1	
TARTE_PLASMA_CELL_VS_B_LYMPHOCYTE_DN 	0	50	34	16954	0.0	1.0	1	
TARTE_PLASMA_CELL_VS_B_LYMPHOCYTE_UP 	0	50	71	16917	0.0	1.0	1	
TAVAZOIE_METASTASIS 	0	50	85	16903	0.0	1.0	1	
TAVOR_CEBPA_TARGETS_UP 	0	50	44	16944	0.0	1.0	1	
TCGA_GLIOBLASTOMA_COPY_NUMBER_DN 	0	50	29	16959	0.0	1.0	1	
TCGA_GLIOBLASTOMA_COPY_NUMBER_UP 	0	50	66	16922	0.0	1.0	1	
TENEDINI_MEGAKARYOCYTE_MARKERS 	0	50	60	16928	0.0	1.0	1	
TERAO_AOX4_TARGETS_SKIN_UP 	0	50	33	16955	0.0	1.0	1	
THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN 	0	50	222	16766	0.0	1.0	1	
THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_UP 	0	50	71	16917	0.0	1.0	1	
THEODOROU_MAMMARY_TUMORIGENESIS 	0	50	26	16962	0.0	1.0	1	
THILLAINADESAN_ZNF217_TARGETS_UP 	0	50	41	16947	0.0	1.0	1	
THUM_SYSTOLIC_HEART_FAILURE_DN 	0	50	208	16780	0.0	1.0	1	
TIEN_INTESTINE_PROBIOTICS_24HR_DN 	0	50	204	16784	0.0	1.0	1	
TIEN_INTESTINE_PROBIOTICS_2HR_DN 	0	50	82	16906	0.0	1.0	1	
TIEN_INTESTINE_PROBIOTICS_6HR_UP 	0	50	55	16933	0.0	1.0	1	
TING_SILENCED_BY_DICER 	0	50	27	16961	0.0	1.0	1	
TOMLINS_PROSTATE_CANCER_DN 	0	50	40	16948	0.0	1.0	1	
TOMLINS_PROSTATE_CANCER_UP 	0	50	39	16949	0.0	1.0	1	
TONG_INTERACT_WITH_PTTG1 	0	50	54	16934	0.0	1.0	1	
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_GRANULOCYTE_UP 	0	50	53	16935	0.0	1.0	1	
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_DN 	0	50	158	16830	0.0	1.0	1	
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_UP 	0	50	170	16818	0.0	1.0	1	
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_DN 	0	50	43	16945	0.0	1.0	1	
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP 	0	50	191	16797	0.0	1.0	1	
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINDED_IN_ERYTHROCYTE_UP 	0	50	43	16945	0.0	1.0	1	
TOOKER_GEMCITABINE_RESISTANCE_DN 	0	50	119	16869	0.0	1.0	1	
TOOKER_GEMCITABINE_RESISTANCE_UP 	0	50	75	16913	0.0	1.0	1	
TORCHIA_TARGETS_OF_EWSR1_FLI1_FUSION_UP 	0	50	237	16751	0.0	1.0	1	
TRACEY_RESISTANCE_TO_IFNA2_DN 	0	50	29	16959	0.0	1.0	1	
TSAI_RESPONSE_TO_RADIATION_THERAPY 	0	50	32	16956	0.0	1.0	1	
TSENG_ADIPOGENIC_POTENTIAL_DN 	0	50	41	16947	0.0	1.0	1	
TSENG_IRS1_TARGETS_DN 	0	50	123	16865	0.0	1.0	1	
TSUNODA_CISPLATIN_RESISTANCE_DN 	0	50	42	16946	0.0	1.0	1	
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_DN 	0	50	158	16830	0.0	1.0	1	
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_UP 	0	50	39	16949	0.0	1.0	1	
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULAR_NORMAL_DN 	0	50	55	16933	0.0	1.0	1	
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULAR_NORMAL_UP 	0	50	67	16921	0.0	1.0	1	
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_DN 	0	50	79	16909	0.0	1.0	1	
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_UP 	0	50	65	16923	0.0	1.0	1	
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_DN 	0	50	71	16917	0.0	1.0	1	
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_UP 	0	50	88	16900	0.0	1.0	1	
TURASHVILI_BREAST_NORMAL_DUCTAL_VS_LOBULAR_UP 	0	50	58	16930	0.0	1.0	1	
UDAYAKUMAR_MED1_TARGETS_DN 	0	50	222	16766	0.0	1.0	1	
UDAYAKUMAR_MED1_TARGETS_UP 	0	50	129	16859	0.0	1.0	1	
UEDA_CENTRAL_CLOCK 	0	50	85	16903	0.0	1.0	1	
ULE_SPLICING_VIA_NOVA2 	0	50	43	16945	0.0	1.0	1	
URS_ADIPOCYTE_DIFFERENTIATION_UP 	0	50	68	16920	0.0	1.0	1	
UZONYI_RESPONSE_TO_LEUKOTRIENE_AND_THROMBIN 	0	50	36	16952	0.0	1.0	1	
VALK_AML_CLUSTER_10 	0	50	30	16958	0.0	1.0	1	
VALK_AML_CLUSTER_11 	0	50	36	16952	0.0	1.0	1	
VALK_AML_CLUSTER_15 	0	50	26	16962	0.0	1.0	1	
VALK_AML_CLUSTER_3 	0	50	28	16960	0.0	1.0	1	
VALK_AML_CLUSTER_4 	0	50	24	16964	0.0	1.0	1	
VALK_AML_CLUSTER_5 	0	50	33	16955	0.0	1.0	1	
VALK_AML_CLUSTER_6 	0	50	33	16955	0.0	1.0	1	
VALK_AML_CLUSTER_9 	0	50	32	16956	0.0	1.0	1	
VALK_AML_WITH_CEBPA 	0	50	28	16960	0.0	1.0	1	
VALK_AML_WITH_FLT3_ITD 	0	50	28	16960	0.0	1.0	1	
VANASSE_BCL2_TARGETS_DN 	0	50	60	16928	0.0	1.0	1	
VANDESLUIS_COMMD1_TARGETS_GROUP_3_DN 	0	50	33	16955	0.0	1.0	1	
VANDESLUIS_COMMD1_TARGETS_GROUP_3_UP 	0	50	71	16917	0.0	1.0	1	
VANHARANTA_UTERINE_FIBROID_DN 	0	50	62	16926	0.0	1.0	1	
VANHARANTA_UTERINE_FIBROID_UP 	0	50	40	16948	0.0	1.0	1	
VANHARANTA_UTERINE_FIBROID_WITH_7Q_DELETION_DN 	0	50	36	16952	0.0	1.0	1	
VANHARANTA_UTERINE_FIBROID_WITH_7Q_DELETION_UP 	0	50	64	16924	0.0	1.0	1	
VANTVEER_BREAST_CANCER_BRCA1_DN 	0	50	41	16947	0.0	1.0	1	
VANTVEER_BREAST_CANCER_BRCA1_UP 	0	50	29	16959	0.0	1.0	1	
VANTVEER_BREAST_CANCER_ESR1_DN 	0	50	202	16786	0.0	1.0	1	
VANTVEER_BREAST_CANCER_METASTASIS_DN 	0	50	101	16887	0.0	1.0	1	
VANTVEER_BREAST_CANCER_POOR_PROGNOSIS 	0	50	46	16942	0.0	1.0	1	
VARELA_ZMPSTE24_TARGETS_DN 	0	50	33	16955	0.0	1.0	1	
VARELA_ZMPSTE24_TARGETS_UP 	0	50	37	16951	0.0	1.0	1	
VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_DN 	0	50	118	16870	0.0	1.0	1	
VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_UP 	0	50	147	16841	0.0	1.0	1	
VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_DN 	0	50	98	16890	0.0	1.0	1	
VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_UP 	0	50	159	16829	0.0	1.0	1	
VERHAAK_AML_WITH_NPM1_MUTATED_DN 	0	50	214	16774	0.0	1.0	1	
VERHAAK_AML_WITH_NPM1_MUTATED_UP 	0	50	146	16842	0.0	1.0	1	
VERHAAK_GLIOBLASTOMA_MESENCHYMAL 	0	50	210	16778	0.0	1.0	1	
VERHAAK_GLIOBLASTOMA_NEURAL 	0	50	122	16866	0.0	1.0	1	
VERHAAK_GLIOBLASTOMA_PRONEURAL 	0	50	167	16821	0.0	1.0	1	
VERNELL_RETINOBLASTOMA_PATHWAY_UP 	0	50	63	16925	0.0	1.0	1	
VERRECCHIA_DELAYED_RESPONSE_TO_TGFB1 	0	50	37	16951	0.0	1.0	1	
VERRECCHIA_EARLY_RESPONSE_TO_TGFB1 	0	50	57	16931	0.0	1.0	1	
VILIMAS_NOTCH1_TARGETS_UP 	0	50	38	16950	0.0	1.0	1	
WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_WITH_H4K20ME1_MARK 	0	50	130	16858	0.0	1.0	1	
WALLACE_PROSTATE_CANCER_RACE_DN 	0	50	75	16913	0.0	1.0	1	
WALLACE_PROSTATE_CANCER_RACE_UP 	0	50	243	16745	0.0	1.0	1	
WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_DN 	0	50	62	16926	0.0	1.0	1	
WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_UP 	0	50	132	16856	0.0	1.0	1	
WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN 	0	50	185	16803	0.0	1.0	1	
WANG_BARRETTS_ESOPHAGUS_AND_ESOPHAGUS_CANCER_DN 	0	50	31	16957	0.0	1.0	1	
WANG_BARRETTS_ESOPHAGUS_UP 	0	50	40	16948	0.0	1.0	1	
WANG_CISPLATIN_RESPONSE_AND_XPC_DN 	0	50	215	16773	0.0	1.0	1	
WANG_CISPLATIN_RESPONSE_AND_XPC_UP 	0	50	168	16820	0.0	1.0	1	
WANG_CLIM2_TARGETS_DN 	0	50	173	16815	0.0	1.0	1	
WANG_CLIM2_TARGETS_UP 	0	50	210	16778	0.0	1.0	1	
WANG_ESOPHAGUS_CANCER_VS_NORMAL_DN 	0	50	95	16893	0.0	1.0	1	
WANG_ESOPHAGUS_CANCER_VS_NORMAL_UP 	0	50	102	16886	0.0	1.0	1	
WANG_HCP_PROSTATE_CANCER 	0	50	102	16886	0.0	1.0	1	
WANG_IMMORTALIZED_BY_HOXA9_AND_MEIS1_UP 	0	50	28	16960	0.0	1.0	1	
WANG_LSD1_TARGETS_DN 	0	50	32	16956	0.0	1.0	1	
WANG_METHYLATED_IN_BREAST_CANCER 	0	50	34	16954	0.0	1.0	1	
WANG_MLL_TARGETS 	0	50	239	16749	0.0	1.0	1	
WANG_PROSTATE_CANCER_ANDROGEN_INDEPENDENT 	0	50	55	16933	0.0	1.0	1	
WANG_RESPONSE_TO_BEXAROTENE_UP 	0	50	27	16961	0.0	1.0	1	
WANG_SMARCE1_TARGETS_UP 	0	50	260	16728	0.0	1.0	1	
WANG_TARGETS_OF_MLL_CBP_FUSION_DN 	0	50	41	16947	0.0	1.0	1	
WANG_TARGETS_OF_MLL_CBP_FUSION_UP 	0	50	38	16950	0.0	1.0	1	
WANG_TUMOR_INVASIVENESS_DN 	0	50	195	16793	0.0	1.0	1	
WARTERS_IR_RESPONSE_5GY 	0	50	40	16948	0.0	1.0	1	
WARTERS_RESPONSE_TO_IR_SKIN 	0	50	68	16920	0.0	1.0	1	
WATANABE_COLON_CANCER_MSI_VS_MSS_DN 	0	50	60	16928	0.0	1.0	1	
WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_DN 	0	50	89	16899	0.0	1.0	1	
WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_UP 	0	50	101	16887	0.0	1.0	1	
WATTEL_AUTONOMOUS_THYROID_ADENOMA_DN 	0	50	48	16940	0.0	1.0	1	
WATTEL_AUTONOMOUS_THYROID_ADENOMA_UP 	0	50	65	16923	0.0	1.0	1	
WEBER_METHYLATED_HCP_IN_FIBROBLAST_DN 	0	50	17	16971	0.0	1.0	1	
WEIGEL_OXIDATIVE_STRESS_BY_HNE_AND_H2O2 	0	50	38	16950	0.0	1.0	1	
WEIGEL_OXIDATIVE_STRESS_BY_HNE_AND_TBH 	0	50	56	16932	0.0	1.0	1	
WEIGEL_OXIDATIVE_STRESS_BY_TBH_AND_H2O2 	0	50	33	16955	0.0	1.0	1	
WEIGEL_OXIDATIVE_STRESS_RESPONSE 	0	50	33	16955	0.0	1.0	1	
WEI_MIR34A_TARGETS 	0	50	142	16846	0.0	1.0	1	
WEINMANN_ADAPTATION_TO_HYPOXIA_DN 	0	50	38	16950	0.0	1.0	1	
WELCSH_BRCA1_TARGETS_UP 	0	50	189	16799	0.0	1.0	1	
WENDT_COHESIN_TARGETS_UP 	0	50	33	16955	0.0	1.0	1	
WENG_POR_TARGETS_LIVER_UP 	0	50	35	16953	0.0	1.0	1	
WESTON_VEGFA_TARGETS 	0	50	89	16899	0.0	1.0	1	
WESTON_VEGFA_TARGETS_12HR 	0	50	28	16960	0.0	1.0	1	
WESTON_VEGFA_TARGETS_3HR 	0	50	60	16928	0.0	1.0	1	
WESTON_VEGFA_TARGETS_6HR 	0	50	49	16939	0.0	1.0	1	
WHITEFORD_PEDIATRIC_CANCER_MARKERS 	0	50	96	16892	0.0	1.0	1	
WHITEHURST_PACLITAXEL_SENSITIVITY 	0	50	32	16956	0.0	1.0	1	
WHITFIELD_CELL_CYCLE_G2 	0	50	160	16828	0.0	1.0	1	
WHITFIELD_CELL_CYCLE_G2_M 	0	50	179	16809	0.0	1.0	1	
WHITFIELD_CELL_CYCLE_M_G1 	0	50	136	16852	0.0	1.0	1	
WHITFIELD_CELL_CYCLE_S 	0	50	137	16851	0.0	1.0	1	
WIEDERSCHAIN_TARGETS_OF_BMI1_AND_PCGF2 	0	50	53	16935	0.0	1.0	1	
WIELAND_UP_BY_HBV_INFECTION 	0	50	89	16899	0.0	1.0	1	
WIERENGA_PML_INTERACTOME 	0	50	38	16950	0.0	1.0	1	
WIERENGA_STAT5A_TARGETS_DN 	0	50	173	16815	0.0	1.0	1	
WIERENGA_STAT5A_TARGETS_GROUP1 	0	50	115	16873	0.0	1.0	1	
WIERENGA_STAT5A_TARGETS_GROUP2 	0	50	49	16939	0.0	1.0	1	
WIERENGA_STAT5A_TARGETS_UP 	0	50	186	16802	0.0	1.0	1	
WILCOX_RESPONSE_TO_PROGESTERONE_DN 	0	50	60	16928	0.0	1.0	1	
WILCOX_RESPONSE_TO_PROGESTERONE_UP 	0	50	125	16863	0.0	1.0	1	
WINNEPENNINCKX_MELANOMA_METASTASIS_DN 	0	50	33	16955	0.0	1.0	1	
WINNEPENNINCKX_MELANOMA_METASTASIS_UP 	0	50	140	16848	0.0	1.0	1	
WINTER_HYPOXIA_DN 	0	50	45	16943	0.0	1.0	1	
WINTER_HYPOXIA_METAGENE 	0	50	216	16772	0.0	1.0	1	
WINTER_HYPOXIA_UP 	0	50	84	16904	0.0	1.0	1	
WNT_SIGNALING 	0	50	83	16905	0.0	1.0	1	
WONG_ENDMETRIUM_CANCER_DN 	0	50	76	16912	0.0	1.0	1	
WONG_MITOCHONDRIA_GENE_MODULE 	0	50	213	16775	0.0	1.0	1	
WONG_PROTEASOME_GENE_MODULE 	0	50	48	16940	0.0	1.0	1	
WOOD_EBV_EBNA1_TARGETS_DN 	0	50	44	16944	0.0	1.0	1	
WOO_LIVER_CANCER_RECURRENCE_DN 	0	50	66	16922	0.0	1.0	1	
WOO_LIVER_CANCER_RECURRENCE_UP 	0	50	100	16888	0.0	1.0	1	
WORSCHECH_TUMOR_REJECTION_UP 	0	50	38	16950	0.0	1.0	1	
WU_APOPTOSIS_BY_CDKN1A_VIA_TP53 	0	50	46	16942	0.0	1.0	1	
WU_CELL_MIGRATION 	0	50	168	16820	0.0	1.0	1	
WU_SILENCED_BY_METHYLATION_IN_BLADDER_CANCER 	0	50	51	16937	0.0	1.0	1	
XU_CREBBP_TARGETS_DN 	0	50	38	16950	0.0	1.0	1	
XU_GH1_AUTOCRINE_TARGETS_DN 	0	50	126	16862	0.0	1.0	1	
XU_GH1_EXOGENOUS_TARGETS_DN 	0	50	96	16892	0.0	1.0	1	
XU_GH1_EXOGENOUS_TARGETS_UP 	0	50	63	16925	0.0	1.0	1	
XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_UP 	0	50	32	16956	0.0	1.0	1	
XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN 	0	50	67	16921	0.0	1.0	1	
YAGI_AML_FAB_MARKERS 	0	50	178	16810	0.0	1.0	1	
YAGI_AML_RELAPSE_PROGNOSIS 	0	50	34	16954	0.0	1.0	1	
YAMASHITA_LIVER_CANCER_STEM_CELL_DN 	0	50	51	16937	0.0	1.0	1	
YAMASHITA_LIVER_CANCER_STEM_CELL_UP 	0	50	41	16947	0.0	1.0	1	
YAMASHITA_LIVER_CANCER_WITH_EPCAM_UP 	0	50	50	16938	0.0	1.0	1	
YAMASHITA_METHYLATED_IN_PROSTATE_CANCER 	0	50	36	16952	0.0	1.0	1	
YAMAZAKI_TCEB3_TARGETS_DN 	0	50	195	16793	0.0	1.0	1	
YAMAZAKI_TCEB3_TARGETS_UP 	0	50	165	16823	0.0	1.0	1	
YANG_BREAST_CANCER_ESR1_LASER_UP 	0	50	30	16958	0.0	1.0	1	
YANG_BREAST_CANCER_ESR1_UP 	0	50	32	16956	0.0	1.0	1	
YAO_HOXA10_TARGETS_VIA_PROGESTERONE_UP 	0	50	66	16922	0.0	1.0	1	
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_0 	0	50	71	16917	0.0	1.0	1	
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_10 	0	50	64	16924	0.0	1.0	1	
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_1 	0	50	63	16925	0.0	1.0	1	
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_11 	0	50	95	16893	0.0	1.0	1	
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_12 	0	50	76	16912	0.0	1.0	1	
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_14 	0	50	133	16855	0.0	1.0	1	
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_15 	0	50	30	16958	0.0	1.0	1	
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_16 	0	50	71	16917	0.0	1.0	1	
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_2 	0	50	71	16917	0.0	1.0	1	
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6 	0	50	68	16920	0.0	1.0	1	
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_7 	0	50	71	16917	0.0	1.0	1	
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_8 	0	50	44	16944	0.0	1.0	1	
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_9 	0	50	68	16920	0.0	1.0	1	
YEGNASUBRAMANIAN_PROSTATE_CANCER 	0	50	91	16897	0.0	1.0	1	
YIH_RESPONSE_TO_ARSENITE_C3 	0	50	35	16953	0.0	1.0	1	
YORDY_RECIPROCAL_REGULATION_BY_ETS1_AND_SP100_DN 	0	50	70	16918	0.0	1.0	1	
YOSHIOKA_LIVER_CANCER_EARLY_RECURRENCE_DN 	0	50	49	16939	0.0	1.0	1	
YOSHIOKA_LIVER_CANCER_EARLY_RECURRENCE_UP 	0	50	35	16953	0.0	1.0	1	
YU_MYC_TARGETS_DN 	0	50	45	16943	0.0	1.0	1	
YU_MYC_TARGETS_UP 	0	50	33	16955	0.0	1.0	1	
ZAMORA_NOS2_TARGETS_DN 	0	50	88	16900	0.0	1.0	1	
ZAMORA_NOS2_TARGETS_UP 	0	50	62	16926	0.0	1.0	1	
ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_DN 	0	50	45	16943	0.0	1.0	1	
ZHANG_BREAST_CANCER_PROGENITORS_DN 	0	50	134	16854	0.0	1.0	1	
ZHANG_GATA6_TARGETS_DN 	0	50	54	16934	0.0	1.0	1	
ZHANG_PROLIFERATING_VS_QUIESCENT 	0	50	49	16939	0.0	1.0	1	
ZHANG_RESPONSE_TO_CANTHARIDIN_DN 	0	50	66	16922	0.0	1.0	1	
ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_DN 	0	50	92	16896	0.0	1.0	1	
ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_UP 	0	50	194	16794	0.0	1.0	1	
ZHANG_TARGETS_OF_EWSR1_FLI1_FUSION 	0	50	83	16905	0.0	1.0	1	
ZHANG_TLX_TARGETS_UP 	0	50	105	16883	0.0	1.0	1	
ZHAN_LATE_DIFFERENTIATION_GENES_UP 	0	50	31	16957	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_CD1_AND_CD2_DN 	0	50	46	16942	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_CD1_AND_CD2_UP 	0	50	79	16909	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_CD1_DN 	0	50	41	16947	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_CD1_VS_CD2_DN 	0	50	45	16943	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_CD2_UP 	0	50	38	16950	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_DN 	0	50	36	16952	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_HP_DN 	0	50	43	16945	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_HP_UP 	0	50	40	16948	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_LB_DN 	0	50	35	16953	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_LB_UP 	0	50	40	16948	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_MF_DN 	0	50	36	16952	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_MF_UP 	0	50	40	16948	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_MS_DN 	0	50	36	16952	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_MS_UP 	0	50	44	16944	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_PR_DN 	0	50	42	16946	0.0	1.0	1	
ZHAN_MULTIPLE_MYELOMA_UP 	0	50	60	16928	0.0	1.0	1	
ZHAN_V1_LATE_DIFFERENTIATION_GENES_UP 	0	50	29	16959	0.0	1.0	1	
ZHAN_V2_LATE_DIFFERENTIATION_GENES 	0	50	41	16947	0.0	1.0	1	
ZHENG_FOXP3_TARGETS_IN_THYMUS_UP 	0	50	177	16811	0.0	1.0	1	
ZHENG_FOXP3_TARGETS_IN_T_LYMPHOCYTE_DN 	0	50	32	16956	0.0	1.0	1	
ZHENG_GLIOBLASTOMA_PLASTICITY_DN 	0	50	54	16934	0.0	1.0	1	
ZHENG_GLIOBLASTOMA_PLASTICITY_UP 	0	50	229	16759	0.0	1.0	1	
ZHENG_IL22_SIGNALING_DN 	0	50	34	16954	0.0	1.0	1	
ZHENG_IL22_SIGNALING_UP 	0	50	46	16942	0.0	1.0	1	
ZHONG_RESPONSE_TO_AZACITIDINE_AND_TSA_UP 	0	50	159	16829	0.0	1.0	1	
ZHONG_SECRETOME_OF_LUNG_CANCER_AND_ENDOTHELIUM 	0	50	63	16925	0.0	1.0	1	
ZHONG_SECRETOME_OF_LUNG_CANCER_AND_FIBROBLAST 	0	50	122	16866	0.0	1.0	1	
ZHONG_SECRETOME_OF_LUNG_CANCER_AND_MACROPHAGE 	0	50	73	16915	0.0	1.0	1	
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_24HR 	0	50	106	16882	0.0	1.0	1	
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_6HR 	0	50	71	16917	0.0	1.0	1	
ZHOU_TNF_SIGNALING_30MIN 	0	50	51	16937	0.0	1.0	1	
ZHOU_TNF_SIGNALING_4HR 	0	50	52	16936	0.0	1.0	1	
ZHU_CMV_24_HR_DN 	0	50	85	16903	0.0	1.0	1	
ZHU_CMV_8_HR_DN 	0	50	51	16937	0.0	1.0	1	
ZHU_CMV_8_HR_UP 	0	50	45	16943	0.0	1.0	1	
ZHU_CMV_ALL_DN 	0	50	120	16868	0.0	1.0	1	
ZUCCHI_METASTASIS_UP 	0	50	38	16950	0.0	1.0	1	
ZWANG_CLASS_2_TRANSIENTLY_INDUCED_BY_EGF 	0	50	37	16951	0.0	1.0	1	
ZWANG_CLASS_3_TRANSIENTLY_INDUCED_BY_EGF 	0	50	196	16792	0.0	1.0	1	
ZWANG_DOWN_BY_2ND_EGF_PULSE 	0	50	199	16789	0.0	1.0	1	
ZWANG_EGF_INTERVAL_DN 	0	50	178	16810	0.0	1.0	1	
ZWANG_EGF_INTERVAL_UP 	0	50	70	16918	0.0	1.0	1	
ZWANG_EGF_PERSISTENTLY_DN 	0	50	53	16935	0.0	1.0	1	
ZWANG_EGF_PERSISTENTLY_UP 	0	50	29	16959	0.0	1.0	1	
	test_inset	test_notinset	background_inset	background_notinset	oddsratio	pvalue	bonferroni-adjusted	testgenes_in_set
